<!DOCTYPE html><html lang="en" prefix="og: https://ogp.me/ns#"><head><meta charset="utf-8"><title data-static-tag-from="prerender">OraSure Technologies, Inc. (OSUR) CEO Stephen Tang on Q3 2020 Results - Earnings Call Transcript | Seeking Alpha</title><script>!function(e,t,o){e&&e.documentElement&&"object"==typeof e.documentElement.dataset&&t&&"function"==typeof t.getItem&&t.getItem(o)&&(e.documentElement.dataset.colorScheme=t.getItem(o))}(document,localStorage,"COLOR_SCHEME")</script><link rel="preconnect" href="https://static.seekingalpha.com"><link rel="preconnect" href="https://static1.seekingalpha.com"><link rel="preconnect" href="https://static2.seekingalpha.com"><link rel="preconnect" href="https://static3.seekingalpha.com"><link rel="preconnect" href="https://www.googletagmanager.com" crossorigin="anonymous"><link rel="preconnect" href="https://www.google-analytics.com" crossorigin="anonymous"><meta name="viewport" content="width=device-width,initial-scale=1,viewport-fit=cover,maximum-scale=1"><meta content="ie=edge" http-equiv="X-UA-Compatible"><meta name="application-name" content="Seeking Alpha"><meta name="HandheldFriendly" content="True"><meta name="apple-mobile-web-app-capable" content="yes"><meta name="apple-mobile-web-app-title" content="SeekingAlpha"><meta name="apple-mobile-web-app-status-bar-style" content="black"><meta name="apple-itunes-app" content="app-id=552799694"><meta name="format-detection" content="telephone=yes"><meta name="theme-color" content="#333333"><meta property="fb:app_id" content="159723149420031"><meta property="fb:pages" content="224867310939090"><meta content="SeekingAlpha" property="al:ios:app_name"><meta content="552799694" property="al:ios:app_store_id"><meta content="SeekingAlpha" property="al:android:app_name"><meta content="com.seekingalpha.webwrapper" property="al:android:package"><meta name="google-site-verification" content="8arRaWMkVniCnxJWf9hbm-0PYkb_LhjaXAk7rGd97iw"><meta name="msvalidate.01" content="0FEA0055AC330065CFA87CA3045E9860"><meta property="og:locale" content="en_US"><meta property="og:site_name" content="Seeking Alpha"><link rel="mask-icon" href="/samw/static/images/favicon.svg" color="#ff7200"><link rel="apple-touch-icon" href="/samw/static/images/apple-touch-icon.png"><link sizes="57x57" rel="apple-touch-icon" href="/samw/static/images/apple-touch-icon-57x57.png"><link sizes="60x60" rel="apple-touch-icon" href="/samw/static/images/apple-touch-icon-60x60.png"><link sizes="72x72" rel="apple-touch-icon" href="/samw/static/images/apple-touch-icon-72x72.png"><link sizes="76x76" rel="apple-touch-icon" href="/samw/static/images/apple-touch-icon-76x76.png"><link sizes="114x114" rel="apple-touch-icon" href="/samw/static/images/apple-touch-icon-114x114.png"><link sizes="120x120" rel="apple-touch-icon" href="/samw/static/images/apple-touch-icon-120x120.png"><link sizes="144x144" rel="apple-touch-icon" href="/samw/static/images/apple-touch-icon-144x144.png"><link sizes="152x152" rel="apple-touch-icon" href="/samw/static/images/apple-touch-icon-152x152.png"><link sizes="180x180" rel="apple-touch-icon" href="/samw/static/images/apple-touch-icon-180x180.png"><link sizes="16x16" rel="icon" type="image/png" href="/samw/static/images/favicon-16x16.png"><link sizes="32x32" rel="icon" type="image/png" href="/samw/static/images/favicon-32x32.png"><link sizes="32x32" rel="icon" type="image/png" href="/samw/static/images/favicon-96x96.png"><link sizes="192x192" rel="icon" type="image/png" href="/samw/static/images/favicon-192x192.png"><link href="https://seekingalpha.com/javascripts/seeking.xml" title="Seeking Alpha&#x27;s Symbol search" type="application/opensearchdescription+xml"><script>performance&&"function"==typeof performance.mark&&performance.mark("SA_booted")</script><script id="sa_build_number">window.SA_PR_NUMBER = "null";
    window.SA_RUN_NUMBER = "12356";
    window.SA_BUILD_DATE = 1696602425426;</script><link href="/samw/favicon.ico" rel="icon"><style data-href="/samw/static/styles/app.217b4ccc.css">@keyframes au_eN{to{transform:rotate(1turn)}}.au_gs{animation:au_eN 1s linear infinite;color:var(--sa-spinner-color,currentColor);height:1em;width:1em}@media screen and (prefers-reduced-motion:reduce){.au_gs{animation:none}}.s_as{padding:0}.s_at{margin:0}.s_au{padding-top:0}.s_av{padding-top:2px}.s_aw{padding-top:4px}.s_ax{padding-top:6px}.s_ay{padding-top:8px}.s_az{padding-top:10px}.s_aA{padding-top:12px}.s_aB{padding-top:14px}.s_aC{padding-top:16px}.s_aE{padding-top:18px}.s_aF{padding-top:20px}.s_aG{padding-top:24px}.s_aH{padding-top:28px}.s_aI{padding-top:30px}.s_aJ{padding-top:32px}.s_aK{padding-top:36px}.s_aL{padding-top:40px}.s_aM{padding-top:42px}.s_aN{padding-top:48px}.s_aO{padding-top:64px}.s_aP{padding-top:72px}.s_aQ{padding-left:0}.s_aR{padding-left:2px}.s_aS{padding-left:4px}.s_aT{padding-left:6px}.s_aU{padding-left:8px}.s_aV{padding-left:10px}.s_aW{padding-left:12px}.s_aX{padding-left:14px}.s_aY{padding-left:16px}.s_aZ{padding-left:18px}.s_a0{padding-left:20px}.s_a1{padding-left:24px}.s_a2{padding-left:28px}.s_a3{padding-left:30px}.s_a4{padding-left:32px}.s_a5{padding-left:36px}.s_a6{padding-left:40px}.s_a7{padding-left:44px}.s_a8{padding-left:48px}.s_a9{padding-left:50px}.s_ba{padding-left:54px}.s_bb{padding-left:64px}.s_bc{padding-left:72px}.s_bd{padding-right:0}.s_be{padding-right:2px}.s_bf{padding-right:4px}.s_bg{padding-right:6px}.s_bh{padding-right:8px}.s_bi{padding-right:10px}.s_bj{padding-right:12px}.s_bk{padding-right:14px}.s_bl{padding-right:16px}.s_bm{padding-right:18px}.s_bn{padding-right:20px}.s_bo{padding-right:24px}.s_bp{padding-right:26px}.s_bq{padding-right:28px}.s_br{padding-right:30px}.s_bs{padding-right:32px}.s_bt{padding-right:36px}.s_bu{padding-right:40px}.s_bv{padding-right:48px}.s_bw{padding-right:64px}.s_bx{padding-right:72px}.s_by{padding-bottom:0}.s_bz{padding-bottom:2px}.s_bA{padding-bottom:4px}.s_bB{padding-bottom:6px}.s_bC{padding-bottom:8px}.s_bD{padding-bottom:10px}.s_bE{padding-bottom:12px}.s_bF{padding-bottom:14px}.s_bG{padding-bottom:16px}.s_bH{padding-bottom:18px}.s_bI{padding-bottom:20px}.s_bJ{padding-bottom:24px}.s_bK{padding-bottom:28px}.s_bL{padding-bottom:30px}.s_bM{padding-bottom:32px}.s_bN{padding-bottom:36px}.s_bO{padding-bottom:40px}.s_bP{padding-bottom:42px}.s_bQ{padding-bottom:44px}.s_bR{padding-bottom:48px}.s_bS{padding-bottom:64px}.s_bT{padding-bottom:72px}.s_bU,.s_bV{margin-top:0}.s_bW{margin-top:2px}.s_bX{margin-top:-2px}.s_bY{margin-top:4px}.s_bZ{margin-top:-4px}.s_b0{margin-top:6px}.s_b1{margin-top:-6px}.s_b2{margin-top:8px}.s_b3{margin-top:-8px}.s_b4{margin-top:10px}.s_b5{margin-top:-10px}.s_b6{margin-top:12px}.s_b7{margin-top:-12px}.s_b8{margin-top:14px}.s_b9{margin-top:-14px}.s_ca{margin-top:16px}.s_cb{margin-top:-16px}.s_cc{margin-top:18px}.s_cd{margin-top:-18px}.s_ce{margin-top:20px}.s_cf{margin-top:-20px}.s_cg{margin-top:24px}.s_ch{margin-top:-24px}.s_ci{margin-top:28px}.s_cj{margin-top:-28px}.s_ck{margin-top:30px}.s_cl{margin-top:-30px}.s_cm{margin-top:32px}.s_cn{margin-top:-32px}.s_co{margin-top:36px}.s_cp{margin-top:-36px}.s_cq{margin-top:40px}.s_cr{margin-top:-40px}.s_cs{margin-top:48px}.s_ct{margin-top:-48px}.s_cu{margin-top:64px}.s_cv{margin-top:-64px}.s_cw{margin-top:72px}.s_cx{margin-top:-72px}.s_cy{margin-left:auto}.s_cA,.s_cz{margin-left:0}.s_cB{margin-left:2px}.s_cC{margin-left:-2px}.s_cD{margin-left:4px}.s_cE{margin-left:-4px}.s_cF{margin-left:6px}.s_cG{margin-left:-6px}.s_cH{margin-left:8px}.s_cI{margin-left:-8px}.s_cJ{margin-left:10px}.s_cK{margin-left:-10px}.s_cL{margin-left:12px}.s_cM{margin-left:-12px}.s_cN{margin-left:14px}.s_cO{margin-left:-14px}.s_cP{margin-left:16px}.s_cQ{margin-left:-16px}.s_cR{margin-left:18px}.s_cS{margin-left:-18px}.s_cT{margin-left:20px}.s_cU{margin-left:-20px}.s_cV{margin-left:24px}.s_cW{margin-left:-24px}.s_cX{margin-left:28px}.s_cY{margin-left:-28px}.s_cZ{margin-left:30px}.s_c0{margin-left:-30px}.s_c1{margin-left:32px}.s_c2{margin-left:-32px}.s_c3{margin-left:36px}.s_c4{margin-left:-36px}.s_c5{margin-left:40px}.s_c6{margin-left:-40px}.s_c7{margin-left:48px}.s_c8{margin-left:-48px}.s_c9{margin-left:64px}.s_da{margin-left:-64px}.s_db{margin-left:72px}.s_dc{margin-left:-72px}.s_dd{margin-right:auto}.s_de,.s_df{margin-right:0}.s_dg{margin-right:2px}.s_dh{margin-right:-2px}.s_di{margin-right:4px}.s_dj{margin-right:-4px}.s_dk{margin-right:6px}.s_dl{margin-right:-6px}.s_dm{margin-right:8px}.s_dn{margin-right:-8px}.s_do{margin-right:10px}.s_dp{margin-right:-10px}.s_dq{margin-right:12px}.s_dr{margin-right:-12px}.s_ds{margin-right:14px}.s_dt{margin-right:-14px}.s_du{margin-right:16px}.s_dv{margin-right:-16px}.s_dw{margin-right:18px}.s_dx{margin-right:-18px}.s_dy{margin-right:20px}.s_dz{margin-right:-20px}.s_dA{margin-right:24px}.s_dB{margin-right:-24px}.s_dC{margin-right:28px}.s_dD{margin-right:-28px}.s_dE{margin-right:30px}.s_dF{margin-right:-30px}.s_dG{margin-right:32px}.s_dH{margin-right:-32px}.s_dI{margin-right:36px}.s_dJ{margin-right:-36px}.s_dK{margin-right:40px}.s_dL{margin-right:-40px}.s_dM{margin-right:48px}.s_dN{margin-right:-48px}.s_dO{margin-right:64px}.s_dP{margin-right:-64px}.s_dQ{margin-right:72px}.s_dR{margin-right:-72px}.s_dS{margin-bottom:auto}.s_dT,.s_dU{margin-bottom:0}.s_dV{margin-bottom:2px}.s_dW{margin-bottom:-2px}.s_dX{margin-bottom:4px}.s_dY{margin-bottom:-4px}.s_dZ{margin-bottom:6px}.s_d0{margin-bottom:-6px}.s_d1{margin-bottom:8px}.s_d2{margin-bottom:-8px}.s_d3{margin-bottom:10px}.s_d4{margin-bottom:-10px}.s_d5{margin-bottom:12px}.s_d6{margin-bottom:-12px}.s_d7{margin-bottom:14px}.s_d8{margin-bottom:-14px}.s_d9{margin-bottom:16px}.s_ea{margin-bottom:-16px}.s_eb{margin-bottom:18px}.s_ec{margin-bottom:-18px}.s_ed{margin-bottom:20px}.s_ee{margin-bottom:-20px}.s_ef{margin-bottom:22px}.s_eg{margin-bottom:24px}.s_eh{margin-bottom:26px}.s_ei{margin-bottom:-24px}.s_ej{margin-bottom:28px}.s_ek{margin-bottom:-28px}.s_el{margin-bottom:30px}.s_em{margin-bottom:-30px}.s_en{margin-bottom:32px}.s_eo{margin-bottom:-32px}.s_ep{margin-bottom:36px}.s_eq{margin-bottom:-36px}.s_er{margin-bottom:40px}.s_es{margin-bottom:42px}.s_et{margin-bottom:-40px}.s_eu{margin-bottom:48px}.s_ev{margin-bottom:-48px}.s_ew{margin-bottom:64px}.s_ex{margin-bottom:-64px}.s_ey{margin-bottom:72px}.s_ez{margin-bottom:-72px}.s_eA{margin-top:auto}.r_4{display:flex}.r_5{display:inline-flex}.r_6{align-items:center}.r_7{align-items:flex-start}.r_8{align-items:flex-end}.r_9{align-items:baseline}.r_aa{align-items:stretch}.r_ab{justify-content:center}.r_ac{justify-content:flex-end}.r_ae{justify-content:flex-start}.r_af{justify-content:space-between}.r_ag{justify-content:space-around}.r_ah{flex-flow:row wrap}.r_ai{flex-flow:column wrap}.r_aj{flex-flow:row}.r_ak{flex-flow:row-reverse}.r_al{flex-flow:row nowrap}.r_am{flex-flow:column}.r_an{flex-flow:column-reverse}.r_ao{flex-flow:column nowrap}.r_ap{flex-grow:1}.r_aq{flex-grow:9999}.r_ar{flex-shrink:0}.U_gW{--modal-padding:36px;max-width:420px;width:calc(100vw - var(--modal-padding))}@media(min-width:768px){.U_gW{flex-grow:0;max-width:none;min-height:566px;width:408px}}.U_gs{font-size:2.5rem}.ax_g{position:relative;text-align:center}@media(min-width:768px){.ax_g{padding:0 54px 28px}}.ax_H{justify-content:center}.ax_iE{background-color:var(--black-5)}@media(min-width:768px){.ax_iE{padding:36px}}[data-color-scheme=dark] .ax_iE:not([data-skip-color-scheme]){background-color:var(--black-95)}.ax_G{border:0;color:var(--sa-link-color);font-weight:500;vertical-align:initial}@media(min-width:768px){.ax_I{left:54px;margin-bottom:0;position:absolute;right:54px}}p+.aR_jh{margin-top:12px}p+.aR_ji{margin-top:18px}p+.aR_jj{margin-top:20px}p+.aR_jk{margin-top:24px}.aS_jl{font-size:.625rem}.aS_jm{font-size:.6875rem}.aS_jn{font-size:.75rem}.aS_jo{font-size:.875rem}.aS_jp{font-size:1rem}.aS_jq{font-size:1.125rem}.aS_jr{font-size:1.25rem}.aS_js{font-size:1.375rem}.aS_jt{font-size:1.5rem}.aS_ju{font-size:1.75rem}.aS_jv{font-size:2rem}.aS_jw{font-size:2.25rem}.aS_jx{font-size:2.375rem}.aS_jy{font-size:3.125rem}.aS_jz{font-size:4.25rem}.aS_jA{line-height:.75rem}.aS_jB{line-height:.8125rem}.aS_jC{line-height:.875rem}.aS_jD{line-height:1.25rem}.aS_jE{line-height:1rem}.aS_jF{line-height:1.75rem}.aS_jG{line-height:1.5rem}.aS_jH{line-height:1.375rem}.aS_jI{line-height:1.625rem}.aS_jJ{line-height:1.875rem}.aS_jK{line-height:2rem}.aS_jL{line-height:2.25rem}.aS_jM{line-height:2.125rem}.aS_jN{line-height:2.375rem}.aS_jO{line-height:2.75rem}.aS_jP{line-height:2.875rem}.aS_jQ{line-height:3.75rem}.aS_jR{line-height:5.125rem}.aS_jS{font-weight:400}.aS_jT{font-weight:700}.aS_jU{font-style:italic}@media(min-width:768px){.aS_jV{font-size:.625rem}.aS_jW{font-size:.6875rem}.aS_jX{font-size:.75rem}.aS_jY{font-size:.875rem}.aS_jZ{font-size:1rem}.aS_j0{font-size:1.125rem}.aS_j1{font-size:1.25rem}.aS_j2{font-size:1.375rem}.aS_j3{font-size:1.5rem}.aS_j4{font-size:1.75rem}.aS_j5{font-size:2rem}.aS_j6{font-size:2.25rem}.aS_j7{font-size:2.375rem}.aS_j8{font-size:3.125rem}.aS_j9{font-size:4.25rem}.aS_ka{line-height:.75rem}.aS_kb{line-height:.8125rem}.aS_kc{line-height:.875rem}.aS_kd{line-height:1.25rem}.aS_ke{line-height:1rem}.aS_kf{line-height:1.75rem}.aS_kg{line-height:1.5rem}.aS_kh{line-height:1.375rem}.aS_ki{line-height:1.625rem}.aS_kj{line-height:1.875rem}.aS_kk{line-height:2rem}.aS_kl{line-height:2.25rem}.aS_km{line-height:2.125rem}.aS_kn{line-height:2.375rem}.aS_ko{line-height:2.75rem}.aS_kp{line-height:2.875rem}.aS_kq{line-height:3.75rem}.aS_kr{line-height:5.125rem}.aS_ks{font-weight:400}.aS_kt{font-weight:700}.aS_ku{font-style:italic}}@media(min-width:1024px){.aS_kv{font-size:.625rem}.aS_kw{font-size:.6875rem}.aS_kx{font-size:.75rem}.aS_ky{font-size:.875rem}.aS_kz{font-size:1rem}.aS_kA{font-size:1.125rem}.aS_kB{font-size:1.25rem}.aS_kC{font-size:1.375rem}.aS_kD{font-size:1.5rem}.aS_kE{font-size:1.75rem}.aS_kF{font-size:2rem}.aS_kG{font-size:2.25rem}.aS_kH{font-size:2.375rem}.aS_kI{font-size:3.125rem}.aS_kJ{font-size:4.25rem}.aS_kK{line-height:.75rem}.aS_kL{line-height:.8125rem}.aS_kM{line-height:.875rem}.aS_kN{line-height:1.25rem}.aS_kO{line-height:1rem}.aS_kP{line-height:1.75rem}.aS_kQ{line-height:1.5rem}.aS_kR{line-height:1.375rem}.aS_kS{line-height:1.625rem}.aS_kT{line-height:1.875rem}.aS_kU{line-height:2rem}.aS_kV{line-height:2.25rem}.aS_kW{line-height:2.125rem}.aS_kX{line-height:2.375rem}.aS_kY{line-height:2.75rem}.aS_kZ{line-height:2.875rem}.aS_k0{line-height:3.75rem}.aS_k1{line-height:5.125rem}.aS_k2{font-weight:400}.aS_k3{font-weight:700}.aS_k4{font-style:italic}}@media(min-width:1200px){.aS_k5{font-size:.625rem}.aS_k6{font-size:.6875rem}.aS_k7{font-size:.75rem}.aS_k8{font-size:.875rem}.aS_k9{font-size:1rem}.aS_la{font-size:1.125rem}.aS_lb{font-size:1.25rem}.aS_lc{font-size:1.375rem}.aS_ld{font-size:1.5rem}.aS_le{font-size:1.75rem}.aS_lf{font-size:2rem}.aS_lg{font-size:2.25rem}.aS_lh{font-size:2.375rem}.aS_li{font-size:3.125rem}.aS_lj{font-size:4.25rem}.aS_lk{line-height:.75rem}.aS_ll{line-height:.8125rem}.aS_lm{line-height:.875rem}.aS_ln{line-height:1.25rem}.aS_lo{line-height:1rem}.aS_lp{line-height:1.75rem}.aS_lq{line-height:1.5rem}.aS_lr{line-height:1.375rem}.aS_ls{line-height:1.625rem}.aS_lt{line-height:1.875rem}.aS_lu{line-height:2rem}.aS_lv{line-height:2.25rem}.aS_lw{line-height:2.125rem}.aS_lx{line-height:2.375rem}.aS_ly{line-height:2.75rem}.aS_lz{line-height:2.875rem}.aS_lA{line-height:3.75rem}.aS_lB{line-height:5.125rem}.aS_lC{font-weight:400}.aS_lD{font-weight:700}.aS_lE{font-style:italic}}.k_g{color:var(--sa-text-color-1);text-align:center}@media(min-width:768px){.k_g{width:590px}}.k_D{max-width:420px}.k_E{word-break:break-all}.k_H{text-align:center}@media(min-width:768px){.k_I{margin-top:36px}}.E_fc{padding:0!important}[data-color-scheme=dark] .E_fc:not([data-skip-color-scheme]){--sa-modal-container-bg-color:var(--white-100)}.E_fc>header{pointer-events:none;position:absolute;width:100%}.E_fd{fill:var(--black-35)}.E_fd:hover{fill:var(--black-50)}.d_m{background-color:var(--red-100);border-radius:50%;bottom:20px;flex-shrink:0;height:30px;position:fixed;right:20px;width:30px;z-index:1070}.t_eB{display:none}.t_eC{display:inline}.t_eD{display:block}.t_eE{display:inline-block}.g_p{align-items:center;background:var(--black-100-alpha-80);justify-content:center;left:0;overflow:hidden;position:fixed;top:0;z-index:1060}.g_g,.g_p{height:100%;width:100%}.g_g{--env-safe-area-inset-left:env(safe-area-inset-left);--env-safe-area-inset-right:env(safe-area-inset-right);--env-safe-area-inset-top:env(safe-area-inset-top);--env-safe-area-inset-bottom:env(safe-area-inset-bottom);background:var(--white-100);margin-left:auto;margin-right:auto;padding-left:18px;padding-right:18px}@supports(padding:max(0px)){.g_g{padding-left:max(18px,var(--env-safe-area-inset-left,0));padding-right:max(18px,var(--env-safe-area-inset-right,0))}}.g_g:before{content:" ";display:block;flex-shrink:0;height:0;width:100%}@supports(height:max(0px)){.g_g:before{height:var(--env-safe-area-inset-top,0)}}@media(min-width:768px){.g_g{height:500px;width:400px}}.g_f{min-height:424px}.px-captcha-visible{display:flex}.c_g{bottom:-56px;height:56px;left:0;opacity:0;position:fixed;right:0;z-index:1070}.c_h{background-color:var(--black-100);border:1px solid var(--black-10);border-radius:28px;color:var(--white-100);font-size:.875rem;font-weight:700;min-width:252px;text-align:center}@media(min-width:1024px){.c_h{min-width:172px}}[data-color-scheme=dark] .c_h:not([data-skip-color-scheme]){background-color:var(--black-10);border-color:var(--black-10);color:var(--black-100)}.c_i{background:var(--red-100-alpha-75)}.c_j{background:var(--teal-100-alpha-75)}@keyframes c_l{0%{bottom:-56px;opacity:0}10%{bottom:26px;opacity:1}90%{bottom:26px;opacity:1}to{bottom:-56px;opacity:0}}.c_k{animation-name:c_l;animation-timing-function:linear}@media screen and (prefers-reduced-motion:reduce){.c_k{animation:none}}.bh_l4{overflow:hidden;text-overflow:ellipsis}.p_g{background-color:var(--orange-60)}.p_a{height:44px}@media(min-width:1024px){.p_a{height:30px}}.p_G{font-size:.875rem;font-weight:700;white-space:nowrap}.p_G,.p_G:focus,.p_G:hover,.p_G:visited{color:var(--white-100);text-decoration:none}.p_G:focus,.p_G:hover{text-decoration:underline}.p_U{height:25px;opacity:.7;position:relative;width:25px}.p_U:focus,.p_U:hover{cursor:pointer;opacity:1}.p_U:after,.p_U:before{background-color:var(--white-100);content:" ";height:25px;left:12.5px;position:absolute;top:0;width:1px}.p_U:before{transform:rotate(45deg)}.p_U:after{transform:rotate(-45deg)}.m_h{min-height:30px;position:relative}.m_N{height:100%;position:absolute;right:0;top:0}.m_O{height:-webkit-fit-content;height:-moz-fit-content;height:fit-content}.m_O:active,.m_O:focus,.m_O:hover{background-color:var(--black-100-alpha-10)}.m_O:active,.m_O:focus{background-color:#0000}.I_fw{--sa-button-size:1.5rem;--sa-button-height:var(--sa-button-size);--sa-button-y-padding:0.0625rem;--sa-button-x-padding:0.75rem;--sa-btn-icon-size:0.875rem;--sa-btn-icon-margin:0.5rem;border:1px solid var(--sa-button-border-color,#0000)}.I_fw.I_fx{--sa-btn-icon-margin:0rem;--sa-button-y-padding:4px;--sa-button-x-padding:4px}.I_fy{--sa-button-size:1.75rem;--sa-button-height:var(--sa-button-size);--sa-button-y-padding:0.0625rem;--sa-button-x-padding:0.75rem;--sa-btn-icon-size:0.875rem;--sa-btn-icon-margin:0.5rem;border:1px solid var(--sa-button-border-color,#0000)}.I_fy.I_fx{--sa-btn-icon-margin:0rem;--sa-button-y-padding:6px;--sa-button-x-padding:6px}.I_fz{--sa-button-size:2.25rem;--sa-button-height:var(--sa-button-size);--sa-button-y-padding:0.0625rem;--sa-button-x-padding:0.75rem;--sa-btn-icon-size:1.5rem;--sa-btn-icon-margin:0.5rem;border:1px solid var(--sa-button-border-color,#0000)}.I_fz.I_fx{--sa-btn-icon-margin:0rem;--sa-button-y-padding:5px;--sa-button-x-padding:5px}.I_fA{--sa-button-size:2.75rem;--sa-button-height:var(--sa-button-size);--sa-button-y-padding:0.0625rem;--sa-button-x-padding:1.125rem;--sa-btn-icon-size:1.5rem;--sa-btn-icon-margin:0.5rem;border:1px solid var(--sa-button-border-color,#0000)}.I_fA.I_fx{--sa-btn-icon-margin:0rem;--sa-button-y-padding:5px;--sa-button-x-padding:5px;min-width:var(--sa-button-size)}.I_fB{--sa-button-size:3.375rem;--sa-button-height:var(--sa-button-size);--sa-button-y-padding:0.0625rem;--sa-button-x-padding:1.125rem;--sa-btn-icon-size:1.5rem;--sa-btn-icon-margin:0.5rem;border:1px solid var(--sa-button-border-color,#0000)}.I_fB.I_fx{--sa-btn-icon-margin:0rem;--sa-button-y-padding:10px;--sa-button-x-padding:10px}@media(min-width:768px){.I_fC{--sa-button-size:1.5rem;--sa-button-height:var(--sa-button-size);--sa-button-y-padding:0.0625rem;--sa-button-x-padding:0.75rem;--sa-btn-icon-size:0.875rem;--sa-btn-icon-margin:0.5rem;border:1px solid var(--sa-button-border-color,#0000)}.I_fC.I_fx{--sa-btn-icon-margin:0rem;--sa-button-y-padding:4px;--sa-button-x-padding:4px}}@media(min-width:768px){.I_fD{--sa-button-size:1.75rem;--sa-button-height:var(--sa-button-size);--sa-button-y-padding:0.0625rem;--sa-button-x-padding:0.75rem;--sa-btn-icon-size:0.875rem;--sa-btn-icon-margin:0.5rem;border:1px solid var(--sa-button-border-color,#0000)}.I_fD.I_fx{--sa-btn-icon-margin:0rem;--sa-button-y-padding:6px;--sa-button-x-padding:6px}}@media(min-width:768px){.I_fE{--sa-button-size:2.25rem;--sa-button-height:var(--sa-button-size);--sa-button-y-padding:0.0625rem;--sa-button-x-padding:0.75rem;--sa-btn-icon-size:1.5rem;--sa-btn-icon-margin:0.5rem;border:1px solid var(--sa-button-border-color,#0000)}.I_fE.I_fx{--sa-btn-icon-margin:0rem;--sa-button-y-padding:5px;--sa-button-x-padding:5px}}@media(min-width:768px){.I_fF{--sa-button-size:2.75rem;--sa-button-height:var(--sa-button-size);--sa-button-y-padding:0.0625rem;--sa-button-x-padding:1.125rem;--sa-btn-icon-size:1.5rem;--sa-btn-icon-margin:0.5rem;border:1px solid var(--sa-button-border-color,#0000)}.I_fF.I_fx{--sa-btn-icon-margin:0rem;--sa-button-y-padding:5px;--sa-button-x-padding:5px;min-width:var(--sa-button-size)}}@media(min-width:768px){.I_fG{--sa-button-size:3.375rem;--sa-button-height:var(--sa-button-size);--sa-button-y-padding:0.0625rem;--sa-button-x-padding:1.125rem;--sa-btn-icon-size:1.5rem;--sa-btn-icon-margin:0.5rem;border:1px solid var(--sa-button-border-color,#0000)}.I_fG.I_fx{--sa-btn-icon-margin:0rem;--sa-button-y-padding:10px;--sa-button-x-padding:10px}}@media(min-width:1024px){.I_fH{--sa-button-size:1.5rem;--sa-button-height:var(--sa-button-size);--sa-button-y-padding:0.0625rem;--sa-button-x-padding:0.75rem;--sa-btn-icon-size:0.875rem;--sa-btn-icon-margin:0.5rem;border:1px solid var(--sa-button-border-color,#0000)}.I_fH.I_fx{--sa-btn-icon-margin:0rem;--sa-button-y-padding:4px;--sa-button-x-padding:4px}}@media(min-width:1024px){.I_fI{--sa-button-size:1.75rem;--sa-button-height:var(--sa-button-size);--sa-button-y-padding:0.0625rem;--sa-button-x-padding:0.75rem;--sa-btn-icon-size:0.875rem;--sa-btn-icon-margin:0.5rem;border:1px solid var(--sa-button-border-color,#0000)}.I_fI.I_fx{--sa-btn-icon-margin:0rem;--sa-button-y-padding:6px;--sa-button-x-padding:6px}}@media(min-width:1024px){.I_fJ{--sa-button-size:2.25rem;--sa-button-height:var(--sa-button-size);--sa-button-y-padding:0.0625rem;--sa-button-x-padding:0.75rem;--sa-btn-icon-size:1.5rem;--sa-btn-icon-margin:0.5rem;border:1px solid var(--sa-button-border-color,#0000)}.I_fJ.I_fx{--sa-btn-icon-margin:0rem;--sa-button-y-padding:5px;--sa-button-x-padding:5px}}@media(min-width:1024px){.I_fK{--sa-button-size:2.75rem;--sa-button-height:var(--sa-button-size);--sa-button-y-padding:0.0625rem;--sa-button-x-padding:1.125rem;--sa-btn-icon-size:1.5rem;--sa-btn-icon-margin:0.5rem;border:1px solid var(--sa-button-border-color,#0000)}.I_fK.I_fx{--sa-btn-icon-margin:0rem;--sa-button-y-padding:5px;--sa-button-x-padding:5px;min-width:var(--sa-button-size)}}@media(min-width:1024px){.I_fL{--sa-button-size:3.375rem;--sa-button-height:var(--sa-button-size);--sa-button-y-padding:0.0625rem;--sa-button-x-padding:1.125rem;--sa-btn-icon-size:1.5rem;--sa-btn-icon-margin:0.5rem;border:1px solid var(--sa-button-border-color,#0000)}.I_fL.I_fx{--sa-btn-icon-margin:0rem;--sa-button-y-padding:10px;--sa-button-x-padding:10px}}@media(min-width:1200px){.I_fM{--sa-button-size:3.375rem;--sa-button-height:var(--sa-button-size);--sa-button-y-padding:0.0625rem;--sa-button-x-padding:1.125rem;--sa-btn-icon-size:1.5rem;--sa-btn-icon-margin:0.5rem;border:1px solid var(--sa-button-border-color,#0000)}.I_fM.I_fx{--sa-btn-icon-margin:0rem;--sa-button-y-padding:10px;--sa-button-x-padding:10px}}.I_fN{--sa-button-size:3rem;--sa-button-border-width:2px;--sa-button-height:var(--sa-button-size);--sa-button-y-padding:0.625rem;--sa-button-x-padding:1.375rem;--sa-btn-icon-size:1.5rem;--sa-btn-icon-margin:0.375rem;border:var(--sa-button-border-width) solid var(--sa-button-border-color,#0000)}.I_fN.I_fx{--sa-btn-icon-margin:0rem;--sa-button-x-padding:0.625rem}.I_fN:active{--sa-button-border-color:#0000}.I_fO{--sa-button-size:2.25rem;--sa-button-border-width:2px;--sa-button-height:var(--sa-button-size);--sa-button-y-padding:0.25rem;--sa-button-x-padding:0.25rem;--sa-btn-icon-size:1.5rem;--sa-btn-icon-margin:0.375rem;border:var(--sa-button-border-width) solid var(--sa-button-border-color)}.I_fO.I_fx{--sa-btn-icon-margin:0rem}.I_fO:active{--sa-button-border-color:#0000}.I_fP{--sa-button-background-color:var(--black-100);--sa-button-color:var(--white-100);--sa-button-border-radius:4px;--sa-btn-icon-color:currentColor;--sa-button-border-color:var(--sa-button-background-color)}.I_fP:active,.I_fP:hover{--sa-button-background-color:var(--black-70)}.I_fP.I_fQ,.I_fP:disabled{--sa-button-background-color:var(--black-20)}[data-color-scheme=dark] .I_fP:not([data-skip-color-scheme]){--sa-button-background-color:var(--black-10);--sa-button-color:var(--black-100)}[data-color-scheme=dark] .I_fP:not([data-skip-color-scheme]):hover{--sa-button-background-color:var(--black-30);--sa-button-border-color:var(--black-70)}[data-color-scheme=dark] .I_fP:not([data-skip-color-scheme]):active{--sa-button-background-color:var(--black-10);--sa-button-border-color:var(--black-10)}[data-color-scheme=dark] .I_fP:not([data-skip-color-scheme]).I_fQ,[data-color-scheme=dark] .I_fP:not([data-skip-color-scheme]):disabled{--sa-button-background-color:var(--black-30)}.I_fR{--sa-button-background-color:#0000;--sa-button-color:var(--black-100);--sa-button-border-color:var(--black-100);--sa-button-border-radius:4px;--sa-btn-icon-color:currentColor}.I_fR:active,.I_fR:hover{--sa-button-color:var(--white-100);--sa-button-background-color:var(--black-100)}.I_fR.I_fQ,.I_fR:disabled{--sa-button-background-color:#0000;--sa-button-color:var(--black-100);opacity:.6}[data-color-scheme=dark] .I_fR:not([data-skip-color-scheme]){--sa-button-color:var(--black-10);--sa-button-border-color:var(--black-10)}[data-color-scheme=dark] .I_fR:not([data-skip-color-scheme]):hover{--sa-button-background-color:#0000;--sa-button-color:var(--black-30);--sa-button-border-color:var(--black-30)}[data-color-scheme=dark] .I_fR:not([data-skip-color-scheme]):active{--sa-button-border-color:var(--black-30);--sa-button-background-color:var(--black-30);--sa-button-color:var(--black-100)}.I_fS{--sa-button-background-color:var(--teal-100);--sa-button-color:var(--white-100);--sa-button-border-radius:4px;--sa-btn-icon-color:currentColor;--sa-button-border-color:var(--sa-button-background-color)}.I_fS:active,.I_fS:hover{--sa-button-background-color:var(--green-90)}.I_fS .I_fQ,.I_fS:disabled{--sa-button-background-color:var(--teal-100);opacity:.6}.I_fT{--sa-button-background-color:var(--red-100);--sa-button-color:var(--white-100);--sa-button-border-radius:4px;--sa-btn-icon-color:currentColor;--sa-button-border-color:var(--sa-button-background-color)}.I_fT:active,.I_fT:hover{--sa-button-background-color:var(--orange-100)}.I_fT .I_fQ,.I_fT:disabled{--sa-button-background-color:var(--black-20)}[data-color-scheme=dark] .I_fT:not([data-skip-color-scheme]){--sa-button-background-color:var(--red-80);--sa-button-color:var(--black-100)}[data-color-scheme=dark] .I_fT:not([data-skip-color-scheme]):active,[data-color-scheme=dark] .I_fT:not([data-skip-color-scheme]):hover{--sa-button-background-color:var(--orange-100)}[data-color-scheme=dark] .I_fT:not([data-skip-color-scheme]) .I_fQ,[data-color-scheme=dark] .I_fT:not([data-skip-color-scheme]):disabled{--sa-button-background-color:var(--black-30)}.I_fU{--sa-button-background-color:#0000;--sa-button-color:var(--red-100);--sa-button-border-color:var(--red-100);--sa-button-border-radius:4px;--sa-btn-icon-color:currentColor}.I_fU:active,.I_fU:hover{--sa-button-color:var(--white-100);--sa-button-background-color:var(--red-100)}.I_fU .I_fQ,.I_fU:disabled{--sa-button-background-color:#0000;--sa-button-color:var(--red-100);opacity:.6}.I_fV{--sa-button-background-color:var(--orange-60);--sa-button-color:var(--white-100);--sa-button-border-radius:4px;--sa-btn-icon-color:currentColor;--sa-button-border-color:var(--sa-button-background-color)}.I_fV:active,.I_fV:hover{--sa-button-background-color:var(--orange-70)}.I_fV .I_fQ,.I_fV:disabled{--sa-button-background-color:var(--black-20)}[data-color-scheme=dark] .I_fV:not([data-skip-color-scheme]){--sa-button-background-color:var(--orange-60);--sa-button-color:var(--black-100)}[data-color-scheme=dark] .I_fV:not([data-skip-color-scheme]):active,[data-color-scheme=dark] .I_fV:not([data-skip-color-scheme]):hover{--sa-button-background-color:var(--orange-70)}[data-color-scheme=dark] .I_fV:not([data-skip-color-scheme]) .I_fQ,[data-color-scheme=dark] .I_fV:not([data-skip-color-scheme]):disabled{--sa-button-background-color:var(--black-30)}.I_fW{--sa-button-background-color:#0000;--sa-button-color:var(--orange-60);--sa-button-border-color:var(--orange-60);--sa-button-border-radius:4px;--sa-btn-icon-color:currentColor}.I_fW:active,.I_fW:hover{--sa-button-color:var(--white-100);--sa-button-background-color:var(--orange-70);--sa-button-border-color:var(--orange-70)}.I_fW .I_fQ,.I_fW:disabled{--sa-button-background-color:#0000;--sa-button-color:var(--orange-60);--sa-button-border-color:var(--orange-60);opacity:.6}.I_fX{--sa-button-background-color:var(--black-5);--sa-button-color:var(--black-70);--sa-button-border-radius:4px;--sa-btn-icon-color:currentColor;--sa-button-border-color:var(--sa-button-background-color)}.I_fX:active,.I_fX:hover{--sa-button-background-color:var(--black-10)}.I_fX .I_fQ,.I_fX:disabled{--sa-button-background-color:var(--black-20)}[data-color-scheme=dark] .I_fX:not([data-skip-color-scheme]){--sa-button-background-color:var(--black-95);--sa-button-border-color:var(--black-80);--sa-button-color:var(--black-30)}[data-color-scheme=dark] .I_fX:not([data-skip-color-scheme]):active,[data-color-scheme=dark] .I_fX:not([data-skip-color-scheme]):hover{--sa-button-background-color:var(--black-80)}[data-color-scheme=dark] .I_fX:not([data-skip-color-scheme]) .I_fQ,[data-color-scheme=dark] .I_fX:not([data-skip-color-scheme]):disabled{--sa-button-background-color:var(--black-30)}.I_fY{--sa-button-background-color:#0000;--sa-button-color:var(--black-50);--sa-button-border-color:var(--black-10);--sa-button-border-radius:4px;--sa-btn-icon-color:currentColor}.I_fY:active,.I_fY:hover{--sa-button-background-color:var(--black-5)}.I_fY .I_fQ,.I_fY:disabled{--sa-button-background-color:#0000;opacity:.6}[data-color-scheme=dark] .I_fY:not([data-skip-color-scheme]){--sa-button-background-color:var(--black-95);--sa-button-color:var(--black-30);--sa-button-border-color:var(--black-80)}[data-color-scheme=dark] .I_fY:not([data-skip-color-scheme]):active,[data-color-scheme=dark] .I_fY:not([data-skip-color-scheme]):hover{--sa-button-background-color:var(--black-80)}[data-color-scheme=dark] .I_fY:not([data-skip-color-scheme]) .I_fQ,[data-color-scheme=dark] .I_fY:not([data-skip-color-scheme]):disabled{--sa-button-background-color:var(--black-95);opacity:.6}.I_fZ{--sa-button-background-color:var(--black-5);--sa-button-color:var(--sa-link-color);--sa-button-border-radius:4px;--sa-btn-icon-color:currentColor;--sa-button-border-color:var(--sa-button-background-color)}.I_fZ:active,.I_fZ:hover{--sa-button-background-color:var(--black-10)}.I_fZ .I_fQ,.I_fZ:disabled{--sa-button-background-color:var(--black-5);opacity:.6}[data-color-scheme=dark] .I_fZ:not([data-skip-color-scheme]){--sa-button-background-color:var(--black-30-alpha-20);--sa-button-color:var(--blue-70)}[data-color-scheme=dark] .I_fZ:not([data-skip-color-scheme]):active,[data-color-scheme=dark] .I_fZ:not([data-skip-color-scheme]):hover{--sa-button-background-color:var(--black-30-alpha-30)}[data-color-scheme=dark] .I_fZ:not([data-skip-color-scheme]) .I_fQ,[data-color-scheme=dark] .I_fZ:not([data-skip-color-scheme]):disabled{--sa-button-background-color:var(--black-30)}.I_f0{--sa-button-background-color:var(--black-10);--sa-button-color:var(--black-50);--sa-button-border-radius:4px;--sa-btn-icon-color:currentColor;--sa-button-border-color:var(--sa-button-background-color)}.I_f0:active,.I_f0:hover{--sa-button-color:var(--white-100);--sa-button-background-color:var(--black-70)}.I_f0 .I_fQ,.I_f0:disabled{--sa-button-color:var(--black-20);--sa-button-background-color:var(--black-10)}[data-color-scheme=dark] .I_f0:not([data-skip-color-scheme]){--sa-button-background-color:var(--black-90);--sa-button-color:var(--black-10)}[data-color-scheme=dark] .I_f0:not([data-skip-color-scheme]):active,[data-color-scheme=dark] .I_f0:not([data-skip-color-scheme]):hover{--sa-button-background-color:var(--black-30);--sa-button-border-color:var(--black-30);--sa-button-color:var(--black-100)}[data-color-scheme=dark] .I_f0:not([data-skip-color-scheme]) .I_fQ,[data-color-scheme=dark] .I_f0:not([data-skip-color-scheme]):disabled{--sa-button-background-color:var(--black-30-alpha-20)}.I_f1{--sa-button-background-color:#0000;--sa-button-color:var(--black-50);--sa-button-border-color:var(--black-10);--sa-button-border-radius:4px;--sa-btn-icon-color:currentColor}.I_f1:active,.I_f1:hover{--sa-button-background-color:var(--black-70);--sa-button-border-color:var(--black-70);--sa-button-color:var(--white-100)}.I_f1 .I_fQ,.I_f1:disabled{--sa-button-background-color:#0000;--sa-button-color:var(--black-95);--sa-button-border-color:var(--black-10);opacity:.6}[data-color-scheme=dark] .I_f1:not([data-skip-color-scheme]){--sa-button-background-color:#0000;--sa-button-color:var(--black-30);--sa-button-border-color:var(--black-80)}[data-color-scheme=dark] .I_f1:not([data-skip-color-scheme]):active,[data-color-scheme=dark] .I_f1:not([data-skip-color-scheme]):hover{--sa-button-background-color:var(--black-30);--sa-button-border-color:var(--black-30);--sa-button-color:var(--black-100)}[data-color-scheme=dark] .I_f1:not([data-skip-color-scheme]) .I_fQ,[data-color-scheme=dark] .I_f1:not([data-skip-color-scheme]):disabled{--sa-button-background-color:#0000;--sa-button-color:var(--black-30);--sa-button-border-color:var(--black-80);opacity:.6}.I_f2{--sa-button-background-color:var(--blue-75);--sa-button-color:var(--white-100);--sa-button-border-radius:4px;--sa-btn-icon-color:currentColor;--sa-button-border-color:var(--sa-button-background-color)}.I_f2:active,.I_f2:hover{--sa-button-background-color:var(--blue-80)}.I_f2 .I_fQ,.I_f2:disabled{--sa-button-background-color:var(--blue-75);opacity:.6}[data-color-scheme=dark] .I_f2:not([data-skip-color-scheme]){--sa-button-background-color:var(--blue-75);--sa-button-color:var(--black-100)}[data-color-scheme=dark] .I_f2:not([data-skip-color-scheme]):active,[data-color-scheme=dark] .I_f2:not([data-skip-color-scheme]):hover{--sa-button-background-color:var(--blue-80)}[data-color-scheme=dark] .I_f2:not([data-skip-color-scheme]) .I_fQ,[data-color-scheme=dark] .I_f2:not([data-skip-color-scheme]):disabled{--sa-button-background-color:var(--black-30)}.I_f3{--sa-button-background-color:#0000;--sa-button-color:var(--blue-75);--sa-button-border-color:var(--blue-75);--sa-button-border-radius:4px;--sa-btn-icon-color:currentColor}.I_f3:active,.I_f3:hover{--sa-button-background-color:var(--blue-75);--sa-button-color:var(--white-100)}.I_f3 .I_fQ,.I_f3:disabled{--sa-button-background-color:#0000;--sa-button-color:var(--blue-75);opacity:.6}.I_f4{--sa-button-background-color:var(--yellow-85);--sa-button-color:var(--white-100);--sa-button-border-radius:4px;--sa-btn-icon-color:currentColor;--sa-button-border-color:var(--sa-button-background-color)}.I_f4:active,.I_f4:hover{--sa-button-background-color:var(--yellow-100)}.I_f4 .I_fQ,.I_f4:disabled{--sa-button-background-color:var(--yellow-85);opacity:.6}[data-color-scheme=dark] .I_f4:not([data-skip-color-scheme]){--sa-button-color:var(--black-100)}[data-color-scheme=dark] .I_f4:not([data-skip-color-scheme]) .I_fQ,[data-color-scheme=dark] .I_f4:not([data-skip-color-scheme]):disabled{--sa-button-background-color:var(--black-30)}.I_f5{--sa-button-background-color:var(--blue-80);--sa-button-color:var(--white-100);--sa-button-border-radius:4px;--sa-btn-icon-color:currentColor;--sa-button-border-color:var(--sa-button-background-color)}.I_f5:active,.I_f5:hover{--sa-button-background-color:var(--blue-100);--sa-button-border-color:var(--blue-80)}.I_f5 .I_fQ,.I_f5:disabled{--sa-button-background-color:var(--blue-80);opacity:.6}.I_f6{--sa-button-background-color:#0000;--sa-button-color:var(--blue-80);--sa-button-border-color:var(--blue-80);--sa-button-border-radius:4px;--sa-btn-icon-color:currentColor}.I_f6:active,.I_f6:hover{--sa-button-background-color:var(--blue-100);--sa-button-color:var(--white-100)}.I_f6 .I_fQ,.I_f6:disabled{--sa-button-background-color:#0000;--sa-button-color:var(--blue-80);opacity:.6}.I_f7{--sa-button-background-color:var(--black-35);--sa-button-color:var(--white-100);--sa-button-border-radius:4px;--sa-btn-icon-color:currentColor;--sa-button-border-color:var(--sa-button-background-color)}.I_f7:active,.I_f7:hover{--sa-button-background-color:var(--black-50)}.I_f7 .I_fQ,.I_f7:disabled{--sa-button-background-color:var(--black-35);opacity:.6}[data-color-scheme=dark] .I_f7:not([data-skip-color-scheme]){--sa-button-background-color:var(--black-30);--sa-button-color:var(--black-100)}[data-color-scheme=dark] .I_f7:not([data-skip-color-scheme]):active,[data-color-scheme=dark] .I_f7:not([data-skip-color-scheme]):hover{--sa-button-background-color:var(--black-10)}[data-color-scheme=dark] .I_f7:not([data-skip-color-scheme]):active{--sa-button-border-color:var(--black-50)}[data-color-scheme=dark] .I_f7:not([data-skip-color-scheme]) .I_fQ,[data-color-scheme=dark] .I_f7:not([data-skip-color-scheme]):disabled{--sa-button-background-color:var(--black-30)}.I_f8{--sa-button-background-color:#0000;--sa-button-color:var(--black-35);--sa-button-border-color:var(--black-35);--sa-button-border-radius:4px;--sa-btn-icon-color:currentColor}.I_f8:active,.I_f8:hover{--sa-button-background-color:var(--black-50);--sa-button-border-color:var(--black-50);--sa-button-color:var(--white-100)}.I_f8 .I_fQ,.I_f8:disabled{--sa-button-background-color:#0000;--sa-button-border-color:var(--black-35);--sa-button-color:var(--black-35);opacity:.6}.I_f9{--sa-button-background-color:var(--black-5);--sa-button-color:var(--black-50);--sa-button-border-radius:4px;--sa-btn-icon-color:currentColor;--sa-button-border-color:var(--sa-button-background-color)}.I_f9:active,.I_f9:hover{--sa-button-background-color:var(--black-10);--sa-button-color:var(--black-70)}.I_f9 .I_fQ,.I_f9:disabled{--sa-button-background-color:var(--black-5);--sa-button-color:var(--black-50);opacity:.6}[data-color-scheme=dark] .I_f9:not([data-skip-color-scheme]){--sa-button-background-color:var(--black-80);--sa-button-color:var(--black-30)}[data-color-scheme=dark] .I_f9:not([data-skip-color-scheme]):active,[data-color-scheme=dark] .I_f9:not([data-skip-color-scheme]):hover{--sa-button-background-color:var(--black-90);--sa-button-color:var(--black-10)}[data-color-scheme=dark] .I_f9:not([data-skip-color-scheme]) .I_fQ,[data-color-scheme=dark] .I_f9:not([data-skip-color-scheme]):disabled{--sa-button-background-color:var(--black-30);--sa-button-color:var(--black-30)}.I_ga{--sa-button-background-color:#0000;--sa-button-color:var(--black-70);--sa-button-border-color:var(--black-50);--sa-button-border-radius:4px;--sa-btn-icon-color:currentColor}.I_ga:active,.I_ga:hover{--sa-button-background-color:var(--black-50);--sa-button-color:var(--white-100)}.I_ga .I_fQ,.I_ga:disabled{--sa-button-background-color:#0000;--sa-button-color:var(--black-70);opacity:.6}.I_G{--sa-button-color:var(--sa-link-color);display:inline}.I_G:active,.I_G:focus,.I_G:hover{text-decoration:underline}.I_gb{--sa-button-background-color:var(--orange-60);--sa-button-color:var(--white-100);--sa-button-border-radius:0;--sa-btn-icon-color:currentColor;text-transform:uppercase}.I_gb:active,.I_gb:hover{--sa-button-background-color:var(--orange-70)}.I_gb:not(:active){--sa-button-border-color:var(--sa-button-background-color)}.I_gb .I_fQ,.I_gb:disabled{--sa-button-background-color:var(--black-20-v2);--sa-button-color:var(--black-60-v2)}.I_gc{--sa-button-background-color:var(--navy-80-v2);--sa-button-color:var(--white-100);--sa-button-border-radius:0;--sa-btn-icon-color:currentColor;text-transform:uppercase}.I_gc:active,.I_gc:hover{--sa-button-background-color:var(--navy-75-v2)}.I_gc:not(:active){--sa-button-border-color:var(--sa-button-background-color)}.I_gc .I_fQ,.I_gc:disabled{--sa-button-background-color:var(--black-25-v2);--sa-button-color:var(--black-70-v2)}[data-color-scheme=dark] .I_gc:not([data-skip-color-scheme]){--sa-button-background-color:var(--navy-100-v2);--sa-button-color:var(--white-100)}[data-color-scheme=dark] .I_gc:not([data-skip-color-scheme]):active,[data-color-scheme=dark] .I_gc:not([data-skip-color-scheme]):hover{--sa-button-background-color:var(--navy-95-v2)}[data-color-scheme=dark] .I_gc:not([data-skip-color-scheme]) .I_fQ,[data-color-scheme=dark] .I_gc:not([data-skip-color-scheme]):disabled{--sa-button-background-color:var(--black-25-v2);--sa-button-color:var(--black-70-v2)}.I_gd{--sa-button-background-color:var(--navy-100-v2);--sa-button-color:var(--white-100);--sa-button-border-radius:0;--sa-btn-icon-color:currentColor;text-transform:uppercase}.I_gd:active,.I_gd:hover{--sa-button-background-color:var(--navy-95-v2)}.I_gd:not(:active){--sa-button-border-color:var(--sa-button-background-color)}.I_gd .I_fQ,.I_gd:disabled{--sa-button-background-color:var(--black-20-v2);--sa-button-color:var(--black-60-v2)}[data-color-scheme=dark] .I_gd:not([data-skip-color-scheme]){--sa-button-background-color:var(--black-70-v2);--sa-button-color:var(--black-20-v2)}[data-color-scheme=dark] .I_gd:not([data-skip-color-scheme]):active,[data-color-scheme=dark] .I_gd:not([data-skip-color-scheme]):hover{--sa-button-background-color:var(--black-65-v2)}[data-color-scheme=dark] .I_gd:not([data-skip-color-scheme]) .I_fQ,[data-color-scheme=dark] .I_gd:not([data-skip-color-scheme]):disabled{--sa-button-background-color:var(--black-25-v2);--sa-button-color:var(--black-70-v2)}.I_ge{--sa-button-background-color:var(--black-20-v2);--sa-button-color:var(--navy-80-v2);--sa-button-border-radius:0;--sa-btn-icon-color:currentColor;text-transform:uppercase}.I_ge:not(:active){--sa-button-border-color:var(--sa-button-background-color)}.I_ge:active,.I_ge:hover{--sa-button-background-color:var(--black-15-v2);--sa-button-color:var(--navy-80-v2)}.I_ge .I_fQ,.I_ge:disabled{--sa-button-background-color:var(--black-20-v2);--sa-button-color:var(--black-25-v2)}[data-color-scheme=dark] .I_ge:not([data-skip-color-scheme]){--sa-button-background-color:var(--black-70-v2);--sa-button-color:var(--black-25-v2)}[data-color-scheme=dark] .I_ge:not([data-skip-color-scheme]):active,[data-color-scheme=dark] .I_ge:not([data-skip-color-scheme]):hover{--sa-button-background-color:var(--black-65-v2)}[data-color-scheme=dark] .I_ge:not([data-skip-color-scheme]) .I_fQ,[data-color-scheme=dark] .I_ge:not([data-skip-color-scheme]):disabled{--sa-button-background-color:var(--black-25-v2);--sa-button-color:var(--black-70-v2)}.I_gf{--sa-button-background-color:var(--navy-80-v2);--sa-button-color:var(--white-100);--sa-button-border-radius:0;--sa-btn-icon-color:currentColor;text-transform:uppercase}.I_gf:active,.I_gf:hover{--sa-button-background-color:var(--navy-75-v2)}.I_gf:not(:active){--sa-button-border-color:var(--sa-button-background-color)}.I_gf .I_fQ,.I_gf:disabled{--sa-button-background-color:var(--black-25-v2);--sa-button-color:var(--black-70-v2)}[data-color-scheme=dark] .I_gf:not([data-skip-color-scheme]){--sa-button-background-color:var(--navy-100-v2);--sa-button-color:var(--white-100)}[data-color-scheme=dark] .I_gf:not([data-skip-color-scheme]):active,[data-color-scheme=dark] .I_gf:not([data-skip-color-scheme]):hover{--sa-button-background-color:var(--navy-95-v2)}[data-color-scheme=dark] .I_gf:not([data-skip-color-scheme]) .I_fQ,[data-color-scheme=dark] .I_gf:not([data-skip-color-scheme]):disabled{--sa-button-background-color:var(--black-25-v2);--sa-button-color:var(--black-70-v2)}.I_gg{--sa-button-background-color:var(--black-60-v2);--sa-button-color:var(--white-100);--sa-button-border-radius:0;--sa-btn-icon-color:currentColor;text-transform:uppercase}.I_gg:not(:active){--sa-button-border-color:var(--sa-button-background-color)}.I_gg:active,.I_gg:hover{--sa-button-background-color:var(--black-55-v2)}.I_gg .I_fQ,.I_gg:disabled{--sa-button-background-color:var(--black-25-v2);--sa-button-color:var(--black-60-v2)}[data-color-scheme=dark] .I_gg:not([data-skip-color-scheme]){--sa-button-background-color:var(--black-70-v2);--sa-button-color:var(--black-25-v2)}[data-color-scheme=dark] .I_gg:not([data-skip-color-scheme]):active,[data-color-scheme=dark] .I_gg:not([data-skip-color-scheme]):hover{--sa-button-background-color:var(--black-65-v2);--sa-button-color:var(--black-20-v2)}[data-color-scheme=dark] .I_gg:not([data-skip-color-scheme]) .I_fQ,[data-color-scheme=dark] .I_gg:not([data-skip-color-scheme]):disabled{--sa-button-background-color:var(--black-20-v2);--sa-button-color:var(--black-60-v2)}.I_gh{--sa-button-background-color:var(--navy-80-v2);--sa-button-color:var(--white-100);--sa-button-border-radius:0;--sa-btn-icon-color:currentColor;text-transform:uppercase}.I_gh:not(:active){--sa-button-border-color:var(--sa-button-background-color)}.I_gh:active,.I_gh:hover{--sa-button-background-color:var(--navy-75-v2)}.I_gh .I_fQ,.I_gh:disabled{--sa-button-background-color:var(--black-25-v2);--sa-button-color:var(--black-70-v2)}[data-color-scheme=dark] .I_gh:not([data-skip-color-scheme]){--sa-button-background-color:var(--navy-100-v2);--sa-button-color:var(--white-100)}[data-color-scheme=dark] .I_gh:not([data-skip-color-scheme]):active,[data-color-scheme=dark] .I_gh:not([data-skip-color-scheme]):hover{--sa-button-background-color:var(--navy-95-v2)}[data-color-scheme=dark] .I_gh:not([data-skip-color-scheme]) .I_fQ,[data-color-scheme=dark] .I_gh:not([data-skip-color-scheme]):disabled{--sa-button-background-color:var(--black-25-v2);--sa-button-color:var(--black-70-v2)}.I_gi{--sa-button-background-color:var(--white-100);--sa-button-color:var(--black-90-v2);--sa-button-border-radius:0;--sa-btn-icon-color:currentColor;text-transform:uppercase}.I_gi:not(:active){--sa-button-border-color:var(--sa-button-background-color)}.I_gi:active,.I_gi:hover{--sa-button-background-color:var(--black-5-v2)}.I_gi .I_fQ,.I_gi:disabled{--sa-button-background-color:var(--black-20-v2);--sa-button-color:var(--black-60-v2)}[data-color-scheme=dark] .I_gi:not([data-skip-color-scheme]){--sa-button-background-color:var(--black-70-v2);--sa-button-color:var(--black-20-v2)}[data-color-scheme=dark] .I_gi:not([data-skip-color-scheme]):active,[data-color-scheme=dark] .I_gi:not([data-skip-color-scheme]):hover{--sa-button-background-color:var(--black-65-v2)}[data-color-scheme=dark] .I_gi:not([data-skip-color-scheme]) .I_fQ,[data-color-scheme=dark] .I_gi:not([data-skip-color-scheme]):disabled{--sa-button-background-color:var(--black-25-v2);--sa-button-color:var(--black-70-v2)}.I_gj{--sa-button-background-color:var(--navy-80-v2);--sa-button-color:var(--white-100);--sa-button-border-radius:0;--sa-btn-icon-color:currentColor;text-transform:uppercase}.I_gj:active,.I_gj:hover{--sa-button-background-color:var(--navy-75-v2)}.I_gj:not(:active){--sa-button-border-color:var(--sa-button-background-color)}.I_gj .I_fQ,.I_gj:disabled{--sa-button-background-color:var(--black-25-v2);--sa-button-color:var(--black-70-v2)}[data-color-scheme=dark] .I_gj:not([data-skip-color-scheme]){--sa-button-background-color:var(--navy-100-v2);--sa-button-color:var(--white-100)}[data-color-scheme=dark] .I_gj:not([data-skip-color-scheme]):active,[data-color-scheme=dark] .I_gj:not([data-skip-color-scheme]):hover{--sa-button-background-color:var(--navy-95-v2)}[data-color-scheme=dark] .I_gj:not([data-skip-color-scheme]) .I_fQ,[data-color-scheme=dark] .I_gj:not([data-skip-color-scheme]):disabled{--sa-button-background-color:var(--black-25-v2);--sa-button-color:var(--black-70-v2)}.I_0{background-clip:padding-box;background-color:var(--sa-button-background-color);border-radius:var(--sa-button-border-radius);color:var(--sa-button-color);cursor:pointer;min-height:var(--sa-button-height);padding:var(--sa-button-y-padding) var(--sa-button-x-padding);position:relative;transition:color .15s ease-in-out,background-color .15s ease-in-out,border-color .15s ease-in-out,box-shadow .15s ease-in-out;-webkit-user-select:none;user-select:none;white-space:nowrap;word-break:break-word}@media screen and (prefers-reduced-motion:reduce){.I_0{transition:none}}.I_0 svg{transition:fill .15s ease-in-out}@media screen and (prefers-reduced-motion:reduce){.I_0 svg{transition:none}}.I_gk{height:var(--sa-btn-icon-size);width:var(--sa-btn-icon-size)}.I_gk svg{fill:var(--sa-btn-icon-color,currentColor);color:var(--sa-btn-icon-color,inherit);display:block;height:100%;width:100%}.I_gl{margin-right:var(--sa-btn-icon-margin)}.I_gm{margin-left:var(--sa-btn-icon-margin)}.I_fx{--sa-btn-icon-margin:0}.I_gn{clip:rect(0,0,0,0);border:0!important;height:1px!important;left:0!important;overflow:hidden;padding:0!important;position:absolute!important;top:0!important;white-space:nowrap;width:1px!important}.I_go{width:100%}.I_gp{white-space:normal}.I_gq{pointer-events:none;position:relative}.I_gr{opacity:0}.I_gs{left:50%;position:absolute;top:50%;transform:translate(-50%,-50%)}.I_gt{color:var(--sa-btn-spinner-color,var(--sa-btn-color));height:var(--sa-btn-icon-size);width:var(--sa-btn-icon-size)}@keyframes I_eN{0%{transform:rotate(0)}to{transform:rotate(1turn)}}.L_G,.L_G:hover{text-decoration:none}.L_gv,.L_gv:visited{--sa-button-color:var(--sa-link-color)}[data-color-scheme=dark] .n_f:not([data-skip-color-scheme]){--sa-modal-container-bg-color:var(--black-98)}@media(min-width:768px){[data-color-scheme=dark] .n_f:not([data-skip-color-scheme]){--sa-modal-container-bg-color:var(--black-80)}}.H_ft{width:130px}.H_e9{max-height:30px;max-width:130px}.H_e9,[data-color-scheme=dark] .H_e9:not([data-skip-color-scheme]){background:0 0}.u_h{padding-top:0}@media(min-width:1024px){.u_h{height:30px;padding-bottom:0;padding-top:0}}.u_eG{width:768px}@media(min-width:1024px){.u_eG .u_h{height:auto}}.u_eH{max-width:576px;width:100%}@media(min-width:1024px){.u_eH .u_h{height:auto}}.u_eI{background:var(--background)}@media(min-width:576px){.u_eI{text-align:center}}.u_O{color:var(--closeColor);position:relative}.u_O:after{background-color:var(--closeColor);content:"";height:100%;left:0;opacity:0;position:absolute;top:0;transition:opacity .2s ease-in-out;width:100%}.u_O:focus,.u_O:hover{background-color:#0000}.u_O:focus:after,.u_O:hover:after{opacity:.4}[data-color-scheme=dark] .u_O:focus:not([data-skip-color-scheme]),[data-color-scheme=dark] .u_O:hover:not([data-skip-color-scheme]){background-color:#0000}.u_eJ{height:100%;opacity:0;position:absolute;width:100%}@media(min-width:768px){.u_eK{margin-left:18px;margin-right:18px}}.u_eK p{color:var(--black-100);margin-bottom:0}@media(min-width:768px){.u_eK p{text-overflow:ellipsis;white-space:nowrap}}.u_eK a,.u_eK a:focus,.u_eK a:hover,.u_eK a:visited{color:currentColor;text-decoration:inherit}.u_eK a:before{bottom:0;content:"";left:0;position:absolute;right:0;top:0}.i_r{--env-safe-area-inset-top:env(safe-area-inset-top);--env-safe-area-inset-bottom:env(safe-area-inset-bottom);--env-safe-area-inset-left:env(safe-area-inset-left);--env-safe-area-inset-right:env(safe-area-inset-right);padding-bottom:0}@supports(padding:max(0px)){.i_r{padding-bottom:var(--env-safe-area-inset-bottom,0)}}.bE_a{--env-safe-area-inset-top:env(safe-area-inset-top);--env-safe-area-inset-bottom:env(safe-area-inset-bottom);--env-safe-area-inset-left:env(safe-area-inset-left);--env-safe-area-inset-right:env(safe-area-inset-right);margin-left:auto;margin-right:auto;padding-left:18px;padding-right:18px;width:100%}@supports(padding:max(0px)){.bE_a{padding-left:max(18px,var(--env-safe-area-inset-left,0));padding-right:max(18px,var(--env-safe-area-inset-right,0))}}.O_gA{color:var(--sa-text-color-2);font-size:.875rem;line-height:1.75}.bP_mY{list-style:none;margin:0;padding-left:0}.bP_G,.bP_G:focus,.bP_G:hover,.bP_G:visited{color:var(--white-100);text-decoration:none}.bP_G:focus,.bP_G:hover{text-decoration:underline}.T_gQ{background-image:url(/samw/static/images/stock-exchange.6df9b8a9.jpg);background-size:cover;height:100%}.T_gR{background-image:linear-gradient(180deg,#0000,#0000001a 0,#0000001c 0,#000 55%)}.T_f{color:var(--white-100);padding-top:170px}.T_gS{font-size:3rem;line-height:1}.T_gT{font-size:.875rem}.T_gU{color:var(--sa-text-color-3);font-weight:400}.T_gV{height:0;visibility:hidden;width:0}@keyframes a_c{0%{transform:translateY(100%)}to{transform:translateY(0)}}.a_a{bottom:0;left:var(--sa-aside-width,0);position:fixed;right:0;z-index:1030}.a_b{animation:a_c .4s ease-out;height:100%}@media screen and (prefers-reduced-motion:reduce){.a_b{animation:none}}.o_P{background-color:var(--sa-modal-container-bg-color);position:relative;text-align:center;width:320px}@media(min-width:576px){.o_P{padding:32px 36px;width:544px}}@media(min-width:768px){.o_P{width:736px}}@media(min-width:1024px){.o_P{width:800px}}.o_f{white-space:break-spaces}@media(min-width:576px){.o_S{padding:32px 0}}.o_T{border-radius:.25rem;height:44px;width:100%}@media(min-width:576px){.o_T{height:35px;width:160px}}.v_g{color:var(--white-100);text-align:center;width:320px}.v_eM{fill:currentColor;animation:v_eN 1.4s linear infinite;height:62px;width:62px}@media screen and (prefers-reduced-motion:reduce){.v_eM{animation:none}}@keyframes v_eN{to{transform:rotate(1turn)}}.f_g{height:100vh;left:0;min-width:100%;position:fixed;top:0;z-index:1040}.f_f{position:relative;z-index:1050}.f_f,.f_n{height:100%;width:100%}.f_n{background:var(--black-100);left:0;opacity:.6;position:fixed;top:0;z-index:1040}.f_o{overflow:hidden}.hf_fd{flex-shrink:0;height:1.125rem;width:1.125rem}.cT_P{--env-safe-area-inset-top:env(safe-area-inset-top);--env-safe-area-inset-bottom:env(safe-area-inset-bottom);background-color:var(--white-100);box-shadow:0 4px 8px 0 #00000040;color:var(--black-100);pointer-events:auto;position:relative;width:100%}.cT_P:before{content:" ";display:block;flex-shrink:0;height:0;width:100%}@supports(height:max(0px)){.cT_P:before{height:var(--env-safe-area-inset-top,0)}}.cT_o8{height:100%;max-height:none;max-width:none;width:100%}@media(min-width:768px){.cT_o9{border-radius:10px;height:608px;max-width:360px;padding-bottom:44px}}.av_n{opacity:0!important}.ex_eM{fill:var(--black-10);animation:ex_eN 1.4s linear infinite;height:54px;width:55px}@media screen and (prefers-reduced-motion:reduce){.ex_eM{animation:none}}@keyframes ex_eN{to{transform:rotate(1turn)}}.scrollLocked .aB_iS{padding-right:var(--scrollbar-width)}@media print{.aQ_jg{display:none!important}}.bodyNavOpened .j_n{background:var(--black-100);height:100%;left:0;opacity:.6;position:fixed;top:0;width:100%;z-index:1040}.scrollLocked{overflow:hidden!important}.j_a{min-width:0}.j_s a:focus,.j_s a:hover{text-decoration:none}.j_t{padding-top:var(--headerFullHeight)}@media print{.j_t{padding-top:0!important}}.j_u{padding-bottom:var(--sa-mobile-bottom-navigation-height)}@media(min-width:768px){.j_v .j_a{display:flex}}.j_v .tp-backdrop,.j_v .tp-modal{display:none!important}.j_v.tp-modal-open{height:auto}.j_w{--env-safe-area-inset-top:env(safe-area-inset-top);--sa-header-bar-height:calc(50px + var(--env-safe-area-inset-top));--sa-drawer-top-offset:0;min-height:100vh;position:relative}@media(min-width:1024px){.j_w{--sa-header-bar-height:calc(90px + var(--env-safe-area-inset-top));z-index:0}}.j_x{--env-safe-area-inset-top:env(safe-area-inset-top);--env-safe-area-inset-bottom:env(safe-area-inset-bottom);min-height:calc(100vh - var(--sa-header-bar-height));padding-top:var(--headerHeight);position:relative}.j_x:after{content:" ";display:block;flex-shrink:0;height:0;width:100%}@supports(height:max(0px)){.j_x:after{height:var(--env-safe-area-inset-bottom,0)}}@media print{.j_x *{font-family:sans-serif!important}}@media(min-width:1024px){.j_y{padding-top:0}}@media(min-width:768px){.j_z{min-height:18px}}@media(min-width:1024px){.j_z{min-height:40px}}.j_A+.j_z{display:none}.J_gu{min-height:1.875rem}.h_f{box-shadow:0 4px 8px 0 #00000040}@media(min-width:768px){.h_f{max-width:500px;width:100%}}.bi_fu{text-align:left}.bi_l5{text-align:center}.bi_fv{text-align:right}.q_g{background:var(--black-100-alpha-50);height:100%;min-height:100vh;position:fixed;top:0;width:100%;z-index:1050}[data-color-scheme=dark] .q_g:not([data-skip-color-scheme]){background:var(--white-100-alpha-50)}.q_V{border-top:1px solid var(--sa-section-separator-thin-color);font-size:.875rem}.q_W{background:var(--sa-card-bg-color);border-radius:10px;box-sizing:border-box;position:relative;width:330px}.q_Y,.q_Z{text-align:center}.q_Z{word-wrap:break-word;font-size:.875rem}.q_0{border-top:1px solid var(--sa-section-separator-thin-color);bottom:0;color:var(--sa-link-color);font-weight:400}.q_1{width:100%}.q_2{left:0;width:50%}.q_3{border-left:1px solid var(--sa-section-separator-thin-color);right:0;width:50%}.aj_e2,.aj_e2:focus,.aj_e2:hover,.aj_e2:visited{color:inherit;text-decoration:none}.aj_gy{height:26px;width:142px}@media(min-width:375px){.aj_gy{height:30px;width:150px}}.aj_hl{color:var(--orange-60)}.aj_hL{fill:var(--orange-60);color:var(--white-100)}.aj_hM{fill:var(--teal-50)}.aj_hN{fill:var(--yellow-85)}.aj_hO{display:none;width:35px}@media(min-width:768px){.aj_hO{display:block}}.aj_hP{height:26px}@media(min-width:1024px){.aj_hP{height:32px;margin-bottom:2px}}.aj_gi{color:var(--white-100)}.aj_fP{color:var(--sa-text-color-1)}.aj_hQ{clip:rect(0,0,0,0);border:0!important;height:1px!important;left:0!important;overflow:hidden;padding:0!important;position:absolute!important;top:0!important;white-space:nowrap;width:1px!important}.aa_g0{display:none}@media(min-width:375px){.aa_g0{display:block}.aa_g1{display:none}}.aa_g2{display:none}@media(min-width:576px){.aa_g2{display:block}.aa_g3{display:none}}.aa_g4{display:none}@media(min-width:768px){.aa_g4{display:block}.aa_g5{display:none}}.aa_g6{display:none}@media(min-width:1024px){.aa_g6{display:block}.aa_g7{display:none}}.aa_g8{display:none}@media(min-width:1200px){.aa_g8{display:block}.aa_g9{display:none}}.aa_ha{display:none}@media(min-width:1540px){.aa_ha{display:block}.aa_hb{display:none}}.R_gL{height:20px;position:relative;width:18px}.R_gM{background-color:var(--white-100);height:2px;position:absolute;top:calc(50% - 1px);transition:background-color .05s ease-in-out .05s;width:18px}@media screen and (prefers-reduced-motion:reduce){.R_gM{transition:none}}.R_gM:before{background-color:var(--white-100);content:"";display:block;height:2px;position:absolute;transform:translateY(-5px);transition:transform .1s ease-in-out;width:18px}@media screen and (prefers-reduced-motion:reduce){.R_gM:before{transition:none}}.R_gM:after{background-color:var(--white-100);content:"";display:block;height:2px;position:absolute;transform:translateY(calc(100% + 3px));transition:transform .1s ease-in-out;width:18px}@media screen and (prefers-reduced-motion:reduce){.R_gM:after{transition:none}}.R_gN{background-color:var(--white-100-alpha-0);transition:background-color .05s ease-in-out}.R_gN:before{transform:rotate(45deg) translateY(0)}.R_gN:after{transform:rotate(-45deg) translateY(0)}.ah_hI{transform:rotate(90deg)}.dz_nE{background-color:var(--orange-60);border:2px solid var(--sa-notification-badge-border-color,var(--black-70));border-radius:4px;color:var(--sa-notification-badge-color,var(--black-100));font-weight:700;min-width:1.25rem;padding:var(--sa-notification-badge-padding,2px);position:absolute;right:0;top:0;transform:translateX(var(--sa-notification-badge-translateX,50%)) translateY(var(--sa-notification-badge-translateY,-25%))}.dG_fd{height:25px;width:31px}.br_mj{--sa-header-sub-menu-bg:var(--white-100);background-color:var(--sa-header-sub-menu-bg);box-shadow:0 0 5px 2px #00000021;z-index:1060}[data-color-scheme=dark] .br_mj:not([data-skip-color-scheme]){--sa-header-sub-menu-bg:var(--black-80)}.br_mk:hover .br_mj{display:block}.br_ml{background-color:var(--sa-header-sub-menu-bg)}.br_ml,.br_ml:focus,.br_ml:hover,.br_ml:visited{color:var(--sa-header-sub-menu-color);text-decoration:none}.br_ml:focus,.br_ml:hover{--sa-header-sub-menu-bg:var(--blue-80);--sa-header-sub-menu-color:var(--white-100);text-decoration:underline;text-decoration:none}[data-color-scheme=dark] .br_ml:focus:not([data-skip-color-scheme]),[data-color-scheme=dark] .br_ml:hover:not([data-skip-color-scheme]){--sa-header-sub-menu-bg:var(--blue-80);--sa-header-sub-menu-color:var(--black-100)}.ce_nE{background-color:var(--orange-100-v2);border:1px solid var(--sa-notification-badge-border-color,var(--white-100));color:var(--sa-notification-badge-color,var(--white-100));font-size:8px;font-weight:600;left:50%;line-height:8px;min-height:.375rem;min-width:.375rem;padding:var(--sa-notification-badge-padding,1px);position:absolute;top:0}.al_a{height:var(--sa-btn-icon-size,24px);line-height:0;width:var(--sa-btn-icon-size,24px)}.ak_a,.al_a{--sa-notification-badge-color:var(--white-100);--sa-notification-badge-border-color:var(--sa-button-background-color,var(--black-90-v2));position:relative}.bz_gd{--sa-button-background-color:var(--navy-100-v2);--sa-button-color:var(--white-100);--sa-button-border-radius:0;--sa-btn-icon-color:currentColor;text-transform:uppercase}.bz_gd:active,.bz_gd:hover{--sa-button-background-color:var(--navy-95-v2)}.bz_gd:not(:active){--sa-button-border-color:var(--sa-button-background-color)}.bz_gd .bz_fQ,.bz_gd:disabled{--sa-button-background-color:var(--black-20-v2);--sa-button-color:var(--black-60-v2)}[data-color-scheme=dark] .bz_gd:not([data-skip-color-scheme]){--sa-button-background-color:var(--black-70-v2);--sa-button-color:var(--black-20-v2)}[data-color-scheme=dark] .bz_gd:not([data-skip-color-scheme]):active,[data-color-scheme=dark] .bz_gd:not([data-skip-color-scheme]):hover{--sa-button-background-color:var(--black-65-v2)}[data-color-scheme=dark] .bz_gd:not([data-skip-color-scheme]) .bz_fQ,[data-color-scheme=dark] .bz_gd:not([data-skip-color-scheme]):disabled{--sa-button-background-color:var(--black-25-v2);--sa-button-color:var(--black-70-v2)}.bz_gi{--sa-button-background-color:var(--white-100);--sa-button-color:var(--black-90-v2);--sa-button-border-radius:0;--sa-btn-icon-color:currentColor;text-transform:uppercase}.bz_gi:not(:active){--sa-button-border-color:var(--sa-button-background-color)}.bz_gi:active,.bz_gi:hover{--sa-button-background-color:var(--black-5-v2)}.bz_gi .bz_fQ,.bz_gi:disabled{--sa-button-background-color:var(--black-20-v2);--sa-button-color:var(--black-60-v2)}[data-color-scheme=dark] .bz_gi:not([data-skip-color-scheme]){--sa-button-background-color:var(--black-70-v2);--sa-button-color:var(--black-20-v2)}[data-color-scheme=dark] .bz_gi:not([data-skip-color-scheme]):active,[data-color-scheme=dark] .bz_gi:not([data-skip-color-scheme]):hover{--sa-button-background-color:var(--black-65-v2)}[data-color-scheme=dark] .bz_gi:not([data-skip-color-scheme]) .bz_fQ,[data-color-scheme=dark] .bz_gi:not([data-skip-color-scheme]):disabled{--sa-button-background-color:var(--black-25-v2);--sa-button-color:var(--black-70-v2)}.bz_gj{--sa-button-background-color:var(--navy-80-v2);--sa-button-color:var(--white-100);--sa-button-border-radius:0;--sa-btn-icon-color:currentColor;text-transform:uppercase}.bz_gj:active,.bz_gj:hover{--sa-button-background-color:var(--navy-75-v2)}.bz_gj:not(:active){--sa-button-border-color:var(--sa-button-background-color)}.bz_gj .bz_fQ,.bz_gj:disabled{--sa-button-background-color:var(--black-25-v2);--sa-button-color:var(--black-70-v2)}[data-color-scheme=dark] .bz_gj:not([data-skip-color-scheme]){--sa-button-background-color:var(--navy-100-v2);--sa-button-color:var(--white-100)}[data-color-scheme=dark] .bz_gj:not([data-skip-color-scheme]):active,[data-color-scheme=dark] .bz_gj:not([data-skip-color-scheme]):hover{--sa-button-background-color:var(--navy-95-v2)}[data-color-scheme=dark] .bz_gj:not([data-skip-color-scheme]) .bz_fQ,[data-color-scheme=dark] .bz_gj:not([data-skip-color-scheme]):disabled{--sa-button-background-color:var(--black-25-v2);--sa-button-color:var(--black-70-v2)}.bz_0{--sa-button-size:2.25rem;--sa-button-y-padding:0.25rem;--sa-button-x-padding:0.25rem;min-height:var(--sa-button-size);min-width:var(--sa-button-size)}@media(min-width:768px){.bz_0{--sa-button-background-color:var(--navy-100-v2);--sa-button-color:var(--white-100);--sa-button-border-radius:0;--sa-btn-icon-color:currentColor;--sa-button-size:2.25rem;--sa-button-border-width:2px;--sa-button-height:var(--sa-button-size);--sa-button-y-padding:0.25rem;--sa-button-x-padding:0.25rem;--sa-btn-icon-size:1.5rem;--sa-btn-icon-margin:0.375rem;border:var(--sa-button-border-width) solid var(--sa-button-border-color);text-transform:uppercase}.bz_0:active,.bz_0:hover{--sa-button-background-color:var(--navy-95-v2)}.bz_0:not(:active){--sa-button-border-color:var(--sa-button-background-color)}.bz_0 .bz_fQ,.bz_0:disabled{--sa-button-background-color:var(--black-20-v2);--sa-button-color:var(--black-60-v2)}[data-color-scheme=dark] .bz_0:not([data-skip-color-scheme]){--sa-button-background-color:var(--black-70-v2);--sa-button-color:var(--black-20-v2)}[data-color-scheme=dark] .bz_0:not([data-skip-color-scheme]):active,[data-color-scheme=dark] .bz_0:not([data-skip-color-scheme]):hover{--sa-button-background-color:var(--black-65-v2)}[data-color-scheme=dark] .bz_0:not([data-skip-color-scheme]) .bz_fQ,[data-color-scheme=dark] .bz_0:not([data-skip-color-scheme]):disabled{--sa-button-background-color:var(--black-25-v2);--sa-button-color:var(--black-70-v2)}.bz_0.bz_fx{--sa-btn-icon-margin:0rem}.bz_0:active{--sa-button-border-color:#0000}}@media(min-width:1024px){.bz_0{--sa-button-background-color:var(--white-100);--sa-button-color:var(--black-90-v2);--sa-button-border-radius:0;--sa-btn-icon-color:currentColor;--sa-button-size:3rem;--sa-button-border-width:2px;--sa-button-height:var(--sa-button-size);--sa-button-y-padding:0.625rem;--sa-button-x-padding:1.375rem;--sa-btn-icon-size:1.5rem;--sa-btn-icon-margin:0.375rem;border:var(--sa-button-border-width) solid var(--sa-button-border-color,#0000);text-transform:uppercase}.bz_0:not(:active){--sa-button-border-color:var(--sa-button-background-color)}.bz_0:active,.bz_0:hover{--sa-button-background-color:var(--black-5-v2)}.bz_0 .bz_fQ,.bz_0:disabled{--sa-button-background-color:var(--black-20-v2);--sa-button-color:var(--black-60-v2)}[data-color-scheme=dark] .bz_0:not([data-skip-color-scheme]){--sa-button-background-color:var(--black-70-v2);--sa-button-color:var(--black-20-v2)}[data-color-scheme=dark] .bz_0:not([data-skip-color-scheme]):active,[data-color-scheme=dark] .bz_0:not([data-skip-color-scheme]):hover{--sa-button-background-color:var(--black-65-v2)}[data-color-scheme=dark] .bz_0:not([data-skip-color-scheme]) .bz_fQ,[data-color-scheme=dark] .bz_0:not([data-skip-color-scheme]):disabled{--sa-button-background-color:var(--black-25-v2);--sa-button-color:var(--black-70-v2)}.bz_0.bz_fx{--sa-btn-icon-margin:0rem;--sa-button-x-padding:0.625rem}.bz_0:active{--sa-button-border-color:#0000}}.bz_f{display:none}@media(min-width:768px){.bz_f{display:flex}}.bz_fd{display:inline-flex}@media(min-width:768px){.bz_fd{display:none}}.Q_gE{margin-left:auto;margin-right:-12px}.Q_0{color:var(--white-100);min-width:36px}.Q_0:empty{display:none}@media(min-width:1024px){.Q_gF{margin-right:20px}}.Q_gG{--sa-notification-badge-padding:1px 2px;--sa-notification-badge-translateX:20%;--sa-notification-badge-translateY:-33%}.Q_gH{--sa-notification-badge-border-color:var(--black-100);--sa-notification-badge-color:var(--black-100)}.Q_gI{--sa-notification-badge-border-color:var(--black-5);--sa-notification-badge-color:var(--white-100)}[data-color-scheme=dark] .Q_gI:not([data-skip-color-scheme]){--sa-notification-badge-border-color:var(--black-98);--sa-notification-badge-color:var(--black-98)}.Q_gJ{width:24px}.Q_gK{fill:var(--sa-text-color-2);color:var(--sa-text-color-2)}.B_B{z-index:1030}.B_eY{min-height:var(--sa-header-bar-height)}.B_eZ{max-width:362px}@media(min-width:1200px){.B_eZ{max-width:430px}}@media(min-width:1540px){.B_eZ{max-width:604px}}.B_eZ .B_e0{--sa-searchbox-results-border-color:var(--navy-40-v2)}[data-color-scheme=dark] .B_eZ .B_e0:not([data-skip-color-scheme]){--sa-searchbox-results-border-color:var(--black-70-v2);--sa-search-category-bg:var(--black-80)}.B_e1{height:36px;width:36px}.B_e2{height:24px;width:120px}@media(min-width:1024px){.B_e2{height:32px;width:140px}}.B_0{--sa-btn-icon-size:18px;min-width:36px}.scrollLocked .B_e3{right:calc(var(--scrollbar-width,0)*-1)}.N_0:active,.N_0:focus,.N_0:hover{text-decoration:underline}.ag_hG{overflow:visible}@media(min-width:768px){.ag_hG{overflow:hidden}}.ag_hG :before{height:0}@media(min-width:768px){.ag_hH{align-items:center;background-color:#0000;box-shadow:none;display:flex;height:100%;max-width:100%}}.A_a{background:var(--white-100);border-bottom:1px solid var(--black-50);color:var(--sa-text-color-3);font-size:.875rem;line-height:1.125rem;padding:15px 0;width:100%;z-index:1}.A_eV{height:10px;width:10px}.A_eW{align-self:center;height:20px;width:20px}[data-color-scheme=dark] .A_eW:not([data-skip-color-scheme]){fill:var(--black-50)}.A_f{max-width:960px}.z_eU{background-color:var(--sa-aside-background-color);left:0;opacity:0;padding:12px;pointer-events:none;position:absolute;right:0;top:0;transform:translateY(-100%);transition:transform .1s ease .1s;z-index:1060}@media screen and (prefers-reduced-motion:reduce){.z_eU{transition:none}}.z_eU,.z_eU:focus,.z_eU:hover,.z_eU:visited{color:var(--white-100);text-decoration:none}.z_eU:focus,.z_eU:hover{text-decoration:underline}.z_eU:focus{opacity:1;pointer-events:auto;transform:translateY(0)}.S_gO{bottom:0;left:var(--sa-aside-width,0);position:fixed;right:0;z-index:1020}.S_gP{visibility:hidden}.S_u{bottom:var(--sa-mobile-bottom-navigation-height)}.aw_fd svg{fill:currentColor;display:block;height:100%;width:100%}.V_gX{height:var(--sa-mobile-bottom-navigation-height)}.V_gY{min-width:60px}@media(min-width:576px){.V_gY{min-width:78px}}.V_gY:last-child{min-width:60px}.l_K{left:0;position:fixed;z-index:1030}.l_K,.l_L{bottom:0;width:100%}.l_L{position:-webkit-sticky;position:sticky;z-index:1029}.P_g{--scrollbar-width:4px}.P_g:after,.P_g:before{content:"";height:24px;left:0;position:absolute;right:0}.P_gB{scrollbar-color:var(--black-50) var(--black-70);scrollbar-width:thin}.P_gB::-webkit-scrollbar-thumb{background-color:var(--black-50);border-radius:0}.P_gB::-webkit-scrollbar-track{background-color:var(--black-70);border-radius:0}.P_gB::-webkit-scrollbar{width:var(--scrollbar-width)}.P_gC:after,.P_gC:before,.P_gD:after,.P_gD:before{pointer-events:none}.P_gC:before{background:linear-gradient(180deg,var(--black-100),var(--black-100-alpha-0) 100%);content:"";top:0;z-index:1}@supports(scrollbar-width:thin){.P_gC:before{margin-right:14px}}@supports not (scrollbar-width:thin){.P_gC:before{margin-right:var(--scrollbar-width)}}.P_gD:after{background:linear-gradient(180deg,var(--black-100-alpha-0) 0,var(--black-100) 100%);bottom:0;content:""}@supports(scrollbar-width:thin){.P_gD:after{margin-right:14px}}@supports not (scrollbar-width:thin){.P_gD:after{margin-right:var(--scrollbar-width)}}.x_eQ{width:var(--sa-aside-width,0)}.x_h,.x_n{top:var(--sa-header-bar-height)}.x_h{transition:transform .3s;width:20rem}@media screen and (prefers-reduced-motion:reduce){.x_h{transition:none}}@media(min-width:768px){.x_h{width:21.875rem}}.x_eR .x_h{transform:translateX(-100%)}@media(min-width:1024px){.x_eS{width:var(--sa-aside-width)}.x_eR .x_eS,.x_eS{transform:translateX(0)}}.hydratingAsideCollapsed .x_eT{display:none}.cX_g{list-style:none;margin:0;padding-left:0}.cX_pf{background-color:var(--sa-accordion-caption-bg);width:100%}.cX_pg{align-items:baseline}@media(min-width:1024px){.cX_pg{align-items:center;padding:20px 0}}.cX_ph{align-items:center}.cX_pg,.cX_ph{text-align:left}@media(min-width:1024px){.cX_pg,.cX_ph{align-items:center}}.cX_pg:focus,.cX_pg:hover,.cX_ph:focus,.cX_ph:hover{text-decoration:underline}.cX_pi,.cX_pj{font-size:1.125rem;font-weight:700;line-height:1.375rem}@media(min-width:1024px){.cX_pi,.cX_pj{font-size:1rem;font-weight:700;line-height:1.25rem}}.cX_pk{--sa-accordion-caption-bg:var(--sa-card-bg-color-2);color:var(--sa-text-color-4);font-weight:500;justify-content:space-between;min-height:55px;position:relative}.cX_pl,.cX_pm{background-color:var(--black-10);border-radius:5px;flex-shrink:0;height:24px;transition:transform .1s linear;width:24px}@media screen and (prefers-reduced-motion:reduce){.cX_pl,.cX_pm{transition:none}}@media(min-width:1024px){.cX_pl,.cX_pm{height:20px;width:20px}}[data-color-scheme=dark] .cX_pl:not([data-skip-color-scheme]),[data-color-scheme=dark] .cX_pm:not([data-skip-color-scheme]){background-color:var(--black-95)}.cX_pm{background-color:var(--black-50);border-radius:0;transition:none}.cX_po{transform:rotate(-90deg)}.cX_pp{transform:rotate(0)}.cX_hI{flex-shrink:0}.cX_pq{fill:currentColor;transition:fill .1s linear;width:.75rem}@media screen and (prefers-reduced-motion:reduce){.cX_pq{transition:none}}.cX_pr,.cX_ps{fill:var(--sa-text-color-3);height:8px;width:14px}@media(min-width:1024px){.cX_pr,.cX_ps{height:6px;width:12px}}.cX_ps{fill:var(--white-100);transition:transform .1s linear}@media screen and (prefers-reduced-motion:reduce){.cX_ps{transition:none}}.cX_pt{order:-1}@media(min-width:1024px){.cX_pv,.cX_pw{margin-left:30px}}.cX_px,.cX_py{order:-1}@media(min-width:1024px){.cX_px,.cX_py{margin-right:30px}}.cX_pz{margin-left:18px;transform:rotate(-90deg);transition:transform .25s}@media screen and (prefers-reduced-motion:reduce){.cX_pz{transition:none}}.cX_pA{background-color:var(--sa-section-separator-color)}.cX_pB .cX_pl{background-color:var(--sa-text-color-3)}.cX_pB .cX_pr{fill:var(--sa-invert-default-color)}.cX_pB .cX_po{transform:rotate(0)}.cX_pB .cX_pp{transform:rotate(-180deg)}.cX_pB .cX_pz{transform:rotate(0)}.cX_pB .cX_pm{background-color:var(--black-50);transform:none}.cX_pB .cX_ps{fill:var(--white-100);transform:rotate(-180deg)}.cX_pB .cX_pA{background-color:var(--black-10)}.cX_pC,.cX_pD{font-size:1rem;font-weight:400;line-height:1.5rem}@media(min-width:1024px){.cX_pC,.cX_pD{font-size:.875rem;font-weight:400;line-height:1.25rem}.cX_pC,.cX_pE{padding-left:54px}}.cX_pF{color:var(--sa-text-color-4)}.cX_pG{border-bottom:1px solid var(--sa-section-separator-color)}.cX_pG:last-child,.cX_pG:only-child{border-bottom:0}.cX_pH:last-child{margin-bottom:0}.cV_eI{--sa-menu-active-color:var(--orange-60)}.cV_pa:after,.cV_pa:before{content:"";height:12px;left:0;pointer-events:none;position:absolute;right:0;width:100%}.cV_pa:before{top:-12px}.cV_pa:after{bottom:-12px}.cV_pa:hover:after,.cV_pa:hover:before{pointer-events:auto}.cV_nr{--sa-link-content-color:var(--black-20)}.cV_pb{pointer-events:none}.cV_pb:before{display:none}.cV_pb.cV_o{--sa-link-bg-color:var(--sa-aside-background-color);--sa-link-active-color:var(--orange-60)}.cV_pc{-ms-overflow-style:none;max-height:var(--sa-hovered-height);scrollbar-width:none}.cV_pc::-webkit-scrollbar{display:none}.dh_o{color:var(--sa-link-active-color)}.cv_oi{width:100%}.cv_oj{width:auto}.jQ_f{text-decoration:none;white-space:nowrap;width:0}.jQ_o4{color:var(--black-20)}.eY_gY{--sa-link-bg-color:var(--sa-aside-background-color);background-color:var(--sa-link-bg-color);min-height:2.75rem}@media(hover:hover)and (pointer:fine){.eY_gY:hover{--sa-link-bg-color:var(--black-30-alpha-20)}}.eY_gY:before{background-color:var(--sa-link-active-color);bottom:10px;content:"";left:0;position:absolute;top:10px;width:4px}@media(min-width:1024px){.eY_tu{min-height:1.875rem}.eY_tu .eY_G,.eY_tu.eY_G{padding-bottom:.25rem;padding-top:.25rem}.eY_tu:before{bottom:0;top:0}}.eY_o{--sa-link-active-color:var(--sa-menu-active-color,var(--orange-60));--sa-link-content-color:var(--orange-60)}.eY_f{color:var(--sa-link-content-color,var(--sa-link-active-color))}.eA_mY{--sa-hovered-menu-width:0;width:var(--sa-hovered-menu-width)}.eA_sB{--sa-hovered-menu-width:288px}.eL_rv{min-width:20px}.bX_m4 .bX_m5,.bX_m4:focus-within .bX_m6,.bX_m4:hover .bX_m6{display:none}.bX_m4:focus-within .bX_m5,.bX_m4:hover .bX_m5{display:flex}.do_a,.do_a:focus,.do_a:hover,.do_a:visited{color:inherit;text-decoration:none}.lV_a{border-width:.0625rem;width:100%}@media(min-width:576px){.lV_a{width:168px}}[data-color-scheme=dark] .lV_a:not([data-skip-color-scheme]){border-color:var(--black-30-alpha-20)}@media(min-width:576px){.lV_La{min-height:2.5rem}.lV_Lb{min-height:1.75rem}}.lV_fi{border-top:1px solid var(--black-10)}[data-color-scheme=dark] .lV_fi:not([data-skip-color-scheme]){border-top:1px solid var(--black-30-alpha-20)}@media(min-width:576px){[data-color-scheme=dark] .lV_fi:not([data-skip-color-scheme]){border-top:none}}.lV_gt{color:var(--sa-btn-spinner-color,var(--sa-btn-color));height:var(--sa-btn-icon-size);width:var(--sa-btn-icon-size)}.hj_Bo{margin-left:-18px;margin-right:-18px}@media(min-width:576px){.hj_Bo{margin-left:2px;margin-right:2px}}[data-color-scheme=dark] .hj_Bp:not([data-skip-color-scheme]){background-color:var(--black-30-alpha-20)}@media(min-width:768px){.cB_eP{max-width:37.5rem;min-width:37.5rem}}.cU_fd{height:16px;width:16px}.bb_o{--sa-link-content-color:var(--blue-75);--sa-menu-active-color:var(--blue-75)}.C_e4{background:var(--largeTopBannerBackground);position:relative}@media(min-width:768px){.C_e4{margin-bottom:24px}}.C_e4.C_eH{max-width:375px}.C_e4.C_eG{max-width:768px}.C_e4.C_eF{max-width:100%}.C_e5.C_eH{height:60px;margin-bottom:18px}.C_e5.C_eG{margin-bottom:26px}.C_e5.C_eF{margin-bottom:36px;width:260px}.C_e5 img{max-height:100%;max-width:100%}.C_e6 p:last-of-type{margin:0}.C_e6.C_eH{text-align:center}.C_e6.C_eG,.C_e6.C_eH{margin-bottom:24px}.C_e6.C_eF{margin-bottom:36px}.C_e7.C_eH{align-items:center}.C_e8{height:100%;width:100%}.C_e8.C_eH{justify-content:center;max-width:339px}.C_e8.C_eG{max-width:331px}.C_e8.C_eF{max-width:535px}.C_e8 img{max-height:100%;max-width:100%}.C_0{background-color:var(--largeTopBannerButtonColor);max-width:235px;width:100%}.C_0,.C_0:visited{color:var(--largeTopBannerButtonCopyColor)}.C_0.C_eH{margin-bottom:12px;max-width:339px}.C_0.C_eG{max-width:272px}.C_0.C_eF{max-width:300px}.C_g{background-position:bottom;background-repeat:no-repeat}.C_g[data-is-asset-exist=false][data-template-type=top_bottom]{padding-bottom:36px}.C_g[data-template-type=left_right]{align-items:flex-end;gap:26px;justify-content:center}.C_g[data-template-type=left_right].C_eF{gap:48px}.C_g[data-template-type=left_right] .C_e7{align-self:center;padding-bottom:18px;padding-top:18px}.C_g[data-template-type=left_right][data-is-asset-exist=true] .C_e6.C_eH{max-width:339px}.C_g[data-template-type=left_right][data-is-asset-exist=true] .C_e6.C_eG{max-width:347px}.C_g[data-template-type=left_right][data-is-asset-exist=true] .C_e6.C_eF{max-width:609px}.C_g[data-fixed-height=true].C_eG{min-height:349px}.C_g[data-fixed-height=true].C_eF{min-height:580px}.C_g[data-template-type=top_bottom]{align-items:center;flex-direction:column}.C_g[data-template-type=top_bottom].C_eH{padding-top:36px}.C_g[data-template-type=top_bottom].C_eF,.C_g[data-template-type=top_bottom].C_eG{padding-top:80px}.C_g[data-template-type=top_bottom] .C_e5{align-content:center;display:flex;flex-flow:column wrap}.C_g[data-template-type=top_bottom] .C_e7{align-items:center;text-align:center}.C_g[data-template-type=top_bottom] .C_e8{justify-content:center}.C_g[data-template-type=top_bottom] .C_0{margin-bottom:12px}.C_e9,[data-color-scheme=dark] .C_e9:not([data-skip-color-scheme]){background-color:#0000}.C_e9.C_eG{margin:0}.C_N{position:absolute;right:18px;top:18px}.C_O{color:var(--largeTopBannerCloseButtonColor);position:relative}.C_O:after{background-color:var(--largeTopBannerCloseButtonColor);content:"";height:100%;left:0;opacity:0;position:absolute;top:0;transition:opacity .2s ease-in-out;width:100%}.C_O:focus,.C_O:hover{background-color:#0000}.C_O:focus:after,.C_O:hover:after{opacity:.4}[data-color-scheme=dark] .C_O:focus:not([data-skip-color-scheme]),[data-color-scheme=dark] .C_O:hover:not([data-skip-color-scheme]){background-color:#0000}.bO_mW{color:var(--black-35);line-height:1.75}.b_d{max-height:100%}@media(orientation:landscape){.b_d{max-height:668px}}@media(min-width:768px){.b_d{max-height:unset}}.b_e.b_f{padding:0;width:100%}@media(min-width:768px){.b_e.b_f{height:668px;max-width:375px}}@media(min-width:1024px){.b_e.b_f{height:656px;max-width:700px}}@media(min-width:768px){.w_eO{display:flex;flex-flow:row}}@media(min-width:768px){.w_eP{flex-grow:0}}.e_a{left:0;position:fixed;right:0;top:90px;width:100%;z-index:1050}@media(min-width:1540px){.e_a{padding-left:26px;padding-right:26px}}</style><style data-href="/samw/static/styles/prerender.680caa56.css">:root{--sa-mobile-bottom-navigation-height:5rem;--env-safe-area-inset-top:env(safe-area-inset-top);--env-safe-area-inset-bottom:env(safe-area-inset-bottom);--env-safe-area-inset-left:env(safe-area-inset-left);--env-safe-area-inset-right:env(safe-area-inset-right);--twitter-color:#38a1f3;--reddit-color:#ff5700;--facebook-color:#3b5998;--linkedIn-color:#0077b5;--email-color:#999;--sa-sticky-top:calc(var(--headerHeight, 0px) + var(--stripBarHeight, 0px) + var(--headerBottomNav, 0px));--black-98-grad:linear-gradient(90deg,var(--black-98-alpha-0) 0%,var(--black-98) 100%);--black-95-grad:linear-gradient(90deg,var(--black-95-alpha-0) 0%,var(--black-95) 100%);--black-90-grad:linear-gradient(90deg,var(--black-90) 0%,var(--black-100-95) 100%);--black-80-grad:linear-gradient(90deg,var(--black-80) 0%,var(--black-95) 100%);--black-70-grad:linear-gradient(90deg,var(--black-70-alpha-0) 0%,var(--black-70) 100%);--black-60-grad:linear-gradient(180deg,var(--black-60-alpha-50) 0%,var(--black-60) 100%);--black-40-grad:linear-gradient(180deg,var(--black-40-alpha-50) 0%,var(--black-40) 100%);--black-10-grad:linear-gradient(90deg,var(--black-10) 0%,var(--white-100) 100%);--black-5-grad:linear-gradient(90deg,var(--black-5-alpha-0) 0%,var(--black-5) 100%);--white-100-grad:linear-gradient(90deg,var(--white-100-alpha-0) 0%,var(--white-100) 100%);--red-90-grad:linear-gradient(90deg,var(--red-90-alpha-50) 0%,var(--red-90) 100%);--orange-60-grad:linear-gradient(90deg,var(--orange-60-alpha-50) 0%,var(--orange-60) 100%);--teal-80-grad:linear-gradient(90deg,var(--teal-80-alpha-50) 0%,var(--teal-80) 100%);--box-shadow:0 8px 8px var(--black-100-alpha-15);--shadow-elevation-1:0 0 10px #0003;--shadow-elevation-2:0 4px 8px #00000040;--shadow-elevation-3:0 0 10px #000000bf;--shadow-elevation-4:0 4px 8px #000000bf;--black-100:#000;--black-100-alpha-80:#000c;--black-100-alpha-75:#000000bf;--black-100-alpha-50:#00000080;--black-100-alpha-25:#00000040;--black-100-alpha-15:#00000026;--black-100-alpha-10:#0000001a;--black-100-alpha-0:#0000;--black-98:#04080b;--black-98-alpha-0:#04080b00;--black-95:#111517;--black-95-alpha-0:#11151700;--black-90:#232a32;--black-90-alpha-0:#232a3200;--black-80:#2c3032;--black-80-alpha-0:#2c303200;--black-70:#333;--black-70-alpha-0:#3330;--black-70-alpha-50:#33333380;--black-60:#434348;--black-60-alpha-50:#43434880;--black-50:#555;--black-50-alpha-10:#55555580;--black-40:#697173;--black-40-alpha-50:#69717380;--black-35:#757575;--black-35-alpha-50:#75757580;--black-35-alpha-0:#75757500;--black-30:#838d8f;--black-30-alpha-30:#838d8f4d;--black-30-alpha-20:#838d8f33;--black-30-alpha-40:#838d8f66;--black-20:#acacac;--black-20-alpha-20:#acacac33;--black-10:#dbdbdb;--black-5:#f2f4f7;--black-5-alpha-0:#f2f4f700;--black-4:#f9f9f9;--black-90-v2:#101114;--black-85-v2:#1c1d20;--black-80-v2:#212224;--black-70-v2:#3f4248;--black-70-v2-alpha-60:#3f424899;--black-65-v2:#464b54;--black-60-v2:#5e6167;--black-55-v2:#72757b;--black-25-v2:#adb1ba;--black-20-v2:#e0e1e4;--black-15-v2:#e8e8e8;--black-10-v2:#f5f2f1;--black-5-v2:#fcfcfc;--white-96:#f3f4f7;--white-100:#fff;--white-100-alpha-75:#ffffffbf;--white-100-alpha-50:#ffffff80;--white-100-alpha-0:#fff0;--red-100:#c9392c;--red-100-alpha-80:#c9392ccc;--red-100-alpha-75:#c9392cbf;--red-100-alpha-20:#c9392c33;--red-95:#e32b30;--red-95-alpha-50:#e32b3080;--red-90:#d23f31;--red-90-alpha-50:#d23f3180;--red-80:#d94d41;--red-80-alpha-20:#d94d4133;--red-100-v2:#7c1f1f;--red-90-v2:#b94848;--red-80-v2:#bf1d1d;--red-70-v2:#ce3434;--red-60-v2:#d66363;--red-50-v2:#de4e4e;--red-40-v2:#e07575;--red-30-v2:#eb8888;--orange-100:#ff1a00;--orange-100-alpha-50:#ff1a0080;--orange-90:#ea4215;--orange-80:#ff3c00;--orange-70:#d15e00;--orange-60:#ff7200;--orange-60-alpha-50:#ff720080;--orange-60-alpha-0:#ff720000;--orange-100-v2:#ef6d0a;--orange-100-v2-alpha-50:#ef6d0a80;--orange-100-v2-alpha-12:#ef6d0a1f;--orange-95-v2:#f47819;--yellow-100:#e59310;--yellow-100-alpha-50:#e5931080;--yellow-90:#efa818;--yellow-90-alpha-50:#efa81880;--yellow-85:#fec20f;--yellow-80:#fcc131;--yellow-70:#dfbf18;--yellow-100-v2:#d6c100;--yellow-90-v2:#e8da58;--yellow-80-v2:#ebd517;--yellow-70-v2:#ffeb33;--yellow-60-v2:#f3e56a;--yellow-50-v2:#fcef7e;--green-100:#3d5f12;--green-90:#5d921c;--green-90-alpha-50:#5d921c80;--green-80:#70c30e;--green-80-alpha-50:#70c30e80;--green-75:#85c90e;--green-60:#9ace49;--green-60-alpha-50:#9ace4980;--green-50:#a9b667;--green-100-v2:#184515;--green-95-v2:#265523;--green-90-v2:#366332;--green-85-v2:#2c7a26;--green-80-v2:#408e3a;--green-75-v2:#489c43;--green-70-v2:#55a550;--green-65-v2:#59a353;--green-60-v2:#62b05d;--green-55-v2:#74bd6f;--green-50-v2:#87c782;--green-45-v2:#99d194;--teal-100:#0a7b44;--teal-100-alpha-75:#0a7b44bf;--teal-100-alpha-50:#0a7b4480;--teal-80:#0f9d58;--teal-80-alpha-50:#0f9d5880;--teal-75:#32a667;--teal-50:#00d885;--teal-45:#67d9a2;--blue-100:#410cda;--blue-80:#2867db;--blue-75:#1a98ff;--blue-75-alpha-20:#1a98ff33;--blue-75-alpha-50:#1a98ff80;--blue-75-alpha-66:#1a98ffa8;--blue-75-alpha-0:#1a98ff00;--blue-70:#5994ff;--blue-50:#7cb5ec;--blue-50-alpha-20:#7cb5ec33;--blue-10:#e8f5ff;--blue-100-v2:#11718f;--blue-30-v2:#b8c8e5;--navy-100-v2:#242832;--navy-95-v2:#373c49;--navy-80-v2:#414a5f;--navy-75-v2:#46526f;--navy-40-v2:#8d929f;--purple-100:#d423c3;--sa-pro-color:#cce55c;--sa-premium-color:#11718f;--seeking-alpha-color:#ff7200;--sa-body-bg-color:var(--white-96);--sa-body-bg-color-2:var(--white-100);--sa-body-bg-color-3:var(--black-5);--sa-body-bg-color-4:var(--black-10-v2);--sa-link-color:var(--blue-80);--sa-card-bg-color:var(--white-100);--sa-card-bg-color-2:var(--black-5);--sa-card-bg-color-3:var(--white-100);--sa-invert-default-color:var(--white-100);--sa-text-color-1:var(--black-100);--sa-text-color-2:var(--black-35);--sa-text-color-3:var(--black-50);--sa-text-color-4:var(--black-70);--sa-text-color-5:var(--black-100);--sa-text-color-6:var(--black-90-v2);--sa-negative-color:var(--red-100);--sa-negative-color-2:var(--red-70-v2);--sa-positive-color:var(--teal-100);--sa-positive-color-2:var(--green-80-v2);--sa-section-separator-color:var(--black-10);--sa-section-separator-thin-color:var(--black-10);--sa-very-bearish-color:var(--red-95);--sa-bearish-color:var(--orange-100);--sa-neutral-color:var(--yellow-90);--sa-bullish-color:var(--green-60);--sa-very-bullish-color:var(--green-90);--sa-modal-container-bg-color:var(--white-100);--sa-card-bg-transparent-color:#fff0;--sa-content-hide-gradient:linear-gradient(to top,var(--white-100),#ffffff80);--sa-spinner-color-1:var(--black-10);--sa-input-border-color:var(--black-10);--sa-disabled-text-color:var(--black-10);--sa-popup-shadow:var(--shadow-elevation-2);--sa-focus-outline-color:#05c;--sa-divider-color:var(--black-20-v2);--sa-aside-background-color:var(--black-100)}[data-color-scheme=dark]{--sa-body-bg-color:var(--black-98);--sa-body-bg-color-2:var(--black-98);--sa-body-bg-color-3:var(--black-98);--sa-body-bg-color-4:var(--black-98);--sa-link-color:var(--blue-70);--sa-card-bg-color:var(--black-95);--sa-card-bg-color-2:var(--black-80);--sa-card-bg-color-3:var(--black-85-v2);--sa-invert-default-color:var(--black-100);--sa-text-color-1:var(--black-10);--sa-text-color-2:var(--black-30);--sa-text-color-3:var(--black-30);--sa-text-color-4:var(--black-30);--sa-text-color-5:var(--black-30);--sa-text-color-6:var(--black-20-v2);--sa-negative-color:var(--red-80);--sa-negative-color-2:var(--red-70-v2);--sa-positive-color:var(--teal-75);--sa-positive-color-2:var(--green-80-v2);--sa-section-separator-color:var(--black-30);--sa-section-separator-thin-color:var(--black-80);--sa-modal-container-bg-color:var(--black-80);--sa-content-hide-gradient:linear-gradient(to top,var(--black-95),#0000);--sa-card-bg-transparent-color:#0000;--sa-spinner-color-1:var(--black-35);--sa-input-border-color:var(--black-30);--sa-disabled-text-color:var(--black-80);--sa-popup-shadow:var(--shadow-elevation-4);--sa-divider-color:var(--black-60-v2);--sa-aside-background-color:var(--black-95)}:root{--sa-border-r-4:4px;--sa-border-r-8:8px;--sa-border-r-10:10px;--sa-border-r-12:12px;--input-size-xs:1.5rem;--input-size-sm:1.875rem;--input-size-md:2.25rem;--input-size-lg:2.75rem;--sa-chart-loading-color:var(--black-100);--sa-chart-axis-label-color:var(--sa-text-color-3);--sa-chart-loading-background-color:var(--black-100-alpha-10);--sa-chart-axis-line-color:var(--black-10);--sa-chart-tooltip-border-color:var(--black-10);--sa-chart-tooltip-bg-color:var(--white-100);--sa-chart-tooltip-color:var(--black-70);--sa-chart-series-start-gradient-color:var(--white-100);--sa-chart-series-stop-gradient-color:var(--orange-60);--sa-chart-series-color:var(--orange-60);--sa-chart-bg-color:#0000;--sa-chart-flag-plot-line-color:var(--black-20);--sa-chart-flag-plot-fill-color:var(--white-100);--sa-chart-axis-tick-color:var(--black-10);--sa-chart-axis-plot-color:var(--black-5);--sa-chart-plot-option-pie-border-color:var(--white-100);--sa-chart-annotation-tooltip-bg-color:var(--black-100)}[data-color-scheme=dark]{--sa-chart-loading-background-color:var(--black-100-alpha-50);--sa-chart-loading-color:var(--black-10);--sa-chart-tooltip-border-color:var(--black-90);--sa-chart-tooltip-bg-color:var(--black-80);--sa-chart-tooltip-color:var(--black-30);--sa-chart-series-start-gradient-color:var(--orange-60-alpha-0);--sa-chart-series-stop-gradient-color:var(--orange-60);--sa-chart-series-color:var(--orange-60);--sa-chart-axis-line-color:var(--black-80);--sa-chart-flag-plot-line-color:var(--black-80);--sa-chart-flag-plot-fill-color:var(--white-96);--sa-chart-axis-tick-color:var(--black-30);--sa-chart-axis-plot-color:var(--black-100);--sa-chart-plot-option-pie-border-color:var(--black-95);--sa-chart-annotation-tooltip-bg-color:var(--black-90)}:root{--badge-gray:var(--black-10);--badge-dark-gray:var(--black-50);--badge-dark-green:var(--green-100);--badge-green:var(--green-90);--badge-light-green:var(--green-80);--sa-buy-color:var(--green-75);--badge-light-lime:var(--green-60);--badge-olive:var(--green-50);--badge-light-orange:var(--yellow-80);--badge-orange:var(--yellow-90);--badge-dark-orange:var(--yellow-100);--badge-light-red:var(--orange-80);--badge-red:var(--orange-100);--badge-amber:var(--orange-90);--badge-dark-red:var(--red-95);--badge-mint:var(--teal-50);--sa-not-covered-color:var(--black-20-v2);--sa-strong-sell-color:var(--red-100-v2);--sa-sell-color:var(--red-70-v2);--sa-hold-color:var(--yellow-80-v2);--sa-buy-color:var(--green-80-v2);--sa-strong-buy-color:var(--green-95-v2);--sa-grade-a-plus:var(--green-100-v2);--sa-grade-a:var(--green-95-v2);--sa-grade-a-minus:var(--green-90-v2);--sa-grade-b-plus:var(--green-85-v2);--sa-grade-b:var(--sa-buy-color);--sa-grade-b-minus:var(--green-65-v2);--sa-grade-c-plus:var(--yellow-100-v2);--sa-grade-c:var(--sa-hold-color);--sa-grade-c-minus:var(--yellow-70-v2);--sa-grade-d-plus:var(--red-50-v2);--sa-grade-d:var(--red-70-v2);--sa-grade-d-minus:var(--red-80-v2);--sa-grade-f:var(--sa-strong-sell-color)}[data-color-scheme=dark]{--sa-not-covered-color:var(--black-70-v2);--sa-strong-sell-color:var(--red-90-v2);--sa-sell-color:var(--red-40-v2);--sa-hold-color:var(--yellow-60-v2);--sa-buy-color:var(--green-50-v2);--sa-strong-buy-color:var(--green-70-v2);--sa-grade-a-plus:var(--green-75-v2);--sa-grade-a:var(--green-70-v2);--sa-grade-a-minus:var(--green-60-v2);--sa-grade-b-plus:var(--green-55-v2);--sa-grade-b:var(--sa-buy-color);--sa-grade-b-minus:var(--green-45-v2);--sa-grade-c-plus:var(--yellow-90-v2);--sa-grade-c-minus:var(--yellow-50-v2);--sa-grade-d-plus:var(--red-30-v2);--sa-grade-d:var(--red-40-v2);--sa-grade-d-minus:var(--red-60-v2)}*,:after,:before{border:0 solid;box-sizing:border-box}:after,:before{--tw-content:""}html{-webkit-text-size-adjust:100%;-ms-text-size-adjust:100%;-ms-overflow-style:scrollbar;-webkit-tap-highlight-color:var(--black-100-alpha-0);font-family:sans-serif;font-size:16px;height:100%;line-height:1.15}html.ios-wrapper{width:100vw}#page_content_wrapper,.root,body,html{display:flex;flex-direction:column}#page_content_wrapper,.root,body{flex-grow:1;flex-shrink:0}@media print{.root,body{display:block}}.root,body,html{position:relative}body{height:var(--sa-window-inner-height);z-index:0}@media(min-width:1024px){body{overflow-y:scroll}}article,aside,figcaption,figure,footer,header,nav,section{display:block}body{background-color:var(--sa-body-bg-color-4);color:var(--black-100);font-family:-apple-system,BlinkMacSystemFont,Roboto,Arial,Segoe UI,sans-serif,Apple Color Emoji,Segoe UI Emoji,Segoe UI Symbol;font-size:1rem;font-weight:400;line-height:1.5;margin:0;text-align:left}[data-color-scheme=dark] body:not([data-skip-color-scheme]){background-color:var(--black-100);color:var(--black-10)}[tabindex="-1"]:focus{outline:0!important}hr{box-sizing:initial;height:0;overflow:visible}h1,h2,h3,h4,h5,h6{margin-bottom:8px;margin-top:0}p{margin-bottom:18px;margin-top:0}abbr[data-original-title],abbr[title]{border-bottom:0;cursor:help;text-decoration:underline;-webkit-text-decoration:underline dotted;text-decoration:underline dotted}address{font-style:normal;line-height:inherit}address,dl,ol,ul{margin-bottom:18px}dl,ol,ul{margin-top:0}ol ol,ol ul,ul ol,ul ul{margin-bottom:0}dt{font-weight:700}dd{margin-bottom:8px;margin-left:0}blockquote{margin:0 0 18px}dfn{font-style:italic}b,strong{font-weight:bolder}small{font-size:80%}sub,sup{font-size:75%;line-height:1;position:relative;vertical-align:initial}sub{bottom:-.25em}sup{top:-.5em}a{-webkit-text-decoration-skip:objects;background-color:#0000;color:var(--sa-link-color)}a,a:focus,a:hover,a:visited{text-decoration:none}a:hover{text-decoration:underline}a:not([href]):not([tabindex]),a:not([href]):not([tabindex]):focus,a:not([href]):not([tabindex]):hover,a:not([href]):not([tabindex]):visited{color:inherit;text-decoration:none}a:not([href]):not([tabindex]):focus{outline:0}code,kbd,pre,samp{font-family:SFMono-Regular,Menlo,Monaco,Consolas,Liberation Mono,Courier New,monospace;font-size:1em}pre{-ms-overflow-style:scrollbar;margin-bottom:18px;margin-top:0;overflow:auto}figure{margin:0 0 18px}img{background-color:var(--white-96);border-style:none;font-size:.75rem;vertical-align:middle}[data-color-scheme=dark] img:not([data-skip-color-scheme]){background-color:var(--black-90)}svg{overflow:hidden;vertical-align:middle}iframe{border:none}table{border-collapse:collapse}caption{caption-side:bottom;color:var(--black-35);padding-bottom:12px;padding-top:12px;text-align:left}th{text-align:inherit}label{display:inline-block;margin-bottom:8px}button{border-radius:0;cursor:pointer;text-align:center}button,input,optgroup,select,textarea{font-family:inherit;font-size:inherit;line-height:inherit;margin:0}button,input{overflow:visible}button,select{text-transform:none}[type=reset],[type=submit],button,html [type=button]{-webkit-appearance:button}button{background:#0000;border:none;color:inherit;font:inherit;margin:0;overflow:hidden;padding:0;width:auto}[type=button]::-moz-focus-inner,[type=reset]::-moz-focus-inner,[type=submit]::-moz-focus-inner,button::-moz-focus-inner{border-style:none;padding:0}button:focus{outline:1px dotted;outline:5px auto -webkit-focus-ring-color}@media(hover:none)and (pointer:coarse){a:active,a:focus,a:hover,button:active,button:focus,button:hover{outline:0!important;text-decoration:none!important}}input{border:1px solid #0000}input[type=password]{font-family:Arial,Helvetica Neue,Helvetica,sans-serif}input[type=checkbox],input[type=radio]{box-sizing:border-box;padding:0}input[type=date],input[type=datetime-local],input[type=month],input[type=time]{-webkit-appearance:listbox}textarea{overflow:auto;resize:vertical}fieldset{border:0;margin:0;min-width:0;padding:0}legend{color:inherit;display:block;font-size:1.5rem;line-height:inherit;margin-bottom:8px;max-width:100%;padding:0;white-space:normal;width:100%}progress{vertical-align:initial}[type=number]::-webkit-inner-spin-button,[type=number]::-webkit-outer-spin-button{height:auto}[type=search]{-webkit-appearance:none;outline-offset:-2px}[type=search]::-webkit-search-cancel-button,[type=search]::-webkit-search-decoration{-webkit-appearance:none}::-webkit-file-upload-button{-webkit-appearance:button;font:inherit}output{display:inline-block}summary{cursor:pointer;display:list-item}template{display:none}[hidden]{display:none!important}[data-intent-mouse=true] [contentEditable=true]:focus,[data-intent-mouse=true] [tabindex="0"]:focus,[data-intent-mouse=true] a[href]:focus,[data-intent-mouse=true] area[href]:focus,[data-intent-mouse=true] button:not([disabled]):focus,[data-intent-mouse=true] iframe:focus,[data-intent-mouse=true] input:not([disabled]):focus,[data-intent-mouse=true] select:not([disabled]):focus,[data-intent-mouse=true] textarea:not([disabled]):focus{outline:0}[data-intent-mouse=false] [contentEditable=true]:focus,[data-intent-mouse=false] [tabindex="0"]:focus,[data-intent-mouse=false] a[href]:focus,[data-intent-mouse=false] area[href]:focus,[data-intent-mouse=false] button:not([disabled]):focus,[data-intent-mouse=false] iframe:focus,[data-intent-mouse=false] input:not([disabled]):focus,[data-intent-mouse=false] select:not([disabled]):focus,[data-intent-mouse=false] textarea:not([disabled]):focus{outline:2px solid var(--sa-focus-outline-color);outline-offset:-1px}@keyframes kef-shift-rightwards{0%{transform:translateX(-100%)}40%{transform:translateX(0)}60%{transform:translateX(0)}to{transform:translateX(100%)}}@keyframes kef-delay-visibility{0%{opacity:0}to{opacity:1}}.loading{align-items:center;background-color:var(--sa-body-bg-color-4);display:flex;justify-content:center;overflow:hidden;z-index:1}[data-color-scheme=dark] .loading:not([data-skip-color-scheme]){background-color:var(--black-90)}@media(hover:none)and (pointer:coarse)and (prefers-color-scheme:dark){[data-color-scheme=system] .loading{background-color:var(--black-90)}}@supports not (-webkit-touch-callout:none){@media(hover:none)and (pointer:coarse)and (prefers-color-scheme:dark){:not([data-color-scheme=dark]) .loading,:not([data-color-scheme=light]) .loading{background-color:var(--black-90)}}}[data-loading-position=fixed]{height:100vh;left:0;position:fixed;top:0;width:100%}[data-loading-position=absolute]{bottom:0;left:0;position:absolute;right:0;top:0}.loadingDelayed{animation:kef-delay-visibility 3s step-end 1}@media screen and (prefers-reduced-motion:reduce){.loadingDelayed{animation:none}}.appLoading{--env-safe-area-inset-top:env(safe-area-inset-top);animation:kef-shift-rightwards 1s ease-in-out infinite;animation-delay:.8s;background:var(--orange-60);height:2px;opacity:1;position:fixed;right:0;top:var(--env-safe-area-inset-top,0);transform:translateX(100%);width:100%;z-index:1051}.appLoaderInvisible{animation:none;opacity:0}@media screen and (prefers-reduced-motion:reduce){.appLoading{animation:none}}.noScript{padding-top:80px;position:relative;text-align:center;z-index:1030}.noScriptDescription,.noScriptTitle{color:var(--sa-text-color-3);font-size:1.125rem;margin-bottom:18px}.noScriptTitle{font-weight:700}*,:after,:before{--tw-border-spacing-x:0;--tw-border-spacing-y:0;--tw-translate-x:0;--tw-translate-y:0;--tw-rotate:0;--tw-skew-x:0;--tw-skew-y:0;--tw-scale-x:1;--tw-scale-y:1;--tw-pan-x: ;--tw-pan-y: ;--tw-pinch-zoom: ;--tw-scroll-snap-strictness:proximity;--tw-gradient-from-position: ;--tw-gradient-via-position: ;--tw-gradient-to-position: ;--tw-ordinal: ;--tw-slashed-zero: ;--tw-numeric-figure: ;--tw-numeric-spacing: ;--tw-numeric-fraction: ;--tw-ring-inset: ;--tw-ring-offset-width:0px;--tw-ring-offset-color:#fff;--tw-ring-color:#3b82f680;--tw-ring-offset-shadow:0 0 #0000;--tw-ring-shadow:0 0 #0000;--tw-shadow:0 0 #0000;--tw-shadow-colored:0 0 #0000;--tw-blur: ;--tw-brightness: ;--tw-contrast: ;--tw-grayscale: ;--tw-hue-rotate: ;--tw-invert: ;--tw-saturate: ;--tw-sepia: ;--tw-drop-shadow: ;--tw-backdrop-blur: ;--tw-backdrop-brightness: ;--tw-backdrop-contrast: ;--tw-backdrop-grayscale: ;--tw-backdrop-hue-rotate: ;--tw-backdrop-invert: ;--tw-backdrop-opacity: ;--tw-backdrop-saturate: ;--tw-backdrop-sepia: }::backdrop{--tw-border-spacing-x:0;--tw-border-spacing-y:0;--tw-translate-x:0;--tw-translate-y:0;--tw-rotate:0;--tw-skew-x:0;--tw-skew-y:0;--tw-scale-x:1;--tw-scale-y:1;--tw-pan-x: ;--tw-pan-y: ;--tw-pinch-zoom: ;--tw-scroll-snap-strictness:proximity;--tw-gradient-from-position: ;--tw-gradient-via-position: ;--tw-gradient-to-position: ;--tw-ordinal: ;--tw-slashed-zero: ;--tw-numeric-figure: ;--tw-numeric-spacing: ;--tw-numeric-fraction: ;--tw-ring-inset: ;--tw-ring-offset-width:0px;--tw-ring-offset-color:#fff;--tw-ring-color:#3b82f680;--tw-ring-offset-shadow:0 0 #0000;--tw-ring-shadow:0 0 #0000;--tw-shadow:0 0 #0000;--tw-shadow-colored:0 0 #0000;--tw-blur: ;--tw-brightness: ;--tw-contrast: ;--tw-grayscale: ;--tw-hue-rotate: ;--tw-invert: ;--tw-saturate: ;--tw-sepia: ;--tw-drop-shadow: ;--tw-backdrop-blur: ;--tw-backdrop-brightness: ;--tw-backdrop-contrast: ;--tw-backdrop-grayscale: ;--tw-backdrop-hue-rotate: ;--tw-backdrop-invert: ;--tw-backdrop-opacity: ;--tw-backdrop-saturate: ;--tw-backdrop-sepia: }.\!container{width:100%!important}.container{width:100%}@media (min-width:1264px){.\!container{max-width:1264px!important}.container{max-width:1264px}}@media (min-width:1300px){.\!container{max-width:1300px!important}.container{max-width:1300px}}.aspect-h-1{--tw-aspect-h:1}.aspect-w-1{--tw-aspect-w:1;padding-bottom:calc(var(--tw-aspect-h)/var(--tw-aspect-w)*100%);position:relative}.aspect-w-1>*{bottom:0;height:100%;left:0;position:absolute;right:0;top:0;width:100%}.spinner{display:block;height:1.25rem;width:1.25rem}.spinner,.spinner:before{border-radius:100%;position:absolute}.spinner:before{--tw-content:"";--tw-translate-y:-50%;--tw-translate-x:-50%;--tw-bg-opacity:1;background-color:rgb(255 255 255/var(--tw-bg-opacity));content:var(--tw-content);height:1rem;left:50%;top:50%;transform:translate(var(--tw-translate-x),var(--tw-translate-y)) rotate(var(--tw-rotate)) skewX(var(--tw-skew-x)) skewY(var(--tw-skew-y)) scaleX(var(--tw-scale-x)) scaleY(var(--tw-scale-y));width:1rem}:is([data-color-scheme=dark] .spinner):before{--tw-bg-opacity:1;background-color:rgb(4 8 11/var(--tw-bg-opacity));content:var(--tw-content)}@keyframes spin{to{transform:rotate(1turn)}}.spinner{animation:spin 1s linear infinite;background-image:conic-gradient(var(--black-35),#0000)}@media (prefers-reduced-motion:reduce){.spinner{transition-property:none}}.sr-only{clip:rect(0,0,0,0);border-width:0;height:1px;margin:-1px;overflow:hidden;padding:0;position:absolute;white-space:nowrap;width:1px}.pointer-events-none{pointer-events:none}.pointer-events-auto{pointer-events:auto}.\!visible{visibility:visible!important}.visible{visibility:visible}.collapse{visibility:collapse}.static{position:static}.fixed{position:fixed}.absolute{position:absolute}.relative{position:relative}.sticky{position:-webkit-sticky;position:sticky}.inset-0{inset:0}.inset-x-0{left:0;right:0}.-right-2{right:-.125rem}.-top-1{top:-.0625rem}.-top-2{top:-.125rem}.bottom-0{bottom:0}.bottom-10{bottom:.625rem}.bottom-full{bottom:100%}.left-0{left:0}.left-1\/2{left:50%}.left-full{left:100%}.right-0{right:0}.right-12{right:.75rem}.right-16{right:1rem}.right-6{right:.375rem}.right-full{right:100%}.top-0{top:0}.top-1{top:.0625rem}.top-1\/2{top:50%}.top-12{top:.75rem}.top-20{top:1.25rem}.top-full{top:100%}.z-0{z-index:0}.z-1{z-index:1}.z-auto{z-index:auto}.z-modal{z-index:1050}.z-modal-backdrop{z-index:1040}.z-sticky{z-index:1020}.z-tooltip{z-index:1070}.order-first{order:-9999}.m-0{margin:0}.m-4{margin:.25rem}.-mx-12{margin-left:-.75rem;margin-right:-.75rem}.-mx-18{margin-left:-1.125rem;margin-right:-1.125rem}.-my-4{margin-bottom:-.25rem;margin-top:-.25rem}.mx-12{margin-left:.75rem;margin-right:.75rem}.mx-18{margin-left:1.125rem;margin-right:1.125rem}.mx-24{margin-left:1.5rem;margin-right:1.5rem}.mx-auto{margin-left:auto;margin-right:auto}.my-0{margin-bottom:0;margin-top:0}.my-12{margin-bottom:.75rem;margin-top:.75rem}.my-14{margin-bottom:.875rem;margin-top:.875rem}.my-16{margin-bottom:1rem;margin-top:1rem}.my-24{margin-bottom:1.5rem;margin-top:1.5rem}.my-48{margin-bottom:3rem;margin-top:3rem}.-ml-12{margin-left:-.75rem}.-ml-18{margin-left:-1.125rem}.-mt-12{margin-top:-.75rem}.-mt-18{margin-top:-1.125rem}.mb-0{margin-bottom:0}.mb-10{margin-bottom:.625rem}.mb-12{margin-bottom:.75rem}.mb-14{margin-bottom:.875rem}.mb-16{margin-bottom:1rem}.mb-18{margin-bottom:1.125rem}.mb-20{margin-bottom:1.25rem}.mb-24{margin-bottom:1.5rem}.mb-28{margin-bottom:1.75rem}.mb-30{margin-bottom:1.875rem}.mb-32{margin-bottom:2rem}.mb-36{margin-bottom:2.25rem}.mb-4{margin-bottom:.25rem}.mb-40{margin-bottom:2.5rem}.mb-48{margin-bottom:3rem}.mb-6{margin-bottom:.375rem}.mb-8{margin-bottom:.5rem}.mb-auto{margin-bottom:auto}.ml-0{margin-left:0}.ml-12{margin-left:.75rem}.ml-14{margin-left:.875rem}.ml-16{margin-left:1rem}.ml-18{margin-left:1.125rem}.ml-2{margin-left:.125rem}.ml-36{margin-left:2.25rem}.ml-4{margin-left:.25rem}.ml-8{margin-left:.5rem}.ml-auto{margin-left:auto}.mr-10{margin-right:.625rem}.mr-12{margin-right:.75rem}.mr-14{margin-right:.875rem}.mr-16{margin-right:1rem}.mr-18{margin-right:1.125rem}.mr-2{margin-right:.125rem}.mr-24{margin-right:1.5rem}.mr-28{margin-right:1.75rem}.mr-30{margin-right:1.875rem}.mr-36{margin-right:2.25rem}.mr-4{margin-right:.25rem}.mr-6{margin-right:.375rem}.mr-8{margin-right:.5rem}.mr-auto{margin-right:auto}.mt-10{margin-top:.625rem}.mt-12{margin-top:.75rem}.mt-14{margin-top:.875rem}.mt-16{margin-top:1rem}.mt-18{margin-top:1.125rem}.mt-2{margin-top:.125rem}.mt-24{margin-top:1.5rem}.mt-32{margin-top:2rem}.mt-4{margin-top:.25rem}.mt-8{margin-top:.5rem}.mt-auto{margin-top:auto}.box-border{box-sizing:border-box}.block{display:block}.inline-block{display:inline-block}.inline{display:inline}.flex{display:flex}.inline-flex{display:inline-flex}.\!table{display:table!important}.table{display:table}.grid{display:grid}.contents{display:contents}.list-item{display:list-item}.\!hidden{display:none!important}.hidden{display:none}.h-0{height:0}.h-1{height:.0625rem}.h-10{height:.625rem}.h-100{height:6.25rem}.h-12{height:.75rem}.h-120{height:7.5rem}.h-14{height:.875rem}.h-16{height:1rem}.h-170{height:10.625rem}.h-18{height:1.125rem}.h-20{height:1.25rem}.h-24{height:1.5rem}.h-240{height:15rem}.h-26{height:1.625rem}.h-28{height:1.75rem}.h-30{height:1.875rem}.h-32{height:2rem}.h-34{height:2.125rem}.h-36{height:2.25rem}.h-38{height:2.375rem}.h-4{height:.25rem}.h-40{height:2.5rem}.h-44{height:2.75rem}.h-48{height:3rem}.h-50{height:3.125rem}.h-60{height:3.75rem}.h-8{height:.5rem}.h-80{height:5rem}.h-auto{height:auto}.h-full{height:100%}.h-screen{height:100vh}.max-h-24{max-height:1.5rem}.max-h-full{max-height:100%}.min-h-0{min-height:0}.min-h-full{min-height:100%}.min-h-min{min-height:-webkit-min-content;min-height:min-content}.w-0{width:0}.w-1\/2{width:50%}.w-1\/4{width:25%}.w-10{width:.625rem}.w-100{width:6.25rem}.w-12{width:.75rem}.w-120{width:7.5rem}.w-14{width:.875rem}.w-16{width:1rem}.w-170{width:10.625rem}.w-18{width:1.125rem}.w-20{width:1.25rem}.w-24{width:1.5rem}.w-240{width:15rem}.w-26{width:1.625rem}.w-3\/4{width:75%}.w-30{width:1.875rem}.w-32{width:2rem}.w-36{width:2.25rem}.w-40{width:2.5rem}.w-44{width:2.75rem}.w-48{width:3rem}.w-50{width:3.125rem}.w-60{width:3.75rem}.w-8{width:.5rem}.w-80{width:5rem}.w-auto{width:auto}.w-full{width:100%}.w-max{width:-webkit-max-content;width:max-content}.min-w-0{min-width:0}.min-w-full{min-width:100%}.max-w-0{max-width:0}.max-w-5xl{max-width:64rem}.max-w-full{max-width:100%}.flex-1{flex:1 1 0%}.flex-auto{flex:1 1 auto}.flex-none{flex:none}.flex-shrink{flex-shrink:1}.flex-shrink-0,.shrink-0{flex-shrink:0}.flex-grow{flex-grow:1}.flex-grow-0{flex-grow:0}.grow{flex-grow:1}.grow-0{flex-grow:0}.basis-0{flex-basis:0px}.basis-full{flex-basis:100%}.-translate-x-1\/2{--tw-translate-x:-50%}.-translate-x-1\/2,.-translate-y-1\/2{transform:translate(var(--tw-translate-x),var(--tw-translate-y)) rotate(var(--tw-rotate)) skewX(var(--tw-skew-x)) skewY(var(--tw-skew-y)) scaleX(var(--tw-scale-x)) scaleY(var(--tw-scale-y))}.-translate-y-1\/2{--tw-translate-y:-50%}.translate-x-0{--tw-translate-x:0px}.translate-x-0,.translate-x-12{transform:translate(var(--tw-translate-x),var(--tw-translate-y)) rotate(var(--tw-rotate)) skewX(var(--tw-skew-x)) skewY(var(--tw-skew-y)) scaleX(var(--tw-scale-x)) scaleY(var(--tw-scale-y))}.translate-x-12{--tw-translate-x:0.75rem}.translate-y-1{--tw-translate-y:0.0625rem}.-rotate-90,.translate-y-1{transform:translate(var(--tw-translate-x),var(--tw-translate-y)) rotate(var(--tw-rotate)) skewX(var(--tw-skew-x)) skewY(var(--tw-skew-y)) scaleX(var(--tw-scale-x)) scaleY(var(--tw-scale-y))}.-rotate-90{--tw-rotate:-90deg}.rotate-0{--tw-rotate:0deg}.rotate-0,.rotate-180{transform:translate(var(--tw-translate-x),var(--tw-translate-y)) rotate(var(--tw-rotate)) skewX(var(--tw-skew-x)) skewY(var(--tw-skew-y)) scaleX(var(--tw-scale-x)) scaleY(var(--tw-scale-y))}.rotate-180{--tw-rotate:180deg}.rotate-90{--tw-rotate:90deg}.rotate-90,.transform{transform:translate(var(--tw-translate-x),var(--tw-translate-y)) rotate(var(--tw-rotate)) skewX(var(--tw-skew-x)) skewY(var(--tw-skew-y)) scaleX(var(--tw-scale-x)) scaleY(var(--tw-scale-y))}.cursor-default{cursor:default}.cursor-none{cursor:none}.cursor-pointer{cursor:pointer}.cursor-text{cursor:text}.select-none{-webkit-user-select:none;user-select:none}.resize{resize:both}.list-inside{list-style-position:inside}.list-none{list-style-type:none}.grid-cols-1{grid-template-columns:repeat(1,minmax(0,1fr))}.flex-row{flex-direction:row}.flex-row-reverse{flex-direction:row-reverse}.flex-col{flex-direction:column}.flex-col-reverse{flex-direction:column-reverse}.flex-wrap{flex-wrap:wrap}.flex-nowrap{flex-wrap:nowrap}.items-start{align-items:flex-start}.items-end{align-items:flex-end}.items-center{align-items:center}.items-baseline{align-items:baseline}.items-stretch{align-items:stretch}.justify-start{justify-content:flex-start}.justify-end{justify-content:flex-end}.justify-center{justify-content:center}.justify-between{justify-content:space-between}.justify-items-center{justify-items:center}.gap-16{gap:1rem}.gap-28{gap:1.75rem}.gap-32{gap:2rem}.gap-y-8{row-gap:.5rem}.self-start{align-self:flex-start}.self-stretch{align-self:stretch}.overflow-auto{overflow:auto}.overflow-hidden{overflow:hidden}.overflow-visible{overflow:visible}.overflow-y-auto{overflow-y:auto}.overflow-x-hidden{overflow-x:hidden}.overscroll-contain{overscroll-behavior:contain}.truncate{overflow:hidden;white-space:nowrap}.text-ellipsis,.truncate{text-overflow:ellipsis}.whitespace-nowrap{white-space:nowrap}.whitespace-pre-line{white-space:pre-line}.rounded-0{border-radius:0}.rounded-3{border-radius:.1875rem}.rounded-4{border-radius:.25rem}.rounded-8{border-radius:.5rem}.rounded-full{border-radius:100%}.rounded-b-0{border-bottom-left-radius:0;border-bottom-right-radius:0}.rounded-b-4{border-bottom-left-radius:.25rem;border-bottom-right-radius:.25rem}.rounded-r-8{border-bottom-right-radius:.5rem;border-top-right-radius:.5rem}.rounded-t-4{border-top-left-radius:.25rem;border-top-right-radius:.25rem}.rounded-bl-8{border-bottom-left-radius:.5rem}.rounded-tl-0{border-top-left-radius:0}.border{border-width:.0625rem}.border-0{border-width:0}.border-2{border-width:.125rem}.border-6{border-width:.375rem}.border-y{border-bottom-width:.0625rem;border-top-width:.0625rem}.border-y-0{border-bottom-width:0;border-top-width:0}.border-b{border-bottom-width:.0625rem}.border-b-0{border-bottom-width:0}.border-l-6{border-left-width:.375rem}.border-r-0{border-right-width:0}.border-r-4{border-right-width:.25rem}.border-t{border-top-width:.0625rem}.border-t-0{border-top-width:0}.border-solid{border-style:solid}.border-black{--tw-border-opacity:1;border-color:rgb(0 0 0/var(--tw-border-opacity))}.border-black-10{--tw-border-opacity:1;border-color:rgb(219 219 219/var(--tw-border-opacity))}.border-black-35{--tw-border-opacity:1;border-color:rgb(117 117 117/var(--tw-border-opacity))}.border-black-50{--tw-border-opacity:1;border-color:rgb(85 85 85/var(--tw-border-opacity))}.border-blue-75{--tw-border-opacity:1;border-color:rgb(26 152 255/var(--tw-border-opacity))}.border-blue-75\/25{border-color:#1a98ff40}.border-blue-75\/50{border-color:#1a98ff80}.border-blue-75\/75{border-color:#1a98ffbf}.border-navy{--tw-border-opacity:1;border-color:rgb(36 40 50/var(--tw-border-opacity))}.border-navy-40{--tw-border-opacity:1;border-color:rgb(141 146 159/var(--tw-border-opacity))}.border-red{--tw-border-opacity:1;border-color:rgb(201 57 44/var(--tw-border-opacity))}.border-share-bg-4{border-color:var(--sa-body-bg-color-4)}.border-share-negative{border-color:var(--sa-negative-color)}.border-share-separator-thin{border-color:var(--sa-section-separator-thin-color)}.border-share-text-2{border-color:var(--sa-text-color-2)}.border-transparent{border-color:#0000}.border-y-black-10{border-top-color:rgb(219 219 219/var(--tw-border-opacity))}.border-b-black-10,.border-y-black-10{--tw-border-opacity:1;border-bottom-color:rgb(219 219 219/var(--tw-border-opacity))}.border-l-blue-75{--tw-border-opacity:1;border-left-color:rgb(26 152 255/var(--tw-border-opacity))}.border-l-transparent{border-left-color:#0000}.border-r-transparent{border-right-color:#0000}.border-t-transparent{border-top-color:#0000}.\!bg-green-90{--tw-bg-opacity:1!important;background-color:rgb(93 146 28/var(--tw-bg-opacity))!important}.bg-black{--tw-bg-opacity:1;background-color:rgb(0 0 0/var(--tw-bg-opacity))}.bg-black-10{--tw-bg-opacity:1;background-color:rgb(219 219 219/var(--tw-bg-opacity))}.bg-black-20{--tw-bg-opacity:1;background-color:rgb(172 172 172/var(--tw-bg-opacity))}.bg-black-30\/40{background-color:#838d8f66}.bg-black-35{--tw-bg-opacity:1;background-color:rgb(117 117 117/var(--tw-bg-opacity))}.bg-black-4{--tw-bg-opacity:1;background-color:rgb(249 249 249/var(--tw-bg-opacity))}.bg-black-5{--tw-bg-opacity:1;background-color:rgb(242 244 247/var(--tw-bg-opacity))}.bg-black-50{--tw-bg-opacity:1;background-color:rgb(85 85 85/var(--tw-bg-opacity))}.bg-black-v2-20{--tw-bg-opacity:1;background-color:rgb(224 225 228/var(--tw-bg-opacity))}.bg-black-v2-90{--tw-bg-opacity:1;background-color:rgb(16 17 20/var(--tw-bg-opacity))}.bg-black\/60{background-color:#0009}.bg-blue-75{--tw-bg-opacity:1;background-color:rgb(26 152 255/var(--tw-bg-opacity))}.bg-brand-sa{background-color:var(--seeking-alpha-color)}.bg-green{--tw-bg-opacity:1;background-color:rgb(61 95 18/var(--tw-bg-opacity))}.bg-green-v2{--tw-bg-opacity:1;background-color:rgb(24 69 21/var(--tw-bg-opacity))}.bg-green-v2-65{--tw-bg-opacity:1;background-color:rgb(89 163 83/var(--tw-bg-opacity))}.bg-green-v2-80{--tw-bg-opacity:1;background-color:rgb(64 142 58/var(--tw-bg-opacity))}.bg-green-v2-85{--tw-bg-opacity:1;background-color:rgb(44 122 38/var(--tw-bg-opacity))}.bg-green-v2-90{--tw-bg-opacity:1;background-color:rgb(54 99 50/var(--tw-bg-opacity))}.bg-green-v2-95{--tw-bg-opacity:1;background-color:rgb(38 85 35/var(--tw-bg-opacity))}.bg-navy{--tw-bg-opacity:1;background-color:rgb(36 40 50/var(--tw-bg-opacity))}.bg-orange-60{--tw-bg-opacity:1;background-color:rgb(255 114 0/var(--tw-bg-opacity))}.bg-red{--tw-bg-opacity:1;background-color:rgb(201 57 44/var(--tw-bg-opacity))}.bg-red-v2{--tw-bg-opacity:1;background-color:rgb(124 31 31/var(--tw-bg-opacity))}.bg-red-v2-50{--tw-bg-opacity:1;background-color:rgb(222 78 78/var(--tw-bg-opacity))}.bg-red-v2-70{--tw-bg-opacity:1;background-color:rgb(206 52 52/var(--tw-bg-opacity))}.bg-red-v2-80{--tw-bg-opacity:1;background-color:rgb(191 29 29/var(--tw-bg-opacity))}.bg-share-aside-bg{background-color:var(--sa-aside-background-color)}.bg-share-bg-2{background-color:var(--sa-body-bg-color-2)}.bg-share-bg-4{background-color:var(--sa-body-bg-color-4)}.bg-share-card-bg{background-color:var(--sa-card-bg-color)}.bg-share-link{background-color:var(--sa-link-color)}.bg-share-modal-container{background-color:var(--sa-modal-container-bg-color)}.bg-share-negative{background-color:var(--sa-negative-color)}.bg-share-positive{background-color:var(--sa-positive-color)}.bg-share-text{background-color:var(--sa-text-color-1)}.bg-share-text-2{background-color:var(--sa-text-color-2)}.bg-share-text-3{background-color:var(--sa-text-color-3)}.bg-teal{--tw-bg-opacity:1;background-color:rgb(10 123 68/var(--tw-bg-opacity))}.bg-transparent{background-color:initial}.bg-white{--tw-bg-opacity:1;background-color:rgb(255 255 255/var(--tw-bg-opacity))}.bg-white-96{--tw-bg-opacity:1;background-color:rgb(243 244 247/var(--tw-bg-opacity))}.bg-yellow-85{--tw-bg-opacity:1;background-color:rgb(254 194 15/var(--tw-bg-opacity))}.bg-yellow-v2{--tw-bg-opacity:1;background-color:rgb(214 193 0/var(--tw-bg-opacity))}.bg-yellow-v2-70{--tw-bg-opacity:1;background-color:rgb(255 235 51/var(--tw-bg-opacity))}.bg-yellow-v2-80{--tw-bg-opacity:1;background-color:rgb(235 213 23/var(--tw-bg-opacity))}.bg-gradient-to-r{background-image:linear-gradient(to right,var(--tw-gradient-stops))}.from-black-10{--tw-gradient-from:#dbdbdb var(--tw-gradient-from-position);--tw-gradient-to:#dbdbdb00 var(--tw-gradient-to-position);--tw-gradient-stops:var(--tw-gradient-from),var(--tw-gradient-to)}.to-white{--tw-gradient-to:#fff var(--tw-gradient-to-position)}.bg-cover{background-size:cover}.bg-clip-padding{background-clip:padding-box}.bg-center{background-position:50%}.bg-no-repeat{background-repeat:no-repeat}.fill-black{fill:#000}.fill-black-10{fill:#dbdbdb}.fill-black-20{fill:#acacac}.fill-black-35{fill:#757575}.fill-black-50{fill:#555}.fill-current{fill:currentColor}.fill-red{fill:#c9392c}.fill-share-negative{fill:var(--sa-negative-color)}.fill-share-positive{fill:var(--sa-positive-color)}.fill-share-text-2{fill:var(--sa-text-color-2)}.fill-share-text-6{fill:var(--sa-text-color-6)}.fill-teal{fill:#0a7b44}.fill-transparent{fill:#0000}.fill-white{fill:#fff}.fill-yellow-90{fill:#efa818}.stroke-black-35{stroke:#757575}.stroke-yellow-90{stroke:#efa818}.object-contain{object-fit:contain}.p-0{padding:0}.p-12{padding:.75rem}.p-16{padding:1rem}.p-18{padding:1.125rem}.p-2{padding:.125rem}.p-4{padding:.25rem}.p-6{padding:.375rem}.p-8{padding:.5rem}.px-0{padding-left:0;padding-right:0}.px-12{padding-left:.75rem;padding-right:.75rem}.px-14{padding-left:.875rem;padding-right:.875rem}.px-18{padding-left:1.125rem;padding-right:1.125rem}.px-20{padding-left:1.25rem;padding-right:1.25rem}.px-24{padding-left:1.5rem;padding-right:1.5rem}.px-32{padding-left:2rem;padding-right:2rem}.px-36{padding-left:2.25rem;padding-right:2.25rem}.px-38{padding-left:2.375rem;padding-right:2.375rem}.px-4{padding-left:.25rem;padding-right:.25rem}.px-6{padding-left:.375rem;padding-right:.375rem}.px-8{padding-left:.5rem;padding-right:.5rem}.py-0{padding-bottom:0;padding-top:0}.py-10{padding-bottom:.625rem;padding-top:.625rem}.py-12{padding-bottom:.75rem;padding-top:.75rem}.py-14{padding-bottom:.875rem;padding-top:.875rem}.py-16{padding-bottom:1rem;padding-top:1rem}.py-18{padding-bottom:1.125rem;padding-top:1.125rem}.py-2{padding-bottom:.125rem;padding-top:.125rem}.py-20{padding-bottom:1.25rem;padding-top:1.25rem}.py-24{padding-bottom:1.5rem;padding-top:1.5rem}.py-26{padding-bottom:1.625rem;padding-top:1.625rem}.py-4{padding-bottom:.25rem;padding-top:.25rem}.py-48{padding-bottom:3rem;padding-top:3rem}.py-6{padding-bottom:.375rem;padding-top:.375rem}.py-8{padding-bottom:.5rem;padding-top:.5rem}.pb-0{padding-bottom:0}.pb-10{padding-bottom:.625rem}.pb-12{padding-bottom:.75rem}.pb-18{padding-bottom:1.125rem}.pb-20{padding-bottom:1.25rem}.pb-24{padding-bottom:1.5rem}.pb-28{padding-bottom:1.75rem}.pb-4{padding-bottom:.25rem}.pb-40{padding-bottom:2.5rem}.pb-48{padding-bottom:3rem}.pb-6{padding-bottom:.375rem}.pb-8{padding-bottom:.5rem}.pl-0{padding-left:0}.pl-12{padding-left:.75rem}.pl-14{padding-left:.875rem}.pl-18{padding-left:1.125rem}.pl-20{padding-left:1.25rem}.pl-24{padding-left:1.5rem}.pl-28{padding-left:1.75rem}.pl-32{padding-left:2rem}.pl-36{padding-left:2.25rem}.pl-40{padding-left:2.5rem}.pr-24{padding-right:1.5rem}.pr-30{padding-right:1.875rem}.pr-38{padding-right:2.375rem}.pr-48{padding-right:3rem}.ps-0{padding-inline-start:0}.pt-0{padding-top:0}.pt-10{padding-top:.625rem}.pt-12{padding-top:.75rem}.pt-14{padding-top:.875rem}.pt-16{padding-top:1rem}.pt-18{padding-top:1.125rem}.pt-2{padding-top:.125rem}.pt-20{padding-top:1.25rem}.pt-24{padding-top:1.5rem}.pt-32{padding-top:2rem}.pt-4{padding-top:.25rem}.pt-42{padding-top:2.625rem}.pt-48{padding-top:3rem}.pt-8{padding-top:.5rem}.text-left{text-align:left}.text-center{text-align:center}.text-right{text-align:right}.align-top{vertical-align:top}.align-middle{vertical-align:middle}.text-2x-large-2-r{font-size:1.25rem;font-weight:400;line-height:1.875rem}.text-2x-large-r{font-size:1.25rem;font-weight:400;line-height:1.5rem}.text-2x-small-b{font-weight:700}.text-2x-small-b,.text-2x-small-r{font-size:.625rem;line-height:.75rem}.text-2x-small-r{font-weight:400}.text-3x-large-2-b{font-size:1.375rem;font-weight:700;line-height:2rem}.text-3x-large-b{font-size:1.375rem;font-weight:700;line-height:1.625rem}.text-4x-large-2-b{font-size:1.5rem;font-weight:700;line-height:2.25rem}.text-4x-large-b{font-weight:700}.text-4x-large-b,.text-4x-large-r{font-size:1.5rem;line-height:1.875rem}.text-4x-large-r{font-weight:400}.text-5x-large-b{font-weight:700}.text-5x-large-b,.text-5x-large-r{font-size:1.75rem;line-height:2.125rem}.text-5x-large-r{font-weight:400}.text-6x-large-b{font-size:2rem;font-weight:700;line-height:2.375rem}.text-7x-large-b{font-weight:700}.text-7x-large-b,.text-7x-large-r{font-size:2.25rem;line-height:2.75rem}.text-7x-large-r{font-weight:400}.text-large-2-r{font-size:1rem;font-weight:400;line-height:1.5rem}.text-large-b{font-weight:700}.text-large-b,.text-large-r{font-size:1rem;line-height:1.25rem}.text-large-r{font-weight:400}.text-medium-2-r{font-size:.875rem;font-weight:400;line-height:1.25rem}.text-medium-3-r{font-size:.875rem;font-weight:400;line-height:1.75rem}.text-medium-b{font-weight:700}.text-medium-b,.text-medium-r{font-size:.875rem;line-height:1rem}.text-medium-r{font-weight:400}.text-small-2-r{font-size:.75rem;font-weight:400;line-height:1.25rem}.text-small-b{font-weight:700}.text-small-b,.text-small-r{font-size:.75rem;line-height:.875rem}.text-small-r{font-weight:400}.text-x-large-2-b{font-weight:700}.text-x-large-2-b,.text-x-large-2-r{font-size:1.125rem;line-height:1.625rem}.text-x-large-2-r{font-weight:400}.text-x-large-b{font-weight:700}.text-x-large-b,.text-x-large-r{font-size:1.125rem;line-height:1.375rem}.text-x-large-r{font-weight:400}.text-x-small-r{font-size:.6875rem;font-weight:400;line-height:.8125rem}.font-bold{font-weight:700}.font-medium{font-weight:500}.font-semibold{font-weight:600}.uppercase{text-transform:uppercase}.capitalize{text-transform:capitalize}.italic{font-style:italic}.ordinal{--tw-ordinal:ordinal;font-variant-numeric:var(--tw-ordinal) var(--tw-slashed-zero) var(--tw-numeric-figure) var(--tw-numeric-spacing) var(--tw-numeric-fraction)}.leading-3{line-height:.75rem}.leading-none{line-height:1}.text-black{--tw-text-opacity:1;color:rgb(0 0 0/var(--tw-text-opacity))}.text-black-10{--tw-text-opacity:1;color:rgb(219 219 219/var(--tw-text-opacity))}.text-black-20{--tw-text-opacity:1;color:rgb(172 172 172/var(--tw-text-opacity))}.text-black-35{--tw-text-opacity:1;color:rgb(117 117 117/var(--tw-text-opacity))}.text-black-50{--tw-text-opacity:1;color:rgb(85 85 85/var(--tw-text-opacity))}.text-black-60{--tw-text-opacity:1;color:rgb(67 67 72/var(--tw-text-opacity))}.text-black-70{--tw-text-opacity:1;color:rgb(51 51 51/var(--tw-text-opacity))}.text-black-v2-70{--tw-text-opacity:1;color:rgb(63 66 72/var(--tw-text-opacity))}.text-black-v2-90{--tw-text-opacity:1;color:rgb(16 17 20/var(--tw-text-opacity))}.text-blue-75{--tw-text-opacity:1;color:rgb(26 152 255/var(--tw-text-opacity))}.text-blue-80{--tw-text-opacity:1;color:rgb(40 103 219/var(--tw-text-opacity))}.text-brand-premium{--tw-text-opacity:1;color:rgb(17 113 143/var(--tw-text-opacity))}.text-brand-pro{--tw-text-opacity:1;color:rgb(204 229 92/var(--tw-text-opacity))}.text-brand-sa{color:var(--seeking-alpha-color)}.text-orange-60{--tw-text-opacity:1;color:rgb(255 114 0/var(--tw-text-opacity))}.text-red{--tw-text-opacity:1;color:rgb(201 57 44/var(--tw-text-opacity))}.text-share-link{color:var(--sa-link-color)}.text-share-negative{color:var(--sa-negative-color)}.text-share-positive{color:var(--sa-positive-color)}.text-share-text{color:var(--sa-text-color-1)}.text-share-text-2{color:var(--sa-text-color-2)}.text-share-text-3{color:var(--sa-text-color-3)}.text-share-text-6{color:var(--sa-text-color-6)}.text-white{--tw-text-opacity:1;color:rgb(255 255 255/var(--tw-text-opacity))}.text-white-96{--tw-text-opacity:1;color:rgb(243 244 247/var(--tw-text-opacity))}.text-yellow-85{--tw-text-opacity:1;color:rgb(254 194 15/var(--tw-text-opacity))}.underline{text-decoration-line:underline}.no-underline{text-decoration-line:none}.opacity-0{opacity:0}.opacity-100{opacity:1}.opacity-30{opacity:.3}.opacity-50{opacity:.5}.opacity-60{opacity:.6}.shadow{--tw-shadow:0 1px 3px 0 #0000001a,0 1px 2px -1px #0000001a;--tw-shadow-colored:0 1px 3px 0 var(--tw-shadow-color),0 1px 2px -1px var(--tw-shadow-color)}.shadow,.shadow-none{box-shadow:var(--tw-ring-offset-shadow,0 0 #0000),var(--tw-ring-shadow,0 0 #0000),var(--tw-shadow)}.shadow-none{--tw-shadow:0 0 #0000;--tw-shadow-colored:0 0 #0000}.shadow-transparent{--tw-shadow-color:#0000;--tw-shadow:var(--tw-shadow-colored)}.outline-none{outline:2px solid #0000;outline-offset:2px}.outline{outline-style:solid}.blur{--tw-blur:blur(8px)}.blur,.invert{filter:var(--tw-blur) var(--tw-brightness) var(--tw-contrast) var(--tw-grayscale) var(--tw-hue-rotate) var(--tw-invert) var(--tw-saturate) var(--tw-sepia) var(--tw-drop-shadow)}.invert{--tw-invert:invert(100%)}.\!filter{filter:var(--tw-blur) var(--tw-brightness) var(--tw-contrast) var(--tw-grayscale) var(--tw-hue-rotate) var(--tw-invert) var(--tw-saturate) var(--tw-sepia) var(--tw-drop-shadow)!important}.filter{filter:var(--tw-blur) var(--tw-brightness) var(--tw-contrast) var(--tw-grayscale) var(--tw-hue-rotate) var(--tw-invert) var(--tw-saturate) var(--tw-sepia) var(--tw-drop-shadow)}.filter-none{filter:none}.transition{transition-duration:.15s;transition-property:color,background-color,border-color,text-decoration-color,fill,stroke,opacity,box-shadow,transform,filter,-webkit-backdrop-filter;transition-property:color,background-color,border-color,text-decoration-color,fill,stroke,opacity,box-shadow,transform,filter,backdrop-filter;transition-property:color,background-color,border-color,text-decoration-color,fill,stroke,opacity,box-shadow,transform,filter,backdrop-filter,-webkit-backdrop-filter;transition-timing-function:cubic-bezier(.4,0,.2,1)}.transition-colors{transition-duration:.15s;transition-property:color,background-color,border-color,text-decoration-color,fill,stroke;transition-timing-function:cubic-bezier(.4,0,.2,1)}.pl-safe{padding-left:env(safe-area-inset-left)}.px-safe-offset-10{padding-left:calc(env(safe-area-inset-left) + .625rem);padding-right:calc(env(safe-area-inset-right) + .625rem)}.px-safe-offset-12{padding-left:calc(env(safe-area-inset-left) + .75rem);padding-right:calc(env(safe-area-inset-right) + .75rem)}.px-safe-offset-18{padding-left:calc(env(safe-area-inset-left) + 1.125rem);padding-right:calc(env(safe-area-inset-right) + 1.125rem)}.px-safe-offset-20{padding-left:calc(env(safe-area-inset-left) + 1.25rem);padding-right:calc(env(safe-area-inset-right) + 1.25rem)}.p-safe-or-20{padding:max(env(safe-area-inset-top),1.25rem) max(env(safe-area-inset-right),1.25rem) max(env(safe-area-inset-bottom),1.25rem) max(env(safe-area-inset-left),1.25rem)}.pt-safe-or-18{padding-top:max(env(safe-area-inset-top),1.125rem)}.pt-safe-or-24{padding-top:max(env(safe-area-inset-top),1.5rem)}.pt-safe-or-6{padding-top:max(env(safe-area-inset-top),.375rem)}.px-safe-or-18{padding-left:max(env(safe-area-inset-left),1.125rem);padding-right:max(env(safe-area-inset-right),1.125rem)}.px-safe-or-20{padding-left:max(env(safe-area-inset-left),1.25rem);padding-right:max(env(safe-area-inset-right),1.25rem)}.sa-row-gap-18{margin-bottom:1.125rem;margin-left:-1.125rem;margin-top:-1.125rem}.sa-row-gap-18>*{padding-left:1.125rem;padding-top:1.125rem}.sa-row-gap-20{margin-bottom:1.25rem;margin-left:-1.25rem;margin-top:-1.25rem}.sa-row-gap-20>*{padding-left:1.25rem;padding-top:1.25rem}.sa-row-gap-22{margin-bottom:1.375rem;margin-left:-1.375rem;margin-top:-1.375rem}.sa-row-gap-22>*{padding-left:1.375rem;padding-top:1.375rem}.sa-row-gap-24{margin-bottom:1.5rem;margin-left:-1.5rem;margin-top:-1.5rem}.sa-row-gap-24>*{padding-left:1.5rem;padding-top:1.5rem}.sa-row-gap-32{margin-bottom:2rem;margin-left:-2rem;margin-top:-2rem}.sa-row-gap-32>*{padding-left:2rem;padding-top:2rem}.sa-row-gap-36{margin-bottom:2.25rem;margin-left:-2.25rem;margin-top:-2.25rem}.sa-row-gap-36>*{padding-left:2.25rem;padding-top:2.25rem}.sa-row-gap-48{margin-bottom:3rem;margin-left:-3rem;margin-top:-3rem}.sa-row-gap-48>*{padding-left:3rem;padding-top:3rem}.sa-row-collapse-gutter{margin-left:0;margin-top:0}.sa-row-collapse-gutter>*{padding-left:0;padding-top:0}.sa-row-collapse-v-gutter{margin-bottom:0;margin-top:0}.sa-row-collapse-v-gutter>*{padding-top:0}.sa-row-stretch-content>.sa-col>*{flex-grow:1}.vendor-clear-input-button{-moz-appearance:textfield}.vendor-clear-input-button::-webkit-calendar-picker-indicator,.vendor-clear-input-button::-webkit-clear-button,.vendor-clear-input-button::-webkit-inner-spin-button{-webkit-appearance:none;appearance:none;display:none}.vendor-clear-input-button::-webkit-autofill{--shadow-color:#fff;--fill-color:#000;-webkit-text-fill-color:var(--fill-color);box-shadow:0 0 0 1000px var(--shadow-color) inset}[data-color-scheme=dark] .vendor-clear-input-button::-webkit-autofill{--shadow-color:#04080b;--fill-color:#dbdbdb}.vendor-clear-input-button::-ms-clear{display:none}.\[prop\:string\]{prop:string}.marker\:text-blue-75 ::marker{color:#1a98ff}.marker\:text-blue-75::marker{color:#1a98ff}.placeholder\:text-black-35::placeholder{--tw-text-opacity:1;color:rgb(117 117 117/var(--tw-text-opacity))}.placeholder\:text-navy-80::placeholder{--tw-text-opacity:1;color:rgb(65 74 95/var(--tw-text-opacity))}.before\:inline-flex:before{content:var(--tw-content);display:inline-flex}.before\:flex-none:before{content:var(--tw-content);flex:none}.before\:items-center:before{align-items:center;content:var(--tw-content)}.before\:justify-center:before{content:var(--tw-content);justify-content:center}.before\:rounded-full:before{border-radius:100%;content:var(--tw-content)}.before\:border:before{border-width:.0625rem;content:var(--tw-content)}.before\:border-solid:before{border-style:solid;content:var(--tw-content)}.before\:border-blue-75:before{--tw-border-opacity:1;border-color:rgb(26 152 255/var(--tw-border-opacity));content:var(--tw-content)}.before\:text-blue-75:before{--tw-text-opacity:1;color:rgb(26 152 255/var(--tw-text-opacity));content:var(--tw-content)}.before\:content-\[counter\(myCounter\)\]:before{--tw-content:counter(myCounter);content:var(--tw-content)}.after\:absolute:after{content:var(--tw-content);position:absolute}.after\:inset-x-20:after{content:var(--tw-content);left:1.25rem;right:1.25rem}.after\:bottom-0:after{bottom:0;content:var(--tw-content)}.after\:right-18:after{content:var(--tw-content);right:1.125rem}.after\:z-1:after{content:var(--tw-content);z-index:1}.after\:block:after{content:var(--tw-content);display:block}.after\:hidden:after{content:var(--tw-content);display:none}.after\:h-1:after{content:var(--tw-content);height:.0625rem}.after\:h-16:after{content:var(--tw-content);height:1rem}.after\:h-8:after{content:var(--tw-content);height:.5rem}.after\:w-16:after{content:var(--tw-content);width:1rem}.after\:w-8:after{content:var(--tw-content);width:.5rem}.after\:w-full:after{content:var(--tw-content);width:100%}.after\:rotate-180:after{content:var(--tw-content);transform:translate(var(--tw-translate-x),var(--tw-translate-y)) rotate(var(--tw-rotate)) skewX(var(--tw-skew-x)) skewY(var(--tw-skew-y)) scaleX(var(--tw-scale-x)) scaleY(var(--tw-scale-y))}.after\:rotate-180:after{--tw-rotate:180deg}.after\:bg-black-v2-25:after{--tw-bg-opacity:1;background-color:rgb(173 177 186/var(--tw-bg-opacity));content:var(--tw-content)}.after\:content-\[\'\'\]:after{--tw-content:"";content:var(--tw-content)}.first\:pl-0:first-child{padding-left:0}.first\:text-left:first-child{text-align:left}.first\:pt-safe-offset-0:first-child{padding-top:calc(env(safe-area-inset-top))}.first\:px-safe-offset-18:first-child{padding-left:calc(env(safe-area-inset-left) + 1.125rem);padding-right:calc(env(safe-area-inset-right) + 1.125rem)}.last\:mb-0:last-child{margin-bottom:0}.last\:mr-0:last-child{margin-right:0}.last\:border-0:last-child{border-width:0}.last\:border-none:last-child{border-style:none}.last\:pr-0:last-child{padding-right:0}.last\:pr-30:last-child{padding-right:1.875rem}.last\:after\:hidden:last-child:after{content:var(--tw-content);display:none}.only\:mb-18:only-child{margin-bottom:1.125rem}.last-of-type\:mr-0:last-of-type{margin-right:0}.visited\:text-black-60:visited{color:#434348}.visited\:text-black-70:visited{color:#333}.visited\:text-share-text:visited{color:var(--sa-text-color-1)}.visited\:text-share-text-6:visited{color:var(--sa-text-color-6)}.visited\:no-underline:visited{text-decoration-line:none}.invalid\:shadow-none:invalid{--tw-shadow:0 0 #0000;--tw-shadow-colored:0 0 #0000;box-shadow:var(--tw-ring-offset-shadow,0 0 #0000),var(--tw-ring-shadow,0 0 #0000),var(--tw-shadow)}.read-only\:bg-black-5:read-only{--tw-bg-opacity:1;background-color:rgb(242 244 247/var(--tw-bg-opacity))}.read-only\:text-black-35:read-only{--tw-text-opacity:1;color:rgb(117 117 117/var(--tw-text-opacity))}.read-only\:text-navy-80:read-only{--tw-text-opacity:1;color:rgb(65 74 95/var(--tw-text-opacity))}.read-only\:opacity-100:read-only{opacity:1}.empty\:hidden:empty{display:none}.focus-within\:border-navy-40:focus-within{--tw-border-opacity:1;border-color:rgb(141 146 159/var(--tw-border-opacity))}.focus-within\:border-share-negative:focus-within{border-color:var(--sa-negative-color)}.hover\:border-black-50:hover{--tw-border-opacity:1;border-color:rgb(85 85 85/var(--tw-border-opacity))}.hover\:bg-black-10:hover{--tw-bg-opacity:1;background-color:rgb(219 219 219/var(--tw-bg-opacity))}.hover\:bg-black-5:hover{--tw-bg-opacity:1;background-color:rgb(242 244 247/var(--tw-bg-opacity))}.hover\:bg-black-50:hover{--tw-bg-opacity:1;background-color:rgb(85 85 85/var(--tw-bg-opacity))}.hover\:fill-black-50:hover{fill:#555}.hover\:text-black-80:hover{--tw-text-opacity:1;color:rgb(44 48 50/var(--tw-text-opacity))}.hover\:text-blue-75:hover{--tw-text-opacity:1;color:rgb(26 152 255/var(--tw-text-opacity))}.hover\:text-share-text:hover{color:var(--sa-text-color-1)}.hover\:text-share-text-6:hover{color:var(--sa-text-color-6)}.hover\:text-white:hover{--tw-text-opacity:1;color:rgb(255 255 255/var(--tw-text-opacity))}.hover\:underline:hover{text-decoration-line:underline}.hover\:no-underline:hover{text-decoration-line:none}.focus\:border-black-35:focus{--tw-border-opacity:1;border-color:rgb(117 117 117/var(--tw-border-opacity))}.focus\:border-red:focus{--tw-border-opacity:1;border-color:rgb(201 57 44/var(--tw-border-opacity))}.focus\:fill-black-50:focus{fill:#555}.focus\:text-share-text:focus{color:var(--sa-text-color-1)}.focus\:text-share-text-6:focus{color:var(--sa-text-color-6)}.focus\:underline:focus{text-decoration-line:underline}.focus\:no-underline:focus{text-decoration-line:none}.active\:bg-black-10:active{--tw-bg-opacity:1;background-color:rgb(219 219 219/var(--tw-bg-opacity))}.disabled\:pointer-events-none:disabled{pointer-events:none}.disabled\:cursor-default:disabled{cursor:default}.disabled\:cursor-none:disabled{cursor:none}.disabled\:border-black-10:disabled{--tw-border-opacity:1;border-color:rgb(219 219 219/var(--tw-border-opacity))}.disabled\:bg-black-5:disabled{--tw-bg-opacity:1;background-color:rgb(242 244 247/var(--tw-bg-opacity))}.disabled\:text-black-10:disabled{--tw-text-opacity:1;color:rgb(219 219 219/var(--tw-text-opacity))}.disabled\:opacity-100:disabled{opacity:1}.disabled\:opacity-40:disabled{opacity:.4}.group:hover .group-hover\:fill-black-35\/50{fill:#75757580}.group:hover .group-hover\:fill-yellow-90\/50{fill:#efa81880}:is([data-color-scheme=dark] .dark\:border-black-10){--tw-border-opacity:1;border-color:rgb(219 219 219/var(--tw-border-opacity))}:is([data-color-scheme=dark] .dark\:border-black-30){--tw-border-opacity:1;border-color:rgb(131 141 143/var(--tw-border-opacity))}:is([data-color-scheme=dark] .dark\:border-black-50){--tw-border-opacity:1;border-color:rgb(85 85 85/var(--tw-border-opacity))}:is([data-color-scheme=dark] .dark\:border-black-80){--tw-border-opacity:1;border-color:rgb(44 48 50/var(--tw-border-opacity))}:is([data-color-scheme=dark] .dark\:border-black-90){--tw-border-opacity:1;border-color:rgb(35 42 50/var(--tw-border-opacity))}:is([data-color-scheme=dark] .dark\:border-black-v2-70){--tw-border-opacity:1;border-color:rgb(63 66 72/var(--tw-border-opacity))}:is([data-color-scheme=dark] .dark\:border-blue-70){--tw-border-opacity:1;border-color:rgb(89 148 255/var(--tw-border-opacity))}:is([data-color-scheme=dark] .dark\:border-red-80){--tw-border-opacity:1;border-color:rgb(217 77 65/var(--tw-border-opacity))}:is([data-color-scheme=dark] .dark\:bg-black){--tw-bg-opacity:1;background-color:rgb(0 0 0/var(--tw-bg-opacity))}:is([data-color-scheme=dark] .dark\:bg-black-10){--tw-bg-opacity:1;background-color:rgb(219 219 219/var(--tw-bg-opacity))}:is([data-color-scheme=dark] .dark\:bg-black-30){--tw-bg-opacity:1;background-color:rgb(131 141 143/var(--tw-bg-opacity))}:is([data-color-scheme=dark] .dark\:bg-black-30\/20){background-color:#838d8f33}:is([data-color-scheme=dark] .dark\:bg-black-80){--tw-bg-opacity:1;background-color:rgb(44 48 50/var(--tw-bg-opacity))}:is([data-color-scheme=dark] .dark\:bg-black-90){--tw-bg-opacity:1;background-color:rgb(35 42 50/var(--tw-bg-opacity))}:is([data-color-scheme=dark] .dark\:bg-black-95){--tw-bg-opacity:1;background-color:rgb(17 21 23/var(--tw-bg-opacity))}:is([data-color-scheme=dark] .dark\:bg-black-98){--tw-bg-opacity:1;background-color:rgb(4 8 11/var(--tw-bg-opacity))}:is([data-color-scheme=dark] .dark\:bg-black-v2-70){--tw-bg-opacity:1;background-color:rgb(63 66 72/var(--tw-bg-opacity))}:is([data-color-scheme=dark] .dark\:bg-black-v2-80){--tw-bg-opacity:1;background-color:rgb(33 34 36/var(--tw-bg-opacity))}:is([data-color-scheme=dark] .dark\:bg-blue-70){--tw-bg-opacity:1;background-color:rgb(89 148 255/var(--tw-bg-opacity))}:is([data-color-scheme=dark] .dark\:bg-green-v2-45){--tw-bg-opacity:1;background-color:rgb(153 209 148/var(--tw-bg-opacity))}:is([data-color-scheme=dark] .dark\:bg-green-v2-50){--tw-bg-opacity:1;background-color:rgb(135 199 130/var(--tw-bg-opacity))}:is([data-color-scheme=dark] .dark\:bg-green-v2-55){--tw-bg-opacity:1;background-color:rgb(116 189 111/var(--tw-bg-opacity))}:is([data-color-scheme=dark] .dark\:bg-green-v2-60){--tw-bg-opacity:1;background-color:rgb(98 176 93/var(--tw-bg-opacity))}:is([data-color-scheme=dark] .dark\:bg-green-v2-70){--tw-bg-opacity:1;background-color:rgb(85 165 80/var(--tw-bg-opacity))}:is([data-color-scheme=dark] .dark\:bg-green-v2-75){--tw-bg-opacity:1;background-color:rgb(72 156 67/var(--tw-bg-opacity))}:is([data-color-scheme=dark] .dark\:bg-orange-v2){--tw-bg-opacity:1;background-color:rgb(239 109 10/var(--tw-bg-opacity))}:is([data-color-scheme=dark] .dark\:bg-red-80){--tw-bg-opacity:1;background-color:rgb(217 77 65/var(--tw-bg-opacity))}:is([data-color-scheme=dark] .dark\:bg-red-v2-30){--tw-bg-opacity:1;background-color:rgb(235 136 136/var(--tw-bg-opacity))}:is([data-color-scheme=dark] .dark\:bg-red-v2-40){--tw-bg-opacity:1;background-color:rgb(224 117 117/var(--tw-bg-opacity))}:is([data-color-scheme=dark] .dark\:bg-red-v2-60){--tw-bg-opacity:1;background-color:rgb(214 99 99/var(--tw-bg-opacity))}:is([data-color-scheme=dark] .dark\:bg-red-v2-90){--tw-bg-opacity:1;background-color:rgb(185 72 72/var(--tw-bg-opacity))}:is([data-color-scheme=dark] .dark\:bg-teal-75){--tw-bg-opacity:1;background-color:rgb(50 166 103/var(--tw-bg-opacity))}:is([data-color-scheme=dark] .dark\:bg-transparent){background-color:initial}:is([data-color-scheme=dark] .dark\:bg-yellow-v2-50){--tw-bg-opacity:1;background-color:rgb(252 239 126/var(--tw-bg-opacity))}:is([data-color-scheme=dark] .dark\:bg-yellow-v2-90){--tw-bg-opacity:1;background-color:rgb(232 218 88/var(--tw-bg-opacity))}:is([data-color-scheme=dark] .dark\:from-black-60){--tw-gradient-from:#434348 var(--tw-gradient-from-position);--tw-gradient-to:#43434800 var(--tw-gradient-to-position);--tw-gradient-stops:var(--tw-gradient-from),var(--tw-gradient-to)}:is([data-color-scheme=dark] .dark\:to-black-80){--tw-gradient-to:#2c3032 var(--tw-gradient-to-position)}:is([data-color-scheme=dark] .dark\:fill-black-10){fill:#dbdbdb}:is([data-color-scheme=dark] .dark\:fill-black-30){fill:#838d8f}:is([data-color-scheme=dark] .dark\:fill-black-35){fill:#757575}:is([data-color-scheme=dark] .dark\:fill-black-50){fill:#555}:is([data-color-scheme=dark] .dark\:fill-black-80){fill:#2c3032}:is([data-color-scheme=dark] .dark\:fill-black-95){fill:#111517}:is([data-color-scheme=dark] .dark\:text-black){--tw-text-opacity:1;color:rgb(0 0 0/var(--tw-text-opacity))}:is([data-color-scheme=dark] .dark\:text-black-10){--tw-text-opacity:1;color:rgb(219 219 219/var(--tw-text-opacity))}:is([data-color-scheme=dark] .dark\:text-black-20){--tw-text-opacity:1;color:rgb(172 172 172/var(--tw-text-opacity))}:is([data-color-scheme=dark] .dark\:text-black-30){--tw-text-opacity:1;color:rgb(131 141 143/var(--tw-text-opacity))}:is([data-color-scheme=dark] .dark\:text-black-80){--tw-text-opacity:1;color:rgb(44 48 50/var(--tw-text-opacity))}:is([data-color-scheme=dark] .dark\:text-black-95){--tw-text-opacity:1;color:rgb(17 21 23/var(--tw-text-opacity))}:is([data-color-scheme=dark] .dark\:text-black-v2-20){--tw-text-opacity:1;color:rgb(224 225 228/var(--tw-text-opacity))}:is([data-color-scheme=dark] .dark\:text-black-v2-90){--tw-text-opacity:1;color:rgb(16 17 20/var(--tw-text-opacity))}:is([data-color-scheme=dark] .dark\:text-blue-70){--tw-text-opacity:1;color:rgb(89 148 255/var(--tw-text-opacity))}:is([data-color-scheme=dark] .dark\:text-white){--tw-text-opacity:1;color:rgb(255 255 255/var(--tw-text-opacity))}:is([data-color-scheme=dark] .dark\:placeholder\:text-black-30)::placeholder{--tw-text-opacity:1;color:rgb(131 141 143/var(--tw-text-opacity))}:is([data-color-scheme=dark] .dark\:visited\:text-black-10:visited){color:#dbdbdb}:is([data-color-scheme=dark] .dark\:visited\:text-black-20:visited){color:#acacac}:is([data-color-scheme=dark] .dark\:read-only\:text-black-30:read-only){--tw-text-opacity:1;color:rgb(131 141 143/var(--tw-text-opacity))}:is([data-color-scheme=dark] .dark\:focus-within\:border-black-v2-70:focus-within){--tw-border-opacity:1;border-color:rgb(63 66 72/var(--tw-border-opacity))}:is([data-color-scheme=dark] .dark\:hover\:bg-black-20:hover){--tw-bg-opacity:1;background-color:rgb(172 172 172/var(--tw-bg-opacity))}:is([data-color-scheme=dark] .dark\:hover\:bg-black-5:hover){--tw-bg-opacity:1;background-color:rgb(242 244 247/var(--tw-bg-opacity))}:is([data-color-scheme=dark] .dark\:hover\:bg-black-80:hover){--tw-bg-opacity:1;background-color:rgb(44 48 50/var(--tw-bg-opacity))}:is([data-color-scheme=dark] .dark\:hover\:bg-black-90:hover){--tw-bg-opacity:1;background-color:rgb(35 42 50/var(--tw-bg-opacity))}:is([data-color-scheme=dark] .dark\:hover\:fill-black-10:hover){fill:#dbdbdb}:is([data-color-scheme=dark] .dark\:hover\:text-black-20:hover){--tw-text-opacity:1;color:rgb(172 172 172/var(--tw-text-opacity))}:is([data-color-scheme=dark] .dark\:hover\:text-share-link:hover){color:var(--sa-link-color)}:is([data-color-scheme=dark] .dark\:focus\:border-black-30:focus){--tw-border-opacity:1;border-color:rgb(131 141 143/var(--tw-border-opacity))}:is([data-color-scheme=dark] .dark\:focus\:border-black-35:focus){--tw-border-opacity:1;border-color:rgb(117 117 117/var(--tw-border-opacity))}:is([data-color-scheme=dark] .dark\:focus\:border-red-80:focus){--tw-border-opacity:1;border-color:rgb(217 77 65/var(--tw-border-opacity))}:is([data-color-scheme=dark] .dark\:focus\:text-share-link:focus){color:var(--sa-link-color)}:is([data-color-scheme=dark] .dark\:active\:bg-black-20:active){--tw-bg-opacity:1;background-color:rgb(172 172 172/var(--tw-bg-opacity))}:is([data-color-scheme=dark] .dark\:disabled\:border-black-80:disabled){--tw-border-opacity:1;border-color:rgb(44 48 50/var(--tw-border-opacity))}:is([data-color-scheme=dark] .dark\:disabled\:bg-black-98:disabled){--tw-bg-opacity:1;background-color:rgb(4 8 11/var(--tw-bg-opacity))}:is([data-color-scheme=dark] .dark\:disabled\:text-black-80:disabled){--tw-text-opacity:1;color:rgb(44 48 50/var(--tw-text-opacity))}@media print{.print\:block{display:block}.print\:hidden{display:none}}@media (min-width:375px){.xs\:block{display:block}.xs\:w-0{width:0}.xs\:w-auto{width:auto}.xs\:max-w-full{max-width:100%}.xs\:grow{flex-grow:1}.xs\:basis-1\/12{flex-basis:8.333333%}.xs\:basis-10\/12{flex-basis:83.333333%}.xs\:basis-11\/12{flex-basis:91.666667%}.xs\:basis-2\/12{flex-basis:16.666667%}.xs\:basis-3\/12{flex-basis:25%}.xs\:basis-4\/12{flex-basis:33.333333%}.xs\:basis-5\/12{flex-basis:41.666667%}.xs\:basis-6\/12{flex-basis:50%}.xs\:basis-7\/12{flex-basis:58.333333%}.xs\:basis-8\/12{flex-basis:66.666667%}.xs\:basis-9\/12{flex-basis:75%}.xs\:basis-auto{flex-basis:auto}.xs\:basis-full{flex-basis:100%}}@media (min-width:576px){.sm\:my-0{margin-top:0}.sm\:mb-0,.sm\:my-0{margin-bottom:0}.sm\:mb-10{margin-bottom:.625rem}.sm\:mb-24{margin-bottom:1.5rem}.sm\:mr-0{margin-right:0}.sm\:mt-0{margin-top:0}.sm\:flex{display:flex}.sm\:hidden{display:none}.sm\:h-10{height:.625rem}.sm\:w-0{width:0}.sm\:w-auto{width:auto}.sm\:max-w-full{max-width:100%}.sm\:grow{flex-grow:1}.sm\:basis-1\/12{flex-basis:8.333333%}.sm\:basis-10\/12{flex-basis:83.333333%}.sm\:basis-11\/12{flex-basis:91.666667%}.sm\:basis-2\/12{flex-basis:16.666667%}.sm\:basis-3\/12{flex-basis:25%}.sm\:basis-4\/12{flex-basis:33.333333%}.sm\:basis-5\/12{flex-basis:41.666667%}.sm\:basis-6\/12{flex-basis:50%}.sm\:basis-7\/12{flex-basis:58.333333%}.sm\:basis-8\/12{flex-basis:66.666667%}.sm\:basis-9\/12{flex-basis:75%}.sm\:basis-auto{flex-basis:auto}.sm\:basis-full{flex-basis:100%}.sm\:flex-row{flex-direction:row}.sm\:flex-col{flex-direction:column}.sm\:self-auto{align-self:auto}.sm\:self-start{align-self:flex-start}.sm\:bg-transparent{background-color:initial}.sm\:p-0{padding:0}.sm\:px-12{padding-left:.75rem;padding-right:.75rem}.sm\:px-18{padding-left:1.125rem;padding-right:1.125rem}.sm\:py-10{padding-bottom:.625rem;padding-top:.625rem}.sm\:pb-24{padding-bottom:1.5rem}.sm\:pb-32{padding-bottom:2rem}.sm\:pt-24{padding-top:1.5rem}.sm\:pt-32{padding-top:2rem}.sm\:text-center{text-align:center}.sm\:text-4x-large-b{font-size:1.5rem;font-weight:700;line-height:1.875rem}.sm\:text-4x-large-r{font-size:1.5rem;font-weight:400;line-height:1.875rem}.sm\:text-large-r{font-size:1rem;font-weight:400;line-height:1.25rem}.sm\:text-small-2-b{font-size:.75rem;font-weight:700;line-height:1.25rem}.sm\:text-small-b{font-size:.75rem;font-weight:700;line-height:.875rem}.sm\:px-safe-or-18{padding-left:max(env(safe-area-inset-left),1.125rem);padding-right:max(env(safe-area-inset-right),1.125rem)}:is([data-color-scheme=dark] .dark\:sm\:bg-transparent){background-color:initial}:is([data-color-scheme=dark] .sm\:dark\:bg-transparent){background-color:initial}}@media (min-width:768px){.md\:absolute{position:absolute}.md\:-mx-24{margin-left:-1.5rem;margin-right:-1.5rem}.md\:-mx-48{margin-left:-3rem;margin-right:-3rem}.md\:-my-16{margin-bottom:-1rem;margin-top:-1rem}.md\:mx-48{margin-left:3rem;margin-right:3rem}.md\:my-0{margin-bottom:0;margin-top:0}.md\:my-32{margin-bottom:2rem;margin-top:2rem}.md\:-mt-40{margin-top:-2.5rem}.md\:mb-0{margin-bottom:0}.md\:mb-12{margin-bottom:.75rem}.md\:mb-16{margin-bottom:1rem}.md\:mb-18{margin-bottom:1.125rem}.md\:mb-20{margin-bottom:1.25rem}.md\:mb-24{margin-bottom:1.5rem}.md\:mb-30{margin-bottom:1.875rem}.md\:mb-32{margin-bottom:2rem}.md\:mb-40{margin-bottom:2.5rem}.md\:mb-6{margin-bottom:.375rem}.md\:mb-8{margin-bottom:.5rem}.md\:ml-60{margin-left:3.75rem}.md\:ml-8{margin-left:.5rem}.md\:mr-20{margin-right:1.25rem}.md\:mr-48{margin-right:3rem}.md\:mr-6{margin-right:.375rem}.md\:mt-0{margin-top:0}.md\:mt-12{margin-top:.75rem}.md\:mt-16{margin-top:1rem}.md\:mt-18{margin-top:1.125rem}.md\:mt-30{margin-top:1.875rem}.md\:mt-32{margin-top:2rem}.md\:mt-8{margin-top:.5rem}.md\:block{display:block}.md\:flex{display:flex}.md\:inline-flex{display:inline-flex}.md\:hidden{display:none}.md\:h-10{height:.625rem}.md\:h-120{height:7.5rem}.md\:h-14{height:.875rem}.md\:h-170{height:10.625rem}.md\:h-240{height:15rem}.md\:h-30{height:1.875rem}.md\:h-36{height:2.25rem}.md\:h-52{height:3.25rem}.md\:h-auto{height:auto}.md\:max-h-full{max-height:100%}.md\:w-0{width:0}.md\:w-1{width:.0625rem}.md\:w-120{width:7.5rem}.md\:w-14{width:.875rem}.md\:w-170{width:10.625rem}.md\:w-240{width:15rem}.md\:w-36{width:2.25rem}.md\:w-52{width:3.25rem}.md\:w-auto{width:auto}.md\:max-w-full{max-width:100%}.md\:flex-auto{flex:1 1 auto}.md\:flex-none{flex:none}.md\:grow{flex-grow:1}.md\:grow-0{flex-grow:0}.md\:basis-1\/12{flex-basis:8.333333%}.md\:basis-1\/2{flex-basis:50%}.md\:basis-10\/12{flex-basis:83.333333%}.md\:basis-11\/12{flex-basis:91.666667%}.md\:basis-2\/12{flex-basis:16.666667%}.md\:basis-3\/12{flex-basis:25%}.md\:basis-4\/12{flex-basis:33.333333%}.md\:basis-5\/12{flex-basis:41.666667%}.md\:basis-6\/12{flex-basis:50%}.md\:basis-7\/12{flex-basis:58.333333%}.md\:basis-8\/12{flex-basis:66.666667%}.md\:basis-9\/12{flex-basis:75%}.md\:basis-auto{flex-basis:auto}.md\:basis-full{flex-basis:100%}.md\:grid-flow-col{grid-auto-flow:column}.md\:flex-row{flex-direction:row}.md\:flex-row-reverse{flex-direction:row-reverse}.md\:flex-col{flex-direction:column}.md\:flex-wrap{flex-wrap:wrap}.md\:items-center{align-items:center}.md\:justify-start{justify-content:flex-start}.md\:justify-between{justify-content:space-between}.md\:gap-20{gap:1.25rem}.md\:gap-24{gap:1.5rem}.md\:self-auto{align-self:auto}.md\:self-end{align-self:flex-end}.md\:overflow-hidden{overflow:hidden}.md\:overflow-y-auto{overflow-y:auto}.md\:border-l-4{border-left-width:.25rem}.md\:border-solid{border-style:solid}.md\:border-l-blue-75{--tw-border-opacity:1;border-left-color:rgb(26 152 255/var(--tw-border-opacity))}.md\:p-0{padding:0}.md\:p-24{padding:1.5rem}.md\:p-36{padding:2.25rem}.md\:px-0{padding-left:0;padding-right:0}.md\:px-10{padding-left:.625rem;padding-right:.625rem}.md\:px-14{padding-left:.875rem;padding-right:.875rem}.md\:px-18{padding-left:1.125rem;padding-right:1.125rem}.md\:px-2{padding-left:.125rem;padding-right:.125rem}.md\:px-20{padding-left:1.25rem;padding-right:1.25rem}.md\:px-24{padding-left:1.5rem;padding-right:1.5rem}.md\:px-32{padding-left:2rem;padding-right:2rem}.md\:px-36{padding-left:2.25rem;padding-right:2.25rem}.md\:px-4{padding-left:.25rem;padding-right:.25rem}.md\:px-48{padding-left:3rem;padding-right:3rem}.md\:px-52{padding-left:3.25rem;padding-right:3.25rem}.md\:py-10{padding-bottom:.625rem;padding-top:.625rem}.md\:py-16{padding-bottom:1rem;padding-top:1rem}.md\:py-18{padding-bottom:1.125rem;padding-top:1.125rem}.md\:py-2{padding-bottom:.125rem;padding-top:.125rem}.md\:py-20{padding-bottom:1.25rem;padding-top:1.25rem}.md\:py-32{padding-bottom:2rem;padding-top:2rem}.md\:py-4{padding-bottom:.25rem;padding-top:.25rem}.md\:py-48{padding-bottom:3rem;padding-top:3rem}.md\:pb-0{padding-bottom:0}.md\:pb-10{padding-bottom:.625rem}.md\:pb-16{padding-bottom:1rem}.md\:pb-2{padding-bottom:.125rem}.md\:pb-20{padding-bottom:1.25rem}.md\:pb-24{padding-bottom:1.5rem}.md\:pb-28{padding-bottom:1.75rem}.md\:pb-32{padding-bottom:2rem}.md\:pb-36{padding-bottom:2.25rem}.md\:pb-40{padding-bottom:2.5rem}.md\:pl-0{padding-left:0}.md\:pl-24{padding-left:1.5rem}.md\:pr-32{padding-right:2rem}.md\:pt-0{padding-top:0}.md\:pt-12{padding-top:.75rem}.md\:pt-16{padding-top:1rem}.md\:pt-20{padding-top:1.25rem}.md\:pt-28{padding-top:1.75rem}.md\:pt-32{padding-top:2rem}.md\:pt-40{padding-top:2.5rem}.md\:pt-48{padding-top:3rem}.md\:pt-8{padding-top:.5rem}.md\:text-left{text-align:left}.md\:text-center{text-align:center}.md\:text-2x-large-2-r{font-size:1.25rem;font-weight:400;line-height:1.875rem}.md\:text-2x-large-b{font-size:1.25rem;font-weight:700;line-height:1.5rem}.md\:text-2x-small-b{font-size:.625rem;font-weight:700;line-height:.75rem}.md\:text-3x-large-2-r{font-size:1.375rem;font-weight:400;line-height:2rem}.md\:text-3x-large-b{font-size:1.375rem;font-weight:700;line-height:1.625rem}.md\:text-4x-large-b{font-size:1.5rem;font-weight:700;line-height:1.875rem}.md\:text-4x-large-r{font-size:1.5rem;font-weight:400;line-height:1.875rem}.md\:text-large-2-r{font-size:1rem;font-weight:400;line-height:1.5rem}.md\:text-large-3-r{font-size:1rem;font-weight:400;line-height:1.75rem}.md\:text-large-b{font-size:1rem;font-weight:700;line-height:1.25rem}.md\:text-large-r{font-size:1rem;font-weight:400;line-height:1.25rem}.md\:text-medium-2-b{font-size:.875rem;font-weight:700;line-height:1.25rem}.md\:text-medium-r{font-size:.875rem;font-weight:400;line-height:1rem}.md\:text-small-b{font-weight:700}.md\:text-small-b,.md\:text-small-r{font-size:.75rem;line-height:.875rem}.md\:text-small-r{font-weight:400}.md\:text-x-large-2-r{font-size:1.125rem;font-weight:400;line-height:1.625rem}.md\:text-x-large-b{font-size:1.125rem;font-weight:700;line-height:1.375rem}.md\:text-x-large-r{font-size:1.125rem;font-weight:400;line-height:1.375rem}.md\:px-safe-offset-24{padding-left:calc(env(safe-area-inset-left) + 1.5rem);padding-right:calc(env(safe-area-inset-right) + 1.5rem)}.md\:px-safe-or-18{padding-left:max(env(safe-area-inset-left),1.125rem);padding-right:max(env(safe-area-inset-right),1.125rem)}.md\:px-safe-or-24{padding-left:max(env(safe-area-inset-left),1.5rem);padding-right:max(env(safe-area-inset-right),1.5rem)}.md\:after\:h-8:after{content:var(--tw-content);height:.5rem}.md\:after\:w-8:after{content:var(--tw-content);width:.5rem}.md\:hover\:underline:hover{text-decoration-line:underline}}@media (min-width:1024px){.lg\:sticky{position:-webkit-sticky;position:sticky}.lg\:top-0{top:0}.lg\:my-12{margin-bottom:.75rem;margin-top:.75rem}.lg\:mb-0{margin-bottom:0}.lg\:mb-12{margin-bottom:.75rem}.lg\:mb-16{margin-bottom:1rem}.lg\:mb-18{margin-bottom:1.125rem}.lg\:mb-2{margin-bottom:.125rem}.lg\:mb-26{margin-bottom:1.625rem}.lg\:mb-32{margin-bottom:2rem}.lg\:mb-48{margin-bottom:3rem}.lg\:mb-64{margin-bottom:4rem}.lg\:mb-8{margin-bottom:.5rem}.lg\:ml-0{margin-left:0}.lg\:mr-12{margin-right:.75rem}.lg\:mr-4{margin-right:.25rem}.lg\:mt-12{margin-top:.75rem}.lg\:mt-16{margin-top:1rem}.lg\:mt-20{margin-top:1.25rem}.lg\:block{display:block}.lg\:flex{display:flex}.lg\:hidden{display:none}.lg\:h-120{height:7.5rem}.lg\:h-16{height:1rem}.lg\:h-28{height:1.75rem}.lg\:h-32{height:2rem}.lg\:h-60{height:3.75rem}.lg\:w-0{width:0}.lg\:w-120{width:7.5rem}.lg\:w-16{width:1rem}.lg\:w-60{width:3.75rem}.lg\:w-auto{width:auto}.lg\:max-w-full{max-width:100%}.lg\:grow{flex-grow:1}.lg\:basis-1\/12{flex-basis:8.333333%}.lg\:basis-10\/12{flex-basis:83.333333%}.lg\:basis-11\/12{flex-basis:91.666667%}.lg\:basis-2\/12{flex-basis:16.666667%}.lg\:basis-3\/12{flex-basis:25%}.lg\:basis-4\/12{flex-basis:33.333333%}.lg\:basis-5\/12{flex-basis:41.666667%}.lg\:basis-6\/12{flex-basis:50%}.lg\:basis-7\/12{flex-basis:58.333333%}.lg\:basis-8\/12{flex-basis:66.666667%}.lg\:basis-9\/12{flex-basis:75%}.lg\:basis-auto{flex-basis:auto}.lg\:basis-full{flex-basis:100%}.lg\:flex-col{flex-direction:column}.lg\:border-0{border-width:0}.lg\:bg-share-bg-4{background-color:var(--sa-body-bg-color-4)}.lg\:fill-share-text-2{fill:var(--sa-text-color-2)}.lg\:p-18{padding:1.125rem}.lg\:py-10{padding-bottom:.625rem;padding-top:.625rem}.lg\:py-20{padding-bottom:1.25rem;padding-top:1.25rem}.lg\:pb-18{padding-bottom:1.125rem}.lg\:pl-30{padding-left:1.875rem}.lg\:pt-0{padding-top:0}.lg\:pt-40{padding-top:2.5rem}.lg\:text-2x-small-b{font-size:.625rem;font-weight:700;line-height:.75rem}.lg\:text-4x-large-b{font-size:1.5rem;font-weight:700;line-height:1.875rem}.lg\:text-4x-large-r{font-size:1.5rem;font-weight:400;line-height:1.875rem}.lg\:text-5x-large-b{font-size:1.75rem;font-weight:700;line-height:2.125rem}.lg\:text-8x-large-b{font-size:2.375rem;font-weight:700;line-height:2.875rem}.lg\:text-medium-2-r{font-size:.875rem;font-weight:400;line-height:1.25rem}.lg\:text-medium-b{font-size:.875rem;font-weight:700;line-height:1rem}.lg\:text-medium-r{font-size:.875rem;font-weight:400;line-height:1rem}.lg\:text-small-r{font-size:.75rem;font-weight:400;line-height:.875rem}.lg\:text-x-large-2-r{font-size:1.125rem;font-weight:400;line-height:1.625rem}.lg\:text-x-large-b{font-size:1.125rem;font-weight:700;line-height:1.375rem}.lg\:text-black-35{--tw-text-opacity:1;color:rgb(117 117 117/var(--tw-text-opacity))}.lg\:px-safe-or-18{padding-left:max(env(safe-area-inset-left),1.125rem);padding-right:max(env(safe-area-inset-right),1.125rem)}:is([data-color-scheme=dark] .dark\:lg\:text-black-30){--tw-text-opacity:1;color:rgb(131 141 143/var(--tw-text-opacity))}}@media (min-width:1200px){.xl\:mx-0{margin-left:0;margin-right:0}.xl\:mx-auto{margin-left:auto;margin-right:auto}.xl\:my-48{margin-bottom:3rem;margin-top:3rem}.xl\:mb-24{margin-bottom:1.5rem}.xl\:mb-38{margin-bottom:2.375rem}.xl\:ml-38{margin-left:2.375rem}.xl\:ml-8{margin-left:.5rem}.xl\:mr-38{margin-right:2.375rem}.xl\:mr-40{margin-right:2.5rem}.xl\:block{display:block}.xl\:flex{display:flex}.xl\:hidden{display:none}.xl\:h-1{height:.0625rem}.xl\:w-0{width:0}.xl\:w-auto{width:auto}.xl\:w-full{width:100%}.xl\:max-w-full{max-width:100%}.xl\:grow{flex-grow:1}.xl\:basis-1\/12{flex-basis:8.333333%}.xl\:basis-10\/12{flex-basis:83.333333%}.xl\:basis-11\/12{flex-basis:91.666667%}.xl\:basis-2\/12{flex-basis:16.666667%}.xl\:basis-3\/12{flex-basis:25%}.xl\:basis-4\/12{flex-basis:33.333333%}.xl\:basis-5\/12{flex-basis:41.666667%}.xl\:basis-6\/12{flex-basis:50%}.xl\:basis-7\/12{flex-basis:58.333333%}.xl\:basis-8\/12{flex-basis:66.666667%}.xl\:basis-9\/12{flex-basis:75%}.xl\:basis-auto{flex-basis:auto}.xl\:basis-full{flex-basis:100%}.xl\:flex-row{flex-direction:row}.xl\:flex-col{flex-direction:column}.xl\:justify-center{justify-content:center}.xl\:p-24{padding:1.5rem}.xl\:px-0{padding-left:0;padding-right:0}.xl\:px-18{padding-left:1.125rem;padding-right:1.125rem}.xl\:px-24{padding-left:1.5rem;padding-right:1.5rem}.xl\:px-48{padding-left:3rem;padding-right:3rem}.xl\:py-0{padding-bottom:0;padding-top:0}.xl\:py-12{padding-bottom:.75rem;padding-top:.75rem}.xl\:py-40{padding-bottom:2.5rem;padding-top:2.5rem}.xl\:py-60{padding-bottom:3.75rem;padding-top:3.75rem}.xl\:pb-40{padding-bottom:2.5rem}.xl\:pt-0{padding-top:0}.xl\:text-4x-large-r{font-size:1.5rem;font-weight:400;line-height:1.875rem}.xl\:text-5x-large-b{font-size:1.75rem;font-weight:700;line-height:2.125rem}.xl\:text-5x-large-r{font-size:1.75rem;font-weight:400;line-height:2.125rem}.xl\:text-6x-large-b{font-size:2rem;font-weight:700;line-height:2.375rem}.xl\:text-9x-large-b{font-size:3.125rem;font-weight:700;line-height:3.125rem}.xl\:text-large-b{font-size:1rem;font-weight:700;line-height:1.25rem}.xl\:text-large-r{font-size:1rem;font-weight:400;line-height:1.25rem}.xl\:text-x-large-r{font-size:1.125rem;font-weight:400;line-height:1.375rem}.xl\:px-safe-or-18{padding-left:max(env(safe-area-inset-left),1.125rem);padding-right:max(env(safe-area-inset-right),1.125rem)}.xl\:sa-row-gap-36{margin-bottom:2.25rem;margin-left:-2.25rem;margin-top:-2.25rem}.xl\:sa-row-gap-36>*{padding-left:2.25rem;padding-top:2.25rem}}@media (min-width:1540px){.xxl\:-mx-24{margin-left:-1.5rem;margin-right:-1.5rem}.xxl\:mx-48{margin-left:3rem;margin-right:3rem}.xxl\:my-0{margin-bottom:0;margin-top:0}.xxl\:mr-80{margin-right:5rem}.xxl\:flex{display:flex}.xxl\:hidden{display:none}.xxl\:h-auto{height:auto}.xxl\:w-0{width:0}.xxl\:w-1{width:.0625rem}.xxl\:w-auto{width:auto}.xxl\:max-w-full{max-width:100%}.xxl\:grow{flex-grow:1}.xxl\:basis-1\/12{flex-basis:8.333333%}.xxl\:basis-10\/12{flex-basis:83.333333%}.xxl\:basis-11\/12{flex-basis:91.666667%}.xxl\:basis-2\/12{flex-basis:16.666667%}.xxl\:basis-3\/12{flex-basis:25%}.xxl\:basis-4\/12{flex-basis:33.333333%}.xxl\:basis-5\/12{flex-basis:41.666667%}.xxl\:basis-6\/12{flex-basis:50%}.xxl\:basis-7\/12{flex-basis:58.333333%}.xxl\:basis-8\/12{flex-basis:66.666667%}.xxl\:basis-9\/12{flex-basis:75%}.xxl\:basis-auto{flex-basis:auto}.xxl\:basis-full{flex-basis:100%}.xxl\:flex-row{flex-direction:row}.xxl\:flex-row-reverse{flex-direction:row-reverse}.xxl\:flex-col{flex-direction:column}.xxl\:px-24{padding-left:1.5rem;padding-right:1.5rem}.xxl\:px-36{padding-left:2.25rem;padding-right:2.25rem}.xxl\:px-64{padding-left:4rem;padding-right:4rem}.xxl\:px-safe-or-36{padding-left:max(env(safe-area-inset-left),2.25rem);padding-right:max(env(safe-area-inset-right),2.25rem)}}</style><meta name="theme-color" content="#333333" ><link rel="manifest" href="/samw/manifest.52d7d67ec34303436765800b76c0582e.json" > <link rel="preload" href="/samw/static/js/app.982fa237.js" as="script"> <link rel="preload" href="/samw/static/js/c.7611.2265ccf6.js" as="script"> <link rel="preload" href="/samw/static/js/c.9048.a372a116.js" as="script"> <link rel="preload" href="/samw/static/js/c.7309.221713ab.js" as="script"> <link rel="preload" href="/samw/static/js/c.7024.e4f9a632.js" as="script"> <link rel="preload" href="/samw/static/js/c.1037.2cb8d213.js" as="script"> <link rel="preload" href="/samw/static/js/c.2971.8a739675.js" as="script"> <link rel="preload" href="/samw/static/js/c.693.b6c2b13b.js" as="script"> <link rel="preload" href="/samw/static/js/c.7723.a12f5d5f.js" as="script"> <link rel="preload" href="/samw/static/js/c.8940.ea3985c6.js" as="script"> <link rel="preload" href="/samw/static/js/c.9323.415f29a9.js" as="script"> <link rel="preload" href="/samw/static/js/c.5169.48e2c582.js" as="script"> <link rel="preload" href="/samw/static/js/c.7683.37daf487.js" as="script"> <link rel="preload" href="/samw/static/js/c.9340.0f228286.js" as="script"> <link rel="preload" href="/samw/static/js/c.3661.f42a537a.js" as="script"> <link rel="preload" href="/samw/static/js/c.9638.453e6eb8.js" as="script"> <link rel="preload" href="/samw/static/js/c.5075.5f3a0046.js" as="script"> <link rel="preload" href="/samw/static/js/c.7103.3b3a4c05.js" as="script"> <link rel="preload" href="/samw/static/js/c.6144.7d7e839c.js" as="script"> <link rel="preload" href="/samw/static/js/c.8383.0a755660.js" as="script"> <link rel="preload" href="/samw/static/js/c.Article-S.a6f4701e.js" as="script"> <link rel="preload" href="/samw/static/js/c.3918.3b2d278a.js" as="script"> <link rel="preload" href="/samw/static/js/c.BelowContentCards-W.0bca6b0a.js" as="script"> <link rel="preload" href="/samw/static/js/c.9340.0f228286.js" as="script"> <link rel="preload" href="/samw/static/js/c.6144.7d7e839c.js" as="script"> <link rel="preload" href="/samw/static/js/c.7531.716caf1b.js" as="script"><link href="https://seekingalpha.com/javascripts/seeking.xml" rel="search" title="OraSure Technologies, Inc. (OSUR) CEO Stephen Tang on Q3 2020 Results - Earnings Call Transcript" type="application/opensearchdescription+xml" data-render="ssr"><link href="https://seekingalpha.com/article/4385063-orasure-technologies-inc-osur-ceo-stephen-tang-on-q3-2020-results-earnings-call-transcript" rel="canonical" data-render="ssr"><meta name="description" content="OraSure Technologies, Inc. (NASDAQ:NASDAQ:OSUR) Q3 2020 Earnings Conference Call November 4, 2020 5:00 PM ETCompany ParticipantsJeanne Mell - Vice President..." data-render="ssr"><meta name="robots" content="noarchive, max-image-preview:large" data-render="ssr"><meta name="twitter:title" content="OraSure Technologies, Inc. (OSUR) CEO Stephen Tang on Q3 2020 Results - Earnings Call Transcript" data-render="ssr"><meta name="twitter:description" content="OraSure Technologies, Inc. (NASDAQ:NASDAQ:OSUR) Q3 2020 Earnings Conference Call November 4, 2020 5:00 PM ETCompany ParticipantsJeanne Mell - Vice President..." data-render="ssr"><meta name="twitter:card" content="summary_large_image" data-render="ssr"><meta name="twitter:site" content="@SeekingAlpha" data-render="ssr"><meta name="twitter:image" content="https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png" data-render="ssr"><meta property="og:title" content="OraSure Technologies, Inc. (OSUR) CEO Stephen Tang on Q3 2020 Results - Earnings Call Transcript" data-render="ssr"><meta property="og:description" content="OraSure Technologies, Inc. (NASDAQ:NASDAQ:OSUR) Q3 2020 Earnings Conference Call November 4, 2020 5:00 PM ETCompany ParticipantsJeanne Mell - Vice President..." data-render="ssr"><meta property="og:type" content="article" data-render="ssr"><meta property="article:publisher" content="https://www.facebook.com/Seekingalpha" data-render="ssr"><meta name="author" content="SA Transcripts" data-render="ssr"><meta property="article:author" content="https://seekingalpha.com/author/sa-transcripts" data-render="ssr"><meta property="article:published_time" content="2020-11-04T20:58:06-05:00" data-render="ssr"><meta property="article:modified_time" content="2020-11-04T20:58:07-05:00" data-render="ssr"><meta property="og:url" content="https://seekingalpha.com/article/4385063-orasure-technologies-inc-osur-ceo-stephen-tang-on-q3-2020-results-earnings-call-transcript" data-render="ssr"><meta property="og:image" content="https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png" data-render="ssr"><script>window.SA_PRELOAD_DATA = {"statusCode":200,"moneData":{"params":"ssr_poc=yes&financial_statements=show&paywalled_article_content=control&ab_test_distribution_fastly=show&test_mcm_was_ever_pro=test"},"show_cookie_settings_link":false};</script><style>
    :root {
      --headerHeight: 50px;
    }

    @media (min-width: 1024px) {
      :root {
        --headerHeight: 68px;
        --sa-aside-width: 15rem;
      }
    }
  </style><link href="/samw/static/styles/3863.d1c4a9bb.css" rel="stylesheet" ><link href="/samw/static/styles/3661.40ac902e.css" rel="stylesheet" ><link href="/samw/static/styles/Article-S.80fc25df.css" rel="stylesheet" ><link href="/samw/static/styles/BelowContentCards-W.e27d7834.css" rel="stylesheet" ><link href="/samw/static/styles/CommentsContent-W.88e3efad.css" rel="stylesheet" >
        <script>window.SSR_DATA = {"article":{"response":{"data":{"id":"4385063","type":"fullArticle","attributes":{"publishOn":"2020-11-04T20:58:06-05:00","isLockedPro":false,"commentCount":1,"gettyImageUrl":null,"videoPreviewUrl":null,"themes":{"sa-transcripts":{"id":96991,"slug":"sa-transcripts","kind":"common","non_theme":true},"osur":{"id":3622,"slug":"osur","kind":"common","non_theme":true},"healthcare":{"id":17896,"slug":"healthcare","kind":"common","path":"\u002Fstock-ideas\u002Fhealthcare","title":"Healthcare ","non_theme":true},"transcripts":{"id":49,"slug":"transcripts","kind":"general","path":"\u002Fearnings\u002Fearnings-call-transcripts","title":"Transcripts"},"has-audio":{"id":586376,"slug":"has-audio","kind":"general"},"us":{"id":326,"slug":"us","kind":"common","non_theme":true},"medical-instruments-supplies":{"id":17909,"slug":"medical-instruments-supplies","kind":"common","non_theme":true},"health-care":{"id":35,"slug":"health-care","kind":"sector","path":"\u002Fstock-ideas\u002Fhealthcare","title":"Healthcare ","sasource":"theme_breadcrumb"}},"title":"OraSure Technologies, Inc. (OSUR) CEO Stephen Tang on Q3 2020 Results - Earnings Call Transcript","summary":[],"isPaywalled":false,"lastModified":"2020-11-04T20:58:07-05:00","closestTradingDate":"2020-11-05","beforeOpeningHours":false,"proPublishOn":"2020-11-04T20:58:06-05:00","isEarningsSlides":false,"isExclusive":false,"isTranscript":true,"excludedByTag":false,"transcriptPath":"https:\u002F\u002Fstatic.seekingalpha.com\u002Fcdn\u002Fs3\u002Ftranscripts_audio\u002F4385063.mp3","likesCount":0,"disabledStatus":"allowed","disabledMessage":null,"status":"published","disclosure":"","articleActionableItem":null,"inEmbargo":false,"isNoindex":false,"isNoarchive":true,"content":"\u003Cp\u003EOraSure Technologies, Inc. (\u003Cspan class=\"ticker-hover-wrapper\"\u003ENASDAQ:\u003Ca href=\"https:\u002F\u002Fseekingalpha.com\u002Fsymbol\u002FOSUR\" title=\"OraSure Technologies, Inc.\"\u003EOSUR\u003C\u002Fa\u003E\u003C\u002Fspan\u003E) Q3 2020 Earnings Conference Call November 4, 2020 5:00 PM ET\u003C\u002Fp\u003E \u003Cp\u003E\u003Cstrong\u003ECompany Participants\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp\u003EJeanne Mell - Vice President of Corporate Communications\u003C\u002Fp\u003E \u003Cp\u003EStephen Tang - President &amp; Chief Executive Officer\u003C\u002Fp\u003E \u003Cp\u003ERoberto Cuca - Chief Financial Officer\u003C\u002Fp\u003E \u003Cp\u003E\u003Cstrong\u003EConference Call Participants\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp\u003EVijay Kumar - Evercore ISI\u003C\u002Fp\u003E \u003Cp\u003EFrank Takkinen - Lake Street Capital\u003C\u002Fp\u003E \u003Cp\u003ECasey Woodring - JPMorgan\u003C\u002Fp\u003E \u003Cp\u003EAndrew Cooper - Raymond James\u003C\u002Fp\u003E \u003Cp\u003EPatrick Donnelly - Citigroup\u003C\u002Fp\u003E \u003Cp\u003EJacob Johnson - Stephens\u003C\u002Fp\u003E \u003Cp\u003E\u003Cstrong\u003EOperator\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp\u003EGood afternoon, everyone, and welcome to the OraSure Technologies 2020 Third Quarter Financial Results Conference Call and Simultaneous Webcast. As a reminder, today's conference is being recorded. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be question-and-answer period. [Operator Instructions]\u003C\u002Fp\u003E \u003Cp\u003EI would turn the call over to Jeanne Mell, Vice President of Corporate Communications for OraSure. Jeanne?\u003C\u002Fp\u003E \u003Cp\u003E\u003Cstrong\u003EJeanne Mell\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp\u003EThank you, operator. With us today are Dr. Stephen Tang, President and Chief Executive Officer; and Mr. Roberto Cuca, Chief Financial Officer. Dr. Tang and Mr. Cuca will begin with opening statements, which will be followed with a question-and-answer session.\u003C\u002Fp\u003E \u003Cp\u003EBefore I turn the call over to Dr. Tang, you should note that this call may contain certain forward-looking statements, including statements with respect to revenues, expenses, profitability, earnings or loss per share, and other financial performance, product development, performance, shipments and markets business plans, regulatory filings and approvals, expectations and strategy.\u003C\u002Fp\u003E \u003Cp\u003EActual results could be significantly different. Factors that could affect results are discussed more fully in the company's SEC filings, including its registration statements, its annual report on Form 10-K for the year ended December 31, 2019, its quarterly reports on Form 10-Q and its other SEC filings.\u003C\u002Fp\u003E \u003Cp\u003EAlthough, forward-looking statements help to provide complete information about future prospects, listeners should keep in mind that forward-looking statements are based solely\u003Cspan class=\"paywall-full-content\"\u003E on information available to management as of today. The company undertakes no obligation to update any forward-looking statements to reflect events or circumstances after this call.\u003C\u002Fspan\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content\"\u003EWith that, I will turn the call over to Dr. Stephen Tang.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content\"\u003E\u003Cstrong\u003EStephen Tang\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content\"\u003EThank you, Jeanne, and thank you everyone for joining us\u003Cspan class=\"paywall-full-content no-summary-bullets\"\u003E today. I know, last night was a late night for many. So I appreciate your attention and interest this afternoon. I hope you and your families are faring well during these challenging times. As you will hear today, OraSure had a strong quarter.\u003C\u002Fspan\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EOur molecular sample collection devices are widely used for lab-based COVID-19 molecular tests. We've submitted our lab-based oral fluid SARS-CoV-2 antibody test to the FDA for emergency use authorization or EUA, and we expect a rapid coronavirus antigen test to be ready for EUA submission in Q1 2021.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EOverall, our ability to address the COVID-19 pandemic through sample collection has contributed positively to our business in the third quarter. We generated $48 million revenue this quarter, a 33% increase over the prior year. This performance was driven by our Molecular Solutions business unit. Our products continue to be in demand as the need for COVID-19 testing continues to rise.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EThe Molecular Solutions business unit generated $18.4 million in COVID-19 related sales in Q3, which is more than double the COVID-19 revenue achieved in the first half of the year. Globally, we're seeing what appears to be the third wave of the pandemic, as the number of COVID-19 cases surges here in the U.S. and around the world.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003ECOVID-19 forecasts are not completely in alignment, but most predict that the current impact will be felt for another year or two years with COVID-19 existing at some level in perpetuity as the disease becomes endemic. While there is hope that, a vaccine will be approved by year-end or early 2021, we expect it will take quite some time for a vaccine to be broadly available in the U.S. and internationally.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EAnd until then and beyond, testing will continue to play a critical role in managing the pandemic. We expect OraSure to continue to play an important and growing role, to address the massive and persistent need for COVID-19 testing and sample collection.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EDuring our Q2 earnings call, I cited an estimate from the Rockefeller Foundation that call for 1.5 billion COVID-19 tests per year to get the pandemic under control. Since then, the foundation has increased its estimate to approximately 2.3 billion tests per year in the U.S. alone.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EWith this in mind, we expect there will continue to be strong demand for COVID-19 testing for the foreseeable future. And we are prepared to help meet that need with our innovative solutions for testing and sample collection.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EAll of OraSure's COVID-19 products are centered on the easy subcollection of samples by individuals an area which we have long experience. Our products are designed to make it easier to obtain results either through oral fluid sample collection for PCR and antibody testing or through a full diagnostic test that consumers can conduct on their own.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EI'd like to address our current COVID-19 innovations, beginning with sample collection for molecular or PCR testing, which is the gold standard when it comes to detecting active COVID-19 infection. Our experience in innovating devices to facilitate at-home self-collection of samples has led to significant interest in our collection devices for molecular COVID-19 testing.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EDevices made by our DNA Genotek subsidiary support both PCR and sequencing-based COVID-19 tests. And these collection kits are now being used for collection at home by consumers or by laboratory staff and healthcare providers. Notably, two of our sample collection devices ORAcollect RNA and OMNIgene Oral received EUAs from the FDA in October. Both EUAs allow for the collection, stabilization and transport of saliva specimens suspected containing SARS-CoV-2 RNA.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EThe authorization also allows the products to be used as a component of an authorized or cleared subcollection kit for unsupervised home use. This means the devices can be part of a kit that is authorized under its own EUA for the use of an individual to collect saliva specimens at home. It's important to note that these devices are not COVID tests. They are components of test that would be run in a lab.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EDNA Genotek's customers which are typically laboratories offering COVID-19 test pipeline would use devices as a sample saliva selection -- collection method for their lab-based COVID-19 tests. OMNIgene Oral and ORAcollect RNA are two of three molecular test collection kits that have been included in six EUAs DNA Genotek customers obtained from the FDA.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EBut the EUAs are only one part of the molecular success story. About half of the third quarter sales of molecular sample collection devices for COVID applications were to customers not currently holding EUAs with the balance of customers operating their COVID tests as Laboratory Developed Tests or LDTs. Use of DNA Genotek collection kits continues to grow in back-to-work settings, back-to-school programs and laboratory testing.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EFor example, 30,000 students were tested at the University of Kansas before returning to campus using kits from Clinical Reference Laboratory. And 64 state University of New York campuses are testing students and employees with tests developed by Quadrant Biosciences.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EOur Oragene Dx saliva collection device is available at Albertsons Companies pharmacies throughout the U.S. as part of Phosphorus Diagnostics' COVID-19 testing program. And back-to-work programs are integrating COVID-19 testing, monitoring assessment and access to telemedicine visits for companies through Azova Inc.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EAdditionally, Costco was selling COVID-19 saliva collection kits in conjunction with P23 Labs which received an FDA EUA for the laboratory test workflows with their PCR test. The workflow includes OMNIgene Oral as a saliva collection device. Easy self-collection samples is essential to ensuring the safety of workers and students and their families by helping to curtail the spread of the virus as people resume normal aspects of life. We expect the sales of molecular collection kits for COVID-19 testing to continue to grow within the U.S. with existing and new customers, but also outside the U.S. as other nations complete their validation work around saliva as a sample type.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EMoving on to antibody testing. We have submitted an EUA application to the FDA for our oral fluid SARS-CoV-2 antibody ELISA and are in the review process. To date, there are no oral fluid antibody tests for COVID-19 authorized for sale in the U.S. Pending receipt of an EUA from the FDA we have the potential to be the first. This saliva-based oral fluid test is intended for the qualitative detection of total antibodies to SARS-CoV-2. \u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EWe have a number of interested customers and are prepared to commercialize our antibody test in the fourth quarter of this year subject to receipt of the EUA. Oral sample collection is quick, painless, noninvasive and requires less human contact in comparison to blood draw both minimizing the need for personal protective equipment or PPE and reducing exposure to potentially infected patients. \u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EWith OraSure's tests individuals would use a collection pad to self-collect an oral fluid sample under the direction of a healthcare professional. The sample will then be placed in the OraSure oral antibody collection device buffer for storage and transport. The sample would later be dispensed onto our proprietary ELISA microplate for analysis in a commercial laboratory to determine the presence of antibodies in the oral fluid sample. \u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EPotential locations for sample collection include physician's offices, labs, testing facilities and drive-through testing sites. We are evaluating whether the EUA subsequently could be amended to permit an unsupervised in-home sample collection option with the sample sent to a central laboratory for testing. \u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EAt an epidemiological level, it is extremely important for public health officials to have an accurate understanding of who's been infected. Antibody tests are well suited for community surveillance and seroprevalence studies as they can help identify people in a population or a community that have mounted antibodies against COVID-19. \u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EAccording to the Centers for Disease Control and Prevention CDC, this information could be used to estimate the number of people who have been previously infected with SARS-CoV-2 and were not included in official case counts. This is critical to maintaining an accurate count of infection rates and in forming decisions that can advance public health. Antibody tests could also potentially complement vaccine development and implementation. \u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003ETurning to our antigen test. OraSure continues to make tangible progress in the development of our OraQuick Coronavirus Rapid Antigen Self-Test. Subject to receipt of an EUA this product would test for active COVID-19 infection using nasal samples self-collected from the lower nostril. Results would be available at the point of collection with no instrumentation needed to interpret results. \u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003ETo date, there are no self-test authorized in the U.S. that enable individuals to test themselves and read the results at the point of collection with no instrumentation needed. We are highly confident that we can bring to market an accurate test and meets FDA standards for a rapid self-test. And as we disclosed previously, we intend to sequentially introduce our antigen test for three different uses subject to regulatory authorization. \u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EFirst, a professional test for use at drive-thru sites, physician offices, public health testing sites and employer and university health centers. In this instance, a physician would prescribe the test and the patient would conduct a self-swab in the presence of a healthcare provider who would then interpret the results. \u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003ESecond, a prescription self-test for use by individual consumers which could be offered by employers or universities on or off-site or by physicians or public health authorities via remote testing or telemedicine. In this instance a physician will prescribe the test and the consumer would conduct the self-swab at home or any location where they would then interpret their own results. \u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EThirdly, an over-the-counter or OTC self-test for use by consumers who would purchase online or at retail without prescription would conduct the test and receive the results themselves anytime, anywhere. We expect to file for the professional test EUA in Q1 2021 and the prescription self-test and OTC self-test EUAs to follow as soon as possible thereafter. \u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EThis is a complex process that cannot be rushed. Between now and the filing of the EUA application, we will finalize the device design and complete the EUA studies necessary to determine the achievement of the high-performance standards that the FDA demands of a self-test. We are committed to delivering a rapid antigen self-test that meets FDA requirements for self-tests and the needs of the pandemic as well as our own rigorous standards for quality and performance.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EWe have made a great amount of progress and completed important benchmarks. Limits of detection studies were conducted with live coronavirus at a certified third-party laboratory to evaluate the analytical sensitivity in comparison to an EUA-authorized instrument-free rapid antigen test.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EThe results from the comparison provided further confidence that the proprietary chemistries incorporated in OraSure's lateral flow test strip will deliver the sensitivity needed. In addition the company currently has prototypes on the OraQuick platform under evaluation at clinical testing locations continually providing data on the performance of the design against FDA requirements.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EBased on what we know at this time, we believe there will be significant demand for our antigen test self-test in 2021 as it puts control of the process in the hands of the user.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EIn the U.S. alone the Rockefeller Foundation estimates demand at approximately 2.3 billion tests annually. The Rockefeller Foundation and others have identified fast and frequent testing as a key to getting COVID-19 under control. This is exactly what our antigen tests will deliver. The timing of the EUA is subject to FDA review. Once EUA is obtained, we are prepared to launch the test without delay.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EMoving on to manufacturing. Early on in this pandemic we understood that increasing our manufacturing capacity would be key. To that end, we are confirming that our plans to increase manufacturing capacity to meet demand for COVID-19 sample collection kits and test continues on track as outlined last quarter.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EWith that, I'll hand it over to Roberto for a report on the quarter's financials. Roberto?\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003E\u003Cstrong\u003ERoberto Cuca\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EThanks Steve. As Steve mentioned earlier, our third quarter net revenues increased 33% to $48 million from the $36 million reported in the third quarter of 2019, primarily as a result of strong sales of molecular sample collection kits for COVID-19 testing, increased international sales of the company's HIV self-test, and higher laboratory services revenues, partially offset by lower sales across all of our other product lines, primarily due to the impact of the COVID-19 pandemic.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003ENet product and service revenues were $46.7 million, a 32% increase from the third quarter of 2019. Total product and services revenues for the company's molecular business unit were $31.2 million during the third quarter of 2020, an increase of 79% from the third quarter of 2019. This increase included $18.4 million in sales of oral food sample collection devices for COVID-19 molecular testing, which was partially offset by a decrease in genomic sales.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EInternational sales of the company's OraQuick HIV Self-Test increased 17% compared to the third quarter of 2019, largely due to higher sales in Africa. Gross profit percentages were 63% and 60% for the three months ended September 30th, 2020 and 2019 respectively. Gross profit percentage in the third quarter of 2020 benefited from an improved product mix associated with higher gross profit percentage product sales.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003ENet income for the third quarter of 2020 was $1 million or $0.01 per share on a fully diluted basis compared to net income of $13.1 million or $0.21 per share on a fully diluted basis for the third quarter of 2019.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EThird quarter 2019 results included two gains associated with the sale of a business and a change in the estimated fair value of our acquisition-related contingent consideration together totaling $12.5 million which accounted for approximately $0.16 per share in 2019. Cash and investments totaled $263.7 million at September 30th, 2020.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EAs we disclosed in our press release, we expect revenues of $55 million to $60 million in the fourth quarter of 2020. As we discussed on our second quarter earnings call, we expect that as we've just seen with the third quarter non-COVID revenues will be flat or improved for each business unit in the fourth quarter compared with second quarter and that COVID-19 product sales will add to this performance.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EFor the full year, we continue to expect that excluding cryosurgical revenues from 2019, non-COVID-19 revenues in both the infectious disease and molecular collection lines of business will be down in 2020 compared to the year ago period, with molecular collection bearing the greater impact. However, as our revenue guidance for the fourth quarter indicates, we anticipate that the revenue opportunities for our COVID-19 sample collection, products and tests will more than offset the year-on-year decrease in our non-COVID-19 lines of business, such that our total revenues will be higher in 2020 than in 2019.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EWith that I'll turn the call back over to Steve.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003E\u003Cstrong\u003EStephen Tang\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EThank you, Roberto. Turning to our legacy businesses. HIV testing remains an important area of global focus for OraSure. Access to testing during the pandemic has been challenging as in-person testing facilities for HIV in the United States have been in many cases shut down. Self-testing, which enables social distancing and helps protect healthcare workers and test users alike is a key strategy in the efforts to help people know their HIV status, especially under the current global pandemic conditions.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EOverall, our net HIV test revenues increased 6% over Q3 2019. This was driven by strong international sales of our OraQuick HIV Self-Test that increased 17% compared to the third quarter of 2019. To put this in perspective, a UNAIDS report noted significant decreases in HIV testing services between January and July in nearly all countries with available data.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003ECDC and other government agencies have encouraged health departments at all levels to consider HIV self-testing as an additional testing strategy to reach persons most affected, which speaks to the usability and convenience of our at-home test, which allows individuals to test themselves and receive the results at home.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003ETo date, OraSure offers the only over-the-counter self-test for HIV in the United States and the only World Health Organization or WHO prequalified rapid oral fluid HIV self-test globally.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EI'd also like to briefly touch on our collection business outside of COVID-19. Although not yet back to pre-COVID levels, we saw increases in our genomics and microbiome kit sales quarter-over-quarter. Third quarter kit sales for genomics and microbiome were up 32% and 114% versus the prior quarter respectively, driven by strength in the commercial market.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EAcademic sales also increased quarter-over-quarter, but to a lesser degree. Our laboratory services revenue showed a slight increase over the previous quarter. We continue to innovate in the microbiome arena, adding new products and services.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EOur DNA Genotek subsidiary has launched a skin microbiome collection kit. OMNIgene SKIN offers a standard method for collecting skin microbiome samples from sebaceous dry and wet skin sites, which will aid researchers in obtaining reproducible high-quality samples. And a great example of how our microbiome services and products team complement each other a start-up company Pure Culture Beauty has partnered with DNA Genotek and Diversigen to use data and science to deliver a comprehensive customized skincare regimen to its customers.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EDNA Genotek will supply the OMNIgene SKIN microbiome collection kits and Diversigen will provide full microbiome service – analytical services offering a complete understanding of the user's skin microbiome. We continue to believe in the promise of our microbiome products and services, and look forward to continued growth.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EIn closing, our business momentum is strong and we expect that trend to continue as evidenced by our guidance. We see COVID-19 testing as a robust part of our business for now and in the foreseeable future. With molecular collection devices already driving significant revenue and our antibody and antigen tests on the road to commercialization OraSure is poised for continued and sustained growth.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EOur work with COVID-19 will help accelerate our growth significantly. We understand the opportunity for our tests and sample collection kits is substantial and their role in the fight against COVID-19 is vital. We want to reiterate our confidence in OraSure's ability to bring our antibody and antigen test to market. We believe they will be worthy of joining the list of our other highly regarded OraSure products.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EWith that, I will open it up the call for your questions.\u003C\u002Fp\u003E \u003Cp id=\"question-answer-session\" class=\"paywall-full-content no-summary-bullets\"\u003E\u003Cstrong\u003EQuestion-and-Answer Session\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003E\u003Cstrong\u003EOperator\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EThank you. [Operator Instructions] Our first question comes from the line of Vijay Kumar with Evercore ISI. Your line is now open.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003E\u003Cstrong\u003E\u003Cspan class=\"question\"\u003EVijay Kumar\u003C\u002Fspan\u003E\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EHey guys, thanks for taking my question. Maybe for the first one, Steve, I want to touch on the collection kit opportunity here, $18 million of revenues in the Q. The Q4 guidance implies a modest step up. And I think when you look at the capacity expansion, the goals that you guys had ramping up kit expansion from $35 million to $80 million. So I'm just curious where are we on the expansion? What is the current capacity? Are you selling every single kit that you're making? What should the normalized revenues be for this part of the business once the capacity ramps up?\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003E\u003Cstrong\u003E\u003Cspan class=\"answer\"\u003EStephen Tang\u003C\u002Fspan\u003E\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EThank you, Vijay. I'll start by first saying, we are very pleased with the performance of our Molecular Solutions business unit. And in particular the COVID-19 products that they're selling three into molecular PCR tests, two products were seeing EUAs as we noted in my prepared remarks.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EWhile we're not breaking out revenue specifically, you're right that there is a step-up that's for molecular collection kits for COVID-19 that's embedded in our guidance of $55 million to $60 million for the fourth quarter. By the way that $55 million to $60 million would be a record fourth quarter for us as a company.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EWe are moving ahead with our expansion plans. We are almost to the point of selling everything we can make, which I think makes up -- so I think that as we look into 2021, the expansion that we announced in August will serve us well in terms of providing additional capacity to meet enormous demand in the marketplace. So this area of our business, which I think has come to fruition nicely in the second and third quarter will continue to grow.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003E\u003Cstrong\u003E\u003Cspan class=\"question\"\u003EVijay Kumar\u003C\u002Fspan\u003E\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EUnderstood. And then I guess one for the follow-up, maybe on the antigen testing side. I understand that there'll be a push out here from Q4 to Q1. Maybe can you give us some color on what drove the push out? I guess, the question on investors' minds is what is causing the delay? Are there any technical challenges here? And as you think about that, I guess the language in the press release said that version two the at-home or self-swabbing version would follow soon after. Is that a first half event? Or I'm curious on how we should be thinking on the self-swab at-home version of the test?\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003E\u003Cstrong\u003E\u003Cspan class=\"answer\"\u003EStephen Tang\u003C\u002Fspan\u003E\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003ERight. So we've only forecasted as you noted an EUA for our professional version of the test in the first quarter. But you may recall, Vijay from our second quarter call back in August that we indicated that even though we were going to seek sequential EUAs. So as you noted professional then prescription self-test then over-the-counter self-test, we will actually be conducting the clinical trials in parallel to shorten the time between each approval.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003ESo part of our plan remains to do so. And while we're not providing specific information about when the prescription self-test and the over-the-counter self-test would be on the market, we believe it will be soon after the professional product is approved. And so we'll leave it at that for now.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EBut I think it's important to step back and see what's been accomplished. What's been impressive to us is the technical work that's gone to essentially validate that our -- the core of our OraQuick technology, which is a test strip effectively. It's performing exceptionally well in limited detection studies, compared to rapid antigen tests that are already on the marketplace.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EAnd so that is a significant progress for us right now. And the clinical trials that will go through between now and the EUA submission process in the first quarter, I think we are very confident we'll validate the success of the product.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EWhat we are trying to do is something that no other company has done before. And that is essentially have a one-step rapid antigen test that is essentially the same design we'll use for the professional the Rx self-test and the OTC self-test ready in design in the professional product. So no other product that's on the market today was designed specifically for that purpose even though all of them are professionally used products in their own right. So we're taking the extra care based on our experience in putting the OraQuick HIV in-home test on the market. And also by the way developing the Ebola Rapid Antigen test back in 2017 in nine months' time to get this on the market as quickly as possible. So, there are always things that are unanticipated that come along in product development, but I think we're very confident in that first quarter EUA with the Rx self-test and the OTC self-tests coming soon thereafter. \u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003E\u003Cstrong\u003E\u003Cspan class=\"question\"\u003EVijay Kumar\u003C\u002Fspan\u003E\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003ESorry, what is the LoD on your antigen testing? And how does it compare to competition?\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003E\u003Cstrong\u003E\u003Cspan class=\"answer\"\u003EStephen Tang\u003C\u002Fspan\u003E\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EWell, so we haven't disclosed the numbers Vijay, but they are competitive with the products that are already on the market. And those are -- that's public information. \u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003E\u003Cstrong\u003EOperator\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EOur next question comes from the line of Frank Takkinen with Lake Street Capital. Your line is now open.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003E\u003Cstrong\u003E\u003Cspan class=\"question\"\u003EFrank Takkinen\u003C\u002Fspan\u003E\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EHi guys. Thanks for taking my questions. Just a couple for you here today. I heard you guys talk in your prepared remarks a little bit about the October EUAs for the two DNA Genotek products. I was hoping you could just go a little bit deeper on that and how that could potentially debottleneck the process to continue to drive the momentum behind this business into the fourth quarter as well as into 2021?\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003E\u003Cstrong\u003E\u003Cspan class=\"answer\"\u003EStephen Tang\u003C\u002Fspan\u003E\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EYes. So Frank thanks for the question. So, I think these are important breakthroughs for the two products that received EUAs. And so that's our ORAcollect RNA and our OMNIgene Oral products. And it's important because essentially there's a pathway now for subcollection that wasn't available on the market before these products were approved provided that they are used in a product that has also received in EUA for an individual to collect their own saliva specimen.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003ESo the use of the product if you will very clearly mimics what we've done for in genomic testing used by companies like 23andMe and others. And so from a technical perspective it was very much in line with our expertise. And so it really does allow a pathway for self-collection for saliva. And I think it's important to recognize how far we've come in molecular testing from nasopharyngeal and oropharyngeal swabs to really the breakthrough which is using saliva which allows people to take their own sample and not subject themselves to the discomfort or pain associated with those deep swabs. So that's the breakthrough.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EAnd I think that evidence of that we provided through the work of our customers. 30000 students at the University of Kansas tested 64 campuses of the State University of New York using the product. So you see widespread distribution of our product and even into the retail channels that we mentioned in our prepared remarks. So that is clearly the breakthrough and that's why we're so excited about the progress and growth in our molecular collections, Molecular Solutions business unit and that will continue into 2021 and beyond. \u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003E\u003Cstrong\u003E\u003Cspan class=\"question\"\u003EFrank Takkinen\u003C\u002Fspan\u003E\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EGreat. And then maybe one for Roberto. We saw gross margins came in at 63%. It's definitely a nice contributor to flipping the model back to profitable fourth quarter. I was curious if you could comment on that level of margins given the increasing mix of molecular collection and the expected continued momentum behind this business?\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003E\u003Cstrong\u003E\u003Cspan class=\"answer\"\u003ERoberto Cuca\u003C\u002Fspan\u003E\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003ESure. So, you correctly deduced that the driver of that is the COVID-19 products and we continue to expect those to be growing contributors to our revenues. So versus the third quarter and the fourth quarter -- in the fourth quarter we expect gross margin to be at least as good as the third quarter and likely a bit better given the historical seasonality in our commercial genomics business. There will be some moderation to the gross margin as we see continued growth in our HIV international business, which is a lower gross margin business. But we do overall see this as a sustainable gross margin level that will see some seasonality from quarter-to-quarter in the coming year.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003E\u003Cstrong\u003E\u003Cspan class=\"question\"\u003EFrank Takkinen\u003C\u002Fspan\u003E\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EGreat. Thanks for taking the questions and congrats on the progress this quarter. \u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003E\u003Cstrong\u003E\u003Cspan class=\"answer\"\u003ESteve Tang\u003C\u002Fspan\u003E\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EThanks, Frank.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003E\u003Cstrong\u003E\u003Cspan class=\"answer\"\u003ERoberto Cuca\u003C\u002Fspan\u003E\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EThanks, Frank.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003E\u003Cstrong\u003EOperator\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EThank you. Our next question comes from the line of Tycho Peterson with JPMorgan. Your line is now open.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003E\u003Cstrong\u003E\u003Cspan class=\"question\"\u003ECasey Woodring\u003C\u002Fspan\u003E\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EHi, guys. This is Casey on for Tycho. I guess first question I have is – are you guys baking in any COVID antibody revenue into your 4Q guide? And then how do you see the market evolving for this test? I guess how much of an advantage is perhaps using oral fluid how much of a competitive advantage is that?\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003E\u003Cstrong\u003E\u003Cspan class=\"answer\"\u003ESteve Tang\u003C\u002Fspan\u003E\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003ESo Casey, we have not broken out individual products into our guide for $55 million to $60 million. But I think as we announced back in August, once we locked prototype on the antibody test we would begin building inventory that is manufacturing at risk. That has come to fruition. We have customers that are now evaluating our product on a research-use-only basis before we get our EUA. So that's moving along nicely.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EI think the market for this oral fluid antibody test is going to be expansive. It's coming at a great time when the discussion in the pandemic has moved towards seroprevalence and surveillance. There was an article out just today that said that there's probably 20% of New York City residents that have been exposed to the disease but they haven't been counted or measured yet. So we really do not know the seroprevalence [indiscernible] possibilities for our product in 2021 and 2022.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EIn the rollout of a vaccine this will be a powerful tool to accompany the vaccine to see what – how much of the population are mounting antibodies to this virus overall. So – and we know from our own experience with genomic testing that oral fluid sampling is a lot better than blood-based sampling. And this is the only product if and when it's approved for EUA by the FDA to use an oral fluid. I think there are over 300 antibody tests that use blood. So it – in the tradition of OraSure these are unique products with unique applications.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003E\u003Cstrong\u003E\u003Cspan class=\"question\"\u003ECasey Woodring\u003C\u002Fspan\u003E\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EGot it. Thanks for that. And maybe just one on the antigen pushout. Just sort of a little more color on the reasoning behind it. I saw last week the FDA updated its antigen test template that called for more studies to be submitted in the asymptomatic population. Just wondering is it a matter of more studies that need to be done? Or was it about getting the sensitivity up to where it needs to be? Just any more color on the reasoning behind the push out?\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003E\u003Cstrong\u003E\u003Cspan class=\"answer\"\u003ESteve Tang\u003C\u002Fspan\u003E\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EWell of course, when you're doing product development, there's always an iterative process involved with it. And then you add to that they need to get clinical data from the field. So that interplay between let's say change in the chemistry and changing aspects of the design of the product to get to the point where we are comfortable with it I think contribute to the new forecast for the first quarter of next year.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EAnd I think that ultimately the pushout won't matter to us commercially because I think we're very confident that once the product is on the market we'll sell as many as we can make. So it has nothing to do with the external factors of what FDA is doing and everything to do with our own standards of performance.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EAnd as I said before, we are the only company that's designing a product specifically to ultimately be a self-test whether it's an Rx self-test or an OTC self-test and designing those principles into the professional use product for which we'll seek the initial EUA. So to do all those things to create a one-step rapid antigen test is a challenge that's not been accomplished by anybody yet. So that's why we're investing the time and effort to do it right.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003E\u003Cstrong\u003E\u003Cspan class=\"question\"\u003ECasey Woodring\u003C\u002Fspan\u003E\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EOkay. Thank you.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003E\u003Cstrong\u003E\u003Cspan class=\"answer\"\u003ESteve Tang\u003C\u002Fspan\u003E\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EThank you, Casey\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003E\u003Cstrong\u003EOperator\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EThank you. Our next question comes from the line of Andrew Cooper with Raymond James. Your line is open.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003E\u003Cstrong\u003E\u003Cspan class=\"question\"\u003EAndrew Cooper\u003C\u002Fspan\u003E\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EHey, thanks for the questions guys. I guess maybe first on the antibody test and thinking about sort of the demand there. I know we've touched on it. But if I think back to when you guys initially talked about it I think the statement was this was somewhat pulled from your substance of user or risk assessment customers saying \"Hey we've got empty labs and we can do this.\" Has that expanded potentially as you're approaching that getting it to market hopefully to additional customers potentially kind of bringing your platform in and your place and going beyond sort of those labs? Or how do we think about the commercial opportunity there?\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003E\u003Cstrong\u003E\u003Cspan class=\"answer\"\u003EStephen Tang\u003C\u002Fspan\u003E\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EYes. Andrew, you've recounted our previous statements correctly. And I think you're also right that we've moved even further beyond that with commercial opportunities. And I think the reason for that is that the use and need for antibody tests has changed since the pandemic first started back in March. And as I said earlier, we are now at a stage where antibody tests are going to be more important than they were in the beginning of the pandemic, particularly with prospects of a vaccine coming into play here. So with that in mind, there's a lot more commercial interest than we started from and we are pursuing that as I said with research-only customers right now in the queue in anticipation of the EUA for the oral fluid antibody ELISA test. So yes, things are moving along and we're seeing a lot of tailwinds for this part of the business.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003E\u003Cstrong\u003E\u003Cspan class=\"question\"\u003EAndrew Cooper\u003C\u002Fspan\u003E\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003E \u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EOkay. Great. And then maybe just quickly on antigen side. Just want to confirm like you said for antibody, like you said before kind of that manufacturing at risk comfort. Is that still the plan once you do have the final design locked in and sort of know what you're submitting to the FDA that you would still start manufacturing as soon as that's done? \u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003E\u003Cstrong\u003E\u003Cspan class=\"answer\"\u003EStephen Tang\u003C\u002Fspan\u003E\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EYes. That is still the plan. And based on significant inbound interest there is very good reason for doing so. We want to be able to satisfy pent-up demand in the marketplace. And as I said the design of the product which aims for ultimately a self-test even though the first EUA is a professional test is something that will be unique in the marketplace.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003E\u003Cstrong\u003E\u003Cspan class=\"question\"\u003EAndrew Cooper\u003C\u002Fspan\u003E\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EOkay. And then maybe just one last one if I could sneak it in. On that understand that there is some of the kind of time line dynamics that have adjusted. But when we think about running some of the trials in parallel, does delaying the professional test maybe push the over-the-counter or the prescription self-test closer to that initial time line? Is there any chance where you can kind of compress the gap between the two as you've had more time to develop some of the data and fine-tune things? Or is it still kind of the same sort of lag here that we might expect as you go from one to two to three?\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003E\u003Cstrong\u003E\u003Cspan class=\"answer\"\u003EStephen Tang\u003C\u002Fspan\u003E\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EWell the lag period is somewhat in our control as you can imagine with the design and resourcing of clinical trials, but it's somewhat out of our control because of course FDA makes the final call on the EUA approval process, right? So we're doing everything we can to ensure that there's minimal time between the EUA submissions and hopefully the approvals. We have evolved our thoughts thinking a lot about what it will take to accomplish these clinical trials and we'll make the investments we need to ensure that we shorten the time as much as possible. So I think that's been an evolving set of priorities for us since we spoke at our second quarter earnings call back in August. And so I think we're in a very good position there to minimize the amount of time overall and control what we can control.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003E\u003Cstrong\u003E\u003Cspan class=\"question\"\u003EAndrew Cooper\u003C\u002Fspan\u003E\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EOkay. Great. I’ll stop there. Thanks again.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003E\u003Cstrong\u003E\u003Cspan class=\"answer\"\u003EStephen Tang\u003C\u002Fspan\u003E\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EThanks, Andrew.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003E\u003Cstrong\u003EOperator\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EThank you. Our next question comes from the line of Patrick Donnelly with Citigroup. Your line is now open.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003E\u003Cstrong\u003E\u003Cspan class=\"question\"\u003EPatrick Donnelly\u003C\u002Fspan\u003E\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EThanks guys. Steve maybe just following on on the capacity side. I mean with the 1Q launch obviously kind of ramping at risk a little bit ahead of time, what type of capacity should we be expecting upon launch of the self-antigen test? I know you talked about expectations of selling pretty much everything you guys can make. So how are you thinking about capacity? And then at the same time, are you thinking about carving that up and directing a certain amount of capacity towards professional prescription OTC? What's the right way to think about that from your side?\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003E\u003Cstrong\u003E\u003Cspan class=\"answer\"\u003EStephen Tang\u003C\u002Fspan\u003E\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EYes. So we are on plan for what we announced previously and that is, we're going to move from 35 million tests per year to 55 million tests per year by the first quarter of 2021 and 70 million tests per quarter by the third quarter 2021.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EAnd remember, embedded in that capacity is about 17 million to 18 million units per year of capacity for our existing HIV, HCV and Ebola tests. So when we come on stream ready to serve the professional market, we will have the capacity that you can calculate from our previous information.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EI think, we're going to sell as many as we can make for the professional products. And then, as we have more certainty about the timing for the Rx self-test and for the OTC self-test, we'll begin making allocation decisions about which products to get what capacity.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EI think we really do see a sweet spot in the self-test whether it's Rx or OTC and we'll make the combination that we need to from there. And I think as I've said before, the design considerations here are to try to make the same form factor and product design for all three use cases, professional Rx self-test and OTC self-test.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EThat's an approach that I think -- I don't think any other company has taken in the marketplaces yet. So that design for manufacturing is really built into our plan here and that's what allows us to have a more fungible discussion between\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003E[Audio Gap]\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003E\u003Cstrong\u003E\u003Cspan class=\"question\"\u003EPatrick Donnelly\u003C\u002Fspan\u003E\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EOkay. Yes. You dropped off there at the end. I think I got most of it. And then one -- \u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003E\u003Cstrong\u003E\u003Cspan class=\"answer\"\u003EStephen Tang\u003C\u002Fspan\u003E\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003ESorry about that. \u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003E\u003Cstrong\u003E\u003Cspan class=\"question\"\u003EPatrick Donnelly\u003C\u002Fspan\u003E\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003ENo, no problem. One more on the antigen self-test. I apologize for circling back on this. But just on the time line, I just wanted to clarify. Last quarter you guys kind of shifted from saliva to lower nasal. Obviously -- I just want to make sure, the design approach, they're fully locked in right now and it's just kind of refining things on your end. The data looks compelling. There's no big changes here outside of, again, kind of the normal course shifting in a few months. Is that correct?\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003E\u003Cstrong\u003E\u003Cspan class=\"answer\"\u003EStephen Tang\u003C\u002Fspan\u003E\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EThat is basically correct, although, we haven't announced prototype lock or anything like that. And we may not announce that. I think our goal is, at least, right now, to announce when we actually submit the EUA for the professional application.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EBut I think we're comfortable with our progress, without revealing too much about what the final design will look like. And because we've had experience with HIV, HCV and Ebola, I think we know a lot about how to scale the manufacturing from there.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003E\u003Cstrong\u003E\u003Cspan class=\"question\"\u003EPatrick Donnelly\u003C\u002Fspan\u003E\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EAll right. Thanks.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003E\u003Cstrong\u003E\u003Cspan class=\"answer\"\u003EStephen Tang\u003C\u002Fspan\u003E\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EThank you, Patrick.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003E\u003Cstrong\u003EOperator\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EThank you. Our next question comes from the line of Jacob Johnson from the line of Stephens. Your line is now open.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003E\u003Cstrong\u003E\u003Cspan class=\"question\"\u003EJacob Johnson\u003C\u002Fspan\u003E\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EHi. Thanks. On COVID-19 collection kits, can you just talk about what you're hearing from customers in terms of near and long-term demand for their tests? I think, given your fourth quarter guidance, it would suggest that demand is pretty strong, at least in the near term. But I would just be interested in any other color there.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003E\u003Cstrong\u003E\u003Cspan class=\"answer\"\u003EStephen Tang\u003C\u002Fspan\u003E\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EJacob, I would say that, we are approaching a point where we will sell everything we can make and the capacity increases that we forecasted back in August will serve us well. And so, we are seeing a rather insatiable demand for our products for molecular testing that we believe will continue, certainly, through 2021 and probably well into 2022.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EIt began certainly in North America and in the U.S., but we're looking outside the U.S. as well right now. So these are great discussions to have, because I think people have really gravitated to the fact that you need saliva and self-collection saliva as a key part of testing.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003E\u003Cstrong\u003E\u003Cspan class=\"question\"\u003EJacob Johnson\u003C\u002Fspan\u003E\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EGot it. That's helpful. And then, just maybe one question on the non-COVID front. You had a nice rebound in the HIV franchise in the quarter both internationally and in the U.S. I guess, on the domestic side, are you beginning to see signs of clinics reopening and domestic test volumes increasing?\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EAnd then a quick little aside there would be with the, I guess, third wave as you described it in COVID here in the U.S. Should we think of, I think, Roberto said fourth quarter you expect to be better than the second quarter. But could we see maybe some of that rebound be muted here in the fourth quarter with COVID cases ticking back up?\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003E\u003Cstrong\u003E\u003Cspan class=\"answer\"\u003EStephen Tang\u003C\u002Fspan\u003E\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EYes. I would say directionally, we are seeing -- we've been seeing a pickup as I think Roberto alluded to in our U.S. based HIV business. Some of that because with the clinic closings, CDC has actually issued guidelines urging those clinics to direct there would-be patients to our self-test. And so having that as an alternative in the marketplace has served us incredibly well.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EAnd so the hedge against the third wave of COVID creating a shutdown again will benefit our OraQuick HIV in-home test domestically for that reason. But we'd rather bet on the economy and clinics staying open which benefit their professional products. So while we haven't given specific guidance by product line that's the way we view the situation. So I think there's upside for us in both scenarios. \u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003E\u003Cstrong\u003E\u003Cspan class=\"question\"\u003EJacob Johnson\u003C\u002Fspan\u003E\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EGot it. That's helpful. Thanks for taking the question.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003E\u003Cstrong\u003E\u003Cspan class=\"answer\"\u003EStephen Tang\u003C\u002Fspan\u003E\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EYou’re welcome.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003E\u003Cstrong\u003EOperator\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EThank you. [Operator Instructions] Our next question comes from the line of Brandon Couillard with Jefferies. \u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003E\u003Cstrong\u003E\u003Cspan class=\"question\"\u003EUnidentified Analyst\u003C\u002Fspan\u003E\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EThanks guys. This is Matt on for Brandon today. Quick one on the Phase 1 rollout of your antigen test into the professional market. Any updated color on how you're thinking about ASP there? And then as well on the gross margin side given the initial customer will largely be in the setting of doctor offices or university health centers that are likely to go through distribution channel, any color there on the margin side as well?\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003E\u003Cstrong\u003E\u003Cspan class=\"answer\"\u003EStephen Tang\u003C\u002Fspan\u003E\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003ERoberto, would you like to take that one?\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003E\u003Cstrong\u003E\u003Cspan class=\"answer\"\u003ERoberto Cuca\u003C\u002Fspan\u003E\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003ESure. So we haven't disclosed the pricing for the antibody test yet -- excuse me, the antigen test yet other than to say that we expect it to be in line with the other products on the same technological platform and with products generally in that market. We have said that we expect the gross margin percentage to be at least as good as for our other products.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EAnd as a reminder because there are three potential product types and product distribution channels, a lot of the actual achieved ASP and gross margin will depend on the mix amongst those three. And that will be an evolving mix as we first of all get the EUAs for the products and then optimize the mix for our customers.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003E\u003Cstrong\u003E\u003Cspan class=\"question\"\u003EUnidentified Analyst\u003C\u002Fspan\u003E\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EMakes sense. And then Stephen if we look at the balance sheet you guys have $260 million of cash. You've done a number of smaller deals here one divestiture. You're clearly spending right now to build out manufacturing, but curious how if at all your M&amp;A appetite has evolved over the last few months. And if anything in the funnel is perhaps more actionable today than it was coming into this year. Thanks.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003E\u003Cstrong\u003E\u003Cspan class=\"answer\"\u003EStephen Tang\u003C\u002Fspan\u003E\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EYeah. We continue to look for attractive opportunities to leverage our balance sheet. I think that our business circumstances have certainly changed with the COVID-19 opportunities. And it remains our objective to look at acquiring companies products technologies that are accretive to our overall growth strategy. But as we look ahead to 2021 and 2022, the growth is going to be, I think, fairly enormous at current course and speed. And so we'll be adjusting our expectations of business development and the size and types of deals accordingly.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EBut the pipeline has been robust, I think, as you suggested both with our own outreach and inbound interest from potential prospects, and we'll continue to look at that. Our balance sheet, I think is stellar. No debt at all on the balance sheet. And I think that will lead us to some interesting opportunities in the very near future.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003E\u003Cstrong\u003E\u003Cspan class=\"question\"\u003EUnidentified Analyst\u003C\u002Fspan\u003E\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003ESuper. Thank you.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003E\u003Cstrong\u003E\u003Cspan class=\"answer\"\u003EStephen Tang\u003C\u002Fspan\u003E\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EYou’re welcome.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003E\u003Cstrong\u003EOperator\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EThank you. We do have a follow-up question from the line of Vijay Kumar with Evercore ISI. Your line is now open.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003E\u003Cstrong\u003E\u003Cspan class=\"question\"\u003EVijay Kumar\u003C\u002Fspan\u003E\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003ESteve just I have one quick follow-up on the antigen testing. Maybe can you -- what should investors expect, over the next few months, right? One, will we have any update -- will The Street have any update? And I'm asking because, we had a push out to Q4 and now it's Q1.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EAnd I think The Street would like some updates in the interim. And the second was when are the trials starting right? Are these in-field clinical trials as in you're testing, in the field on live cases given these have to be self-swabbed? Is that what's causing the delay perhaps? And has the prototype for the device been locked yet? Thank you.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003E\u003Cstrong\u003E\u003Cspan class=\"answer\"\u003EStephen Tang\u003C\u002Fspan\u003E\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EYeah, Vijay, we have not announced prototype locks. So we haven't said anything about that. I do understand the interest in our product and the product development. I mentioned earlier, in response to a separate question, that we do plan to announce the submission of our EUA application, for the professional test. That's our plan right now.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EBeyond that we will have to see, what we'll communicate and when. There are obviously some competitive issues that would -- we have to account for, in any particular announcement. But, the delays are not due to any particular factor other than we had very high expectations, for the performance of the product. And the clinical trials are running to validate the particular design and performance of the product.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003ESo that interplay has continued and ramped up, since our August Q2 earnings call. So that will [Indiscernible] what I said before is that, we will use what we understand are the standards for the FDA targeting a self-test. And our own internal quality and performance standard as the measuring stick. And that's a very high bar, which is why it takes time to get this product on the market. But we are very confident that we're on the road to getting this product to the EUA process in the first quarter. And following with the Rx self-test and the OTC self-test shortly thereafter.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003E\u003Cstrong\u003E\u003Cspan class=\"question\"\u003EVijay Kumar\u003C\u002Fspan\u003E\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EThanks Steve.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003E\u003Cstrong\u003E\u003Cspan class=\"answer\"\u003EStephen Tang\u003C\u002Fspan\u003E\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EThank you, Vijay.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003E\u003Cstrong\u003EOperator\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EThank you. This concludes today's question-and-answer session. I would now like to turn the call back to, Stephen Tang, for closing remarks.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003E\u003Cstrong\u003EStephen Tang\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EWe'd like to thank everybody for participating on the call and your interest in OraSure Technologies. We hope that, you keep well and safe wherever you are. And continue to enjoy your afternoon or your evening. Thank you very much.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003E\u003Cstrong\u003EOperator\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003ELadies and gentlemen, this concludes today's conference call. Thank you for your participation. You may now disconnect.\u003C\u002Fp\u003E","twitContent":"$OSUR - OraSure Technologies, Inc. (OSUR) CEO Stephen Tang on Q3 2020 Results - Earnings Call Transcript. https:\u002F\u002Fseekingalpha.com\u002Farticle\u002F4385063-orasure-technologies-inc-osur-ceo-stephen-tang-on-q3-2020-results-earnings-call-transcript?source=tweet ","innerMarketing":null,"marketingBullet":null,"isReit":false,"videoData":null,"marketingBulletVariant":null,"marketingBio":null},"relationships":{"author":{"data":{"id":"44211","type":"author"}},"sentiments":{"data":[]},"primaryTickers":{"data":[{"id":"3622","type":"tag"}]},"secondaryTickers":{"data":[]},"otherTags":{"data":[{"id":"96991","type":"tag"},{"id":"17896","type":"tag"},{"id":"49","type":"tag"},{"id":"586376","type":"tag"},{"id":"326","type":"tag"},{"id":"17909","type":"tag"}]},"coAuthors":{"data":[]},"presentations":{"data":[]},"updates":{"data":[]},"corrections":{"data":[]}},"links":{"self":"\u002Farticle\u002F4385063-orasure-technologies-inc-osur-ceo-stephen-tang-on-q3-2020-results-earnings-call-transcript","canonical":"https:\u002F\u002Fseekingalpha.com\u002Farticle\u002F4385063-orasure-technologies-inc-osur-ceo-stephen-tang-on-q3-2020-results-earnings-call-transcript","uriImage":"https:\u002F\u002Fstatic.seekingalpha.com\u002Fassets\u002Fog_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png","schemaImage":null}},"included":[{"id":"44211","type":"author","attributes":{"company":null,"slug":"sa-transcripts","userId":101639,"tagId":96991,"image":{"small":"https:\u002F\u002Fstatic3.seekingalpha.com\u002Fimages\u002Fusers_profile\u002F000\u002F101\u002F639\u002Fsmall_pic.png","medium":"https:\u002F\u002Fstatic3.seekingalpha.com\u002Fimages\u002Fusers_profile\u002F000\u002F101\u002F639\u002Fmedium_pic.png","big":"https:\u002F\u002Fstatic3.seekingalpha.com\u002Fimages\u002Fusers_profile\u002F000\u002F101\u002F639\u002Fbig_pic.png","extra_large":"https:\u002F\u002Fstatic3.seekingalpha.com\u002Fimages\u002Fusers_profile\u002F000\u002F101\u002F639\u002Fextra_large_pic.png"},"nick":"SA Transcripts","bio":"Seeking Alpha's transcripts team is responsible for the development of all of our transcript-related projects. We currently publish thousands of quarterly earnings calls per quarter on our site and are continuing to grow and expand our coverage. The purpose of this profile is to allow us to share with our readers new transcript-related developments. Thanks, SA Transcripts Team","deactivated":null,"memberSince":2007,"contributorSince":2013,"followersCount":140691},"relationships":{"user":{"data":{"id":"101639","type":"user"}},"userBioTags":{"data":[{"id":"958652","type":"userBioTag"}]},"authorResearch":{"data":null}},"links":{"self":"\u002Fauthor\u002Fsa-transcripts","profileUrl":"\u002Fauthor\u002Fsa-transcripts","site":null,"linkedinUrl":null,"twitterUrl":null}},{"id":"3622","type":"tag","attributes":{"slug":"osur","name":"OSUR","company":"OraSure Technologies, Inc.","tagKind":"Tags::Ticker","equityType":"currency","exchange":"NASDAQ","fundTypeId":0,"isDefunct":false,"currency":"USD","isBdc":false,"isReit":false,"isEtf":false},"relationships":{"sector":{},"subIndustry":{}},"links":{"self":"\u002Fsymbol\u002FOSUR"}},{"id":"96991","type":"tag","attributes":{"slug":"sa-transcripts","name":"SA Transcripts","company":null,"tagKind":"Tags::AuthorTag"},"links":{"self":"\u002Fauthor\u002Fsa-transcripts"}},{"id":"17896","type":"tag","attributes":{"slug":"healthcare","name":"Healthcare","company":null,"tagKind":"Tag"},"links":{"self":"\u002Ftag\u002Fhealthcare"}},{"id":"49","type":"tag","attributes":{"slug":"transcripts","name":"Transcripts","company":null,"tagKind":"Tag"},"links":{"self":"\u002Ftag\u002Ftranscripts"}},{"id":"586376","type":"tag","attributes":{"slug":"has-audio","name":"Has Audio","company":null,"tagKind":"Tag"},"links":{"self":"\u002Ftag\u002Fhas-audio"}},{"id":"326","type":"tag","attributes":{"slug":"us","name":"United States","company":null,"tagKind":"Tags::Country"},"links":{"self":"\u002Farticles?filters=us"}},{"id":"17909","type":"tag","attributes":{"slug":"medical-instruments-supplies","name":"Medical Instruments & Supplies","company":null,"tagKind":"Tag"},"links":{"self":"\u002Ftag\u002Fmedical-instruments-supplies"}}],"meta":{"proStatus":0,"page":{"title":"OraSure Technologies, Inc. (OSUR) CEO Stephen Tang on Q3 2020 Results - Earnings Call Transcript","description":"OraSure Technologies, Inc. (NASDAQ:NASDAQ:OSUR) Q3 2020 Earnings Conference Call November 4, 2020 5:00 PM ETCompany ParticipantsJeanne Mell - Vice President..."},"path":"\u002Fapi\u002Fv3\u002Farticles\u002F4385063"}},"type":"article","authorData":{"response":{"data":{"id":"44211","type":"fullAuthor","attributes":{"company":null,"slug":"sa-transcripts","userId":101639,"tagId":96991,"image":{"small":"https:\u002F\u002Fstatic3.seekingalpha.com\u002Fimages\u002Fusers_profile\u002F000\u002F101\u002F639\u002Fsmall_pic.png","medium":"https:\u002F\u002Fstatic3.seekingalpha.com\u002Fimages\u002Fusers_profile\u002F000\u002F101\u002F639\u002Fmedium_pic.png","big":"https:\u002F\u002Fstatic3.seekingalpha.com\u002Fimages\u002Fusers_profile\u002F000\u002F101\u002F639\u002Fbig_pic.png","extra_large":"https:\u002F\u002Fstatic3.seekingalpha.com\u002Fimages\u002Fusers_profile\u002F000\u002F101\u002F639\u002Fextra_large_pic.png"},"nick":"SA Transcripts","bio":"Seeking Alpha's transcripts team is responsible for the development of all of our transcript-related projects. We currently publish thousands of quarterly earnings calls per quarter on our site and are continuing to grow and expand our coverage. The purpose of this profile is to allow us to share with our readers new transcript-related developments. Thanks, SA Transcripts Team","deactivated":null,"memberSince":2007,"contributorSince":2013,"followersCount":140691,"count":{"followers":140691,"articles":334318,"instablogs":0,"marketing_instablogs":0,"following":4,"comments":1,"likes":0,"comment_likes":1,"news":0,"mp_articles":0},"createdAt":"2013-02-20T14:49:48-05:00","showHeadlines":null,"podcasts":{}},"relationships":{"user":{"data":{"id":"101639","type":"user"}},"userBioTags":{"data":[{"id":"958652","type":"userBioTag"}]},"authorResearch":{"data":null}},"links":{"self":"\u002Fauthor\u002Fsa-transcripts","profileUrl":"\u002Fauthor\u002Fsa-transcripts","site":{"url":"https:\u002F\u002Fseekingalpha.com\u002Fearnings\u002Fearnings-call-transcripts","name":"Recent earnings call transcripts","clicks":38681},"linkedinUrl":"","twitterUrl":""}},"included":[{"id":"958652","type":"userBioTag","attributes":{"priority":0,"name":"We cover over 4K calls\u002Fquarter"}}]},"type":"fullAuthor"}}};</script></head><body><script>
        (() => {
          try {
            if (
              window.matchMedia &&
              window.matchMedia('(min-width: 1024px)').matches &&
              window.localStorage.getItem('isAsideOpened') === 'false'
            ) {
              window.document.documentElement.style.setProperty('--sa-aside-width', '3rem')
              window.document.body.classList.add('hydratingAsideCollapsed');
            }
          } catch (err) {
            console.error(err);
          }
        })()
      </script><div class="appLoading appLoaderInvisible" id="app-loader"></div><span id="sprite-source"><svg style="position:absolute;width:0;height:0;visibility:hidden" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink"><symbol viewBox="0 0 16 16" id="alpha" xmlns="http://www.w3.org/2000/svg"><path d="M3.763 8.396c0 2.468 1.209 4.508 2.82 4.458 2.257-.065 2.918-2.007 2.918-4.474 0-2.468-1.306-4.492-2.917-4.475-1.983.016-2.82 2.023-2.82 4.491Zm-1.756 0C2.345 3.116 6.407 3 6.407 3c2.949.016 3.787 3.225 3.787 3.225.048.18 1.756-2.995 1.756-2.995h.967c-1.982 4.36-1.901 6.137-1.901 6.137-.161 2.352 1.128 3.158 1.128 3.158 1.209.79 1.29-1.513 1.29-1.513.273-.099.434-.197.434-.197.645 3.191-1.289 2.977-1.289 2.977-1.499.165-2.144-2.336-2.144-2.336-2.127 2.863-4.577 2.238-4.577 2.238-4.19-.527-3.851-5.298-3.851-5.298Z"></path></symbol><symbol fill="none" viewBox="0 0 24 23" id="alpha-picks" xmlns="http://www.w3.org/2000/svg"><path fill="#1A98FF" d="M22.562 16.845s-.159 4.545-2.544 2.987c0 0-2.545-1.591-2.227-6.234 0 0-.068-1.54 1.022-5.081-.412.54-.805 1.066-1.172 1.606a35.72 35.72 0 0 0-1.361 2.2l-.008.014-.01.014c-.378.624-.74 1.28-1.076 1.95l-.01.019-.01.019c-.305.565-.569 1.16-.849 1.788l-.003.007-.002.005c-.024.053-.05.104-.078.155-.743 2.465-2.305 4.103-5.189 4.187-3.18.097-5.565-3.928-5.565-8.798s1.653-8.83 5.565-8.863c2.006-.02 3.77 1.56 4.8 3.952.193-.218.382-.419.565-.61.098-.104.197-.207.295-.313l.018-.02.019-.018.363-.366.17-.17c-1.018-1.842-3.017-4.22-6.58-4.24 0 0-8.014.227-8.682 10.648 0 0-.668 9.415 7.601 10.454 0 0 4.834 1.233 9.032-4.415 0 0 1.273 4.934 4.23 4.61 0 0 3.817.421 2.545-5.877 0 0-.318.195-.859.39Z" opacity=".75"></path><path fill="#1A98FF" d="M5.668 7.958c-.213.118-.284.377-.047.637a62.52 62.52 0 0 1 1.605 1.91c.78.92 1.394 1.957 1.937 3.042.33.66.614 1.344.944 2.005.296.612.787.897 1.455.897l.08-.001c.567 0 1.134-.378 1.37-.896.283-.637.566-1.274.897-1.887.354-.707.732-1.391 1.133-2.052.45-.778.921-1.556 1.417-2.287a45.491 45.491 0 0 1 1.582-2.146c.45-.566.898-1.132 1.394-1.675a88.988 88.988 0 0 1 2.078-2.146c.566-.566 1.18-1.108 1.77-1.65.19-.19.378-.354.567-.52.166-.14.19-.306.095-.495A.304.304 0 0 0 23.644.5a.546.546 0 0 0-.077.006.83.83 0 0 0-.33.141c-.284.212-.59.401-.874.613-.662.472-1.346.967-2.007 1.462-.59.449-1.134.92-1.7 1.392-.496.4-.969.825-1.418 1.25-.519.471-.991.967-1.487 1.462-.307.33-.614.637-.921.99-.496.59-.992 1.156-1.464 1.746a56.8 56.8 0 0 0-1.44 1.886c-.237.307-.45.637-.685.967a6.364 6.364 0 0 0-.709-.684c-.496-.495-.968-.99-1.487-1.462-.425-.4-.898-.755-1.346-1.108-.496-.401-1.04-.779-1.559-1.156a.416.416 0 0 0-.267-.105.412.412 0 0 0-.205.058Z"></path></symbol><symbol viewBox="0 0 16 16" id="analysis-icon" xmlns="http://www.w3.org/2000/svg"><path fill-rule="evenodd" clip-rule="evenodd" d="M11.275 3.108 10.125 2l-3.18 3.064 3.18 3.065 1.15-1.107-1.219-1.175H14V4.282h-3.944l1.219-1.174Zm-5.212 2.74H2V4.281h4.063v1.565Zm-1.338 7.049 1.15 1.107 3.18-3.063-3.18-3.066-1.15 1.108 1.219 1.174H2v1.566h3.944l-1.219 1.174Zm5.212-2.74H14v1.565H9.937v-1.565Z"></path></symbol><symbol viewBox="0 0 16 16" id="arrow-icon" xmlns="http://www.w3.org/2000/svg"><path d="m7.9 4.6-.8.8 2.2 2.1H5.5v1h3.8l-2.2 2.1.8.8L11.2 8 7.9 4.6Z"></path></symbol><symbol viewBox="0 0 16 16" id="authors-icon" xmlns="http://www.w3.org/2000/svg"><path fill-rule="evenodd" clip-rule="evenodd" d="M10 5a2 2 0 1 1-4 0 2 2 0 0 1 4 0Zm.935 2.718a4 4 0 1 0-5.87 0C3.235 8.68 2 10.518 2 12.625V15h12v-2.375c0-2.107-1.236-3.944-3.065-4.907ZM8 9c-2.333 0-4 1.743-4 3.625V13h8v-.375C12 10.743 10.333 9 8 9Z"></path></symbol><symbol viewBox="0 0 20 24" id="bell" xmlns="http://www.w3.org/2000/svg"><path d="M16.88 10.49c0-3.54-2.02-5.98-3.54-6.4-1.52-.43-1.46-2.05-1.46-2.05C11.88.91 11.04 0 10 0S8.12.91 8.12 2.04c0 0 .06 1.62-1.46 2.05-1.52.42-3.54 2.86-3.54 6.4C3.12 18 0 17.56 0 20.16h20c0-2.6-3.12-2.15-3.12-9.67zM6.46 21.12A3.72 3.72 0 0 0 10 24a3.7 3.7 0 0 0 3.54-2.88H6.46z"></path></symbol><symbol viewBox="0 0 16 16" fill="none" id="beta" xmlns="http://www.w3.org/2000/svg"><path fill="#555" d="M0 0h16v16H0z"></path><path d="M5.322 14.11h1.02v-3.053h.094c.316.65.984 1.06 1.927 1.06 1.524 0 2.631-1.101 2.631-2.666V9.44c0-1.171-.615-1.95-1.781-2.244v-.093c.744-.323 1.195-.99 1.195-1.776v-.012c0-1.365-.99-2.255-2.49-2.255-1.64 0-2.596 1.066-2.596 2.912v8.138Zm2.989-2.895c-1.172 0-1.97-.844-1.97-2.186V6.076c0-1.394.54-2.115 1.606-2.115.885 0 1.453.562 1.453 1.412v.012c0 .914-.568 1.406-1.564 1.406h-.522v.902h.516c1.377 0 2.121.61 2.121 1.776v.011c0 .997-.726 1.735-1.64 1.735Z" fill="#fff"></path></symbol><symbol viewBox="0 0 31 25" id="chat" xmlns="http://www.w3.org/2000/svg"><path d="M28.92 5.18a14.04 14.04 0 0 0-5.64-3.79A21.22 21.22 0 0 0 15.5 0c-2.1 0-4.1.28-6.02.82a17.31 17.31 0 0 0-4.95 2.22 11.4 11.4 0 0 0-3.3 3.33A7.42 7.42 0 0 0 0 10.41c0 1.63.52 3.16 1.57 4.58a12.47 12.47 0 0 0 4.28 3.58 9.93 9.93 0 0 1-1.48 3.02c-.17.23-.35.44-.54.65l-.6.62a56.87 56.87 0 0 0-.67.7l-.12.14-.1.15c-.06.08-.09.13-.08.15a.3.3 0 0 1-.04.16c-.03.1-.02.16.01.2v.02c.04.18.15.35.3.47a.7.7 0 0 0 .53.14A19.33 19.33 0 0 0 13 20.7c.87.1 1.7.14 2.51.14 2.81 0 5.41-.46 7.78-1.4a13.88 13.88 0 0 0 5.64-3.78A7.84 7.84 0 0 0 31 10.4c0-1.88-.7-3.63-2.08-5.23z"></path></symbol><symbol viewBox="0 0 16 16" id="chevron-icon" xmlns="http://www.w3.org/2000/svg"><path fill-rule="evenodd" d="m8.793 8-2.647 2.646.708.707L10.207 8 6.854 4.646l-.708.708L8.793 8Z" clip-rule="evenodd"></path></symbol><symbol viewBox="0 0 16 16" id="comparison-icon" xmlns="http://www.w3.org/2000/svg"><path fill-rule="evenodd" clip-rule="evenodd" d="m11.767 1-1.132 1.137 1.3 1.307H9.068v1.608h2.87L10.635 6.36l1.132 1.137L15 4.248 11.767 1ZM3.098 3.068h2.335v2.36H3.098v-2.36Zm-1.5-1.5h5.335V6.928H1.598V1.568Zm8.969 9.004h2.335v2.36h-2.335v-2.36Zm-1.5-1.5h5.335V14.432H9.067V9.072Zm-3.702.569L4.233 8.504 1 11.752 4.233 15l1.132-1.137-1.3-1.307h2.868V10.95h-2.87L5.365 9.64Z"></path></symbol><symbol viewBox="0 0 24 24" fill="none" id="contributor-icon" xmlns="http://www.w3.org/2000/svg"><path d="M4.333 2.125c-1.45.002-2.581 1.293-2.583 2.833v13.46c.002 1.539 1.134 2.83 2.583 2.832h13.095c1.449-.002 2.581-1.293 2.583-2.832V13.83c0-.399-.298-.766-.717-.766s-.716.367-.716.766v4.586c-.001.742-.539 1.3-1.15 1.3H4.333c-.612 0-1.15-.558-1.15-1.3V4.957c0-.74.538-1.298 1.15-1.299h4.143c.419 0 .717-.367.717-.766s-.298-.767-.717-.767H4.333Z" fill="currentColor" stroke="currentColor" stroke-width=".5"></path><path d="M21.898 3.964c.46-.46.526-1.143.15-1.526L20.588.96c-.222-.225-.548-.296-.873-.223a1.332 1.332 0 0 0-.644.362l-.62.62 2.827 2.865.62-.619ZM8.74 11.418c-.27.271-2.032 4.873-2.032 4.873s4.587-1.737 4.857-2.007L19.74 6.12l-2.827-2.865-8.173 8.163Z" fill="currentColor"></path></symbol><symbol fill="none" viewBox="0 0 16 16" id="crown" xmlns="http://www.w3.org/2000/svg"><path fill="currentColor" fill-rule="evenodd" d="M10.438 7.927 8 4.558l-2.438 3.37-2.555-1.093.898 4.665h8.19l.898-4.665-2.555 1.092ZM15 4.346 13.334 13H2.666L1 4.346l4.05 1.73L8 2l2.95 4.077L15 4.346Z" clip-rule="evenodd"></path></symbol><symbol viewBox="0 0 20 20" id="drag" xmlns="http://www.w3.org/2000/svg"><path d="M7 2a2 2 0 1 0 0 4 2 2 0 0 0 0-4m0 6a2 2 0 1 0 0 4 2 2 0 0 0 0-4m0 6a2 2 0 1 0 0 4 2 2 0 0 0 0-4m6-8a2 2 0 1 0 0-4 2 2 0 0 0 0 4m0 2a2 2 0 1 0 0 4 2 2 0 0 0 0-4m0 6a2 2 0 1 0 0 4 2 2 0 0 0 0-4"></path></symbol><symbol viewBox="0 0 5 21" id="info" xmlns="http://www.w3.org/2000/svg"><circle cx="2.5" cy="2.5" r="2.5"></circle><circle cx="2.5" cy="10.5" r="2.5"></circle><circle cx="2.5" cy="18.5" r="2.5"></circle></symbol><symbol viewBox="0 0 9 10" id="lock" xmlns="http://www.w3.org/2000/svg"><path d="M7.77 4.36h-.36V3.08A3 3 0 0 0 4.5 0a3 3 0 0 0-2.9 3.08v1.28h-.37c-.4 0-.73.34-.73.77v4.1c0 .43.33.77.73.77h6.54c.4 0 .73-.34.73-.77v-4.1a.75.75 0 0 0-.73-.77zm-5.12 0V3.08A1.9 1.9 0 0 1 4.5 1.12a1.9 1.9 0 0 1 1.85 1.96v1.28h-3.7z"></path></symbol><symbol viewBox="0 0 131 26" id="logo" xmlns="http://www.w3.org/2000/svg"><path fill="currentColor" d="M.4 18a9.26 9.26 0 0 1-.4 1.82C.7 20.58 2.34 21 3.34 21c2.8 0 5.07-1.74 5.07-4.68 0-4.37-6.46-2.85-6.46-6.63 0-1.45 1.17-2.4 2.58-2.4 1.21 0 2.12.68 2.55 1.79h.2c.17-.58.31-1.15.56-1.68a4.6 4.6 0 0 0-2.94-.99c-2.46 0-4.55 1.3-4.55 3.94 0 4.64 6.42 2.95 6.42 6.77 0 1.62-1.19 3-2.85 3-1.6 0-2.52-.82-3.32-2.14H.4zm11.33-3.28c.12-1.73.96-3.57 2.9-3.57 2.02 0 2.52 1.78 2.56 3.57h-5.46zm6.59 3.6a4.55 4.55 0 0 1-3.04 1.42c-2.48 0-3.73-1.97-3.55-4.27h2.9c1.37 0 2.76.02 4.16.07.2-3.43-1.89-5.03-4.17-5.03-3.05 0-4.7 2.2-4.7 5.05 0 3.18 2.02 5.04 4.85 5.04 1.25 0 2.52-.49 3.52-1.2l.03-1.08zm3.92-3.6c.12-1.73.96-3.57 2.9-3.57 2.02 0 2.52 1.78 2.56 3.57h-5.46zm6.58 3.6a4.54 4.54 0 0 1-3.03 1.42c-2.48 0-3.74-1.97-3.55-4.27h2.9c1.37 0 2.76.02 4.16.07.2-3.43-1.9-5.03-4.17-5.03-3.05 0-4.7 2.2-4.7 5.05 0 3.18 2.02 5.04 4.85 5.04 1.25 0 2.52-.49 3.53-1.2l.01-1.08zm3.77-13.07c-.31.03-.56.07-.83.07-.28 0-.55-.04-.82-.07v15.41c.27-.02.54-.06.82-.06.27 0 .52.04.83.06v-4.18c0-.89.28-.95.73-.43 1.32 1.5 2.94 3.32 3.92 4.61.33-.02.66-.06 1.03-.06.33 0 .61.04 1 .06v-.1c-1.62-1.85-3.34-3.9-4.82-5.6 1.9-1.79 3.7-3.22 4.52-3.96v-.14c-.31.01-.56.06-.8.06-.3 0-.56-.05-.82-.06l-1.6 1.76-1.28 1.3c-.26.26-1.35 1.43-1.78 1.2-.19-.1-.1-.4-.1-.67v-9.2zm10.37 2.22c0-.58-.5-1.05-1.04-1.05a1.05 1.05 0 0 0 0 2.1c.55 0 1.04-.48 1.04-1.05zm-.22 3.5c-.31.03-.56.07-.82.07-.3 0-.56-.04-.83-.06v9.8c.27-.02.54-.06.83-.06.26 0 .5.04.82.06v-9.8zm1.63 9.47c.27-.02.54-.06.82-.06.27 0 .52.04.82.06v-4.76c0-2.53.54-4.1 2.7-4.1 1.92 0 2.27 1.5 2.27 3.4v5.46c.26-.02.53-.06.82-.06.26 0 .51.04.82.06V14.5c0-2.7-.92-4-3.3-4-1.46 0-2.59.74-3.3 1.99v-1.87c-.31.02-.56.06-.83.06-.28 0-.55-.04-.82-.06v9.8zm11.21-6.68c0-1.56.84-2.7 2.32-2.7 1.62 0 2.2 1.22 2.2 2.8 0 1.4-.79 2.69-2.28 2.69-1.5 0-2.3-1.34-2.24-2.8zm6.9-3.18c-.48.08-.97.1-1.47.04l-2.85-.1c-2.99-.1-4.14 1.27-4.14 3.26 0 1.51.76 2.36 1.99 2.93-.8.35-1.41.78-1.41 1.77 0 1.25.65 1.55 1.25 1.66v.16c-1.28.23-2.14 1-2.14 2.48 0 2.16 2.03 3.02 3.72 3.02 3.13 0 5.2-1.64 5.2-4.04 0-1.75-1.12-2.73-3.54-2.73h-1.32c-1.23 0-1.97-.12-1.97-.99 0-1.19 1.24-.98 1.48-.98 2.38 0 4.37-.95 4.37-3.18 0-1.15-.57-2.05-1.41-2.7l2.25.18v-.78zm-4.34 9.7c1.54 0 3.02.14 3.02 2.28 0 1.93-1.77 2.62-3.24 2.62-1.7 0-2.95-.82-2.95-2.48 0-1.66 1.04-2.44 3.17-2.42zm19.16-5.92h-4.5l2.23-5.25 2.28 5.25zm-1.53-7.94h-.47l-6.4 14.34c.22-.02.45-.06.71-.06.25 0 .47.04.76.06.58-1.93 1.32-3.73 2.03-5.54h5.21a77.59 77.59 0 0 1 2.16 5.54c.35-.02.7-.06 1.09-.06.34 0 .67.04 1.06.06L75.77 6.42zm7.73 14.24c.26-.02.52-.06.81-.06.27 0 .51.04.82.06V5.26c-.3.02-.55.06-.82.06-.29 0-.55-.04-.82-.07v15.41zm5.13-2.03h.04c.68 1.28 1.69 1.97 3.16 1.97 2.63 0 4.43-2.03 4.43-5.4 0-2.45-1.47-4.7-4.12-4.7-2.48 0-3.12 1.5-3.47 2.2h-.04v-2.07c-.3.02-.55.06-.82.06-.28 0-.55-.04-.82-.06V25.7c.27-.02.54-.06.82-.06.27 0 .52.04.82.06v-7.06zm0-2.83c0-1.9.62-4.6 3-4.6 2.21 0 2.83 2.08 2.83 4.09 0 2.38-.74 4.45-2.81 4.45-2.1 0-3.02-1.74-3.02-3.94zm9.46 4.86c.26-.02.53-.06.82-.06.26 0 .51.04.82.06v-5.58c0-2.13.84-3.28 2.68-3.28 1.75 0 2.28 1.13 2.28 3.4v5.46c.27-.02.53-.06.82-.06.27 0 .52.04.82.06v-5.93c0-2.58-.92-4-3.3-4-1.45 0-2.58.74-3.3 2V5.24c-.31.03-.56.07-.82.07-.29 0-.56-.04-.82-.07v15.41zm15.23-2.34c0 .15-.41.5-.56.64-.39.4-1.08.78-1.64.78-1.25 0-2-.63-2-1.93 0-1.86 2.08-2.07 3.48-2.34l.72-.14v3zm1.64-4.36c0-2.32-1.17-3.45-3.33-3.45-1.2 0-2.31.45-3.3 1.13v1.15h.23c.14-.45.94-1.42 2.44-1.42 1.54 0 2.4.88 2.4 2.4 0 .99-.56 1.1-2.18 1.38-1.93.3-3.8.61-3.8 2.95 0 1.52 1.28 2.5 2.74 2.5 1.23 0 2.17-.43 3.03-1.29l.19-.18c.16 1.2 1.05 1.37 2.11 1.19.23-.04.47-.15.62-.2v-.46c-1.21.27-1.15-.14-1.15-.94v-4.76z"></path><path color="currentColor" d="M116.78 6.12c.38-5.99 5.1-6.12 5.1-6.12 3.4.02 4.37 3.65 4.37 3.65.04.2 2.02-3.4 2.02-3.4h1.12c-2.28 4.95-2.19 6.98-2.19 6.98-.19 2.66 1.31 3.57 1.31 3.57 1.4.9 1.49-1.71 1.49-1.71.3-.12.5-.22.5-.22.74 3.62-1.49 3.37-1.49 3.37-1.74.18-2.48-2.64-2.48-2.64-2.46 3.24-5.3 2.54-5.3 2.54-4.85-.62-4.45-6.02-4.45-6.02m2.03 0c0 2.8 1.4 5.1 3.26 5.05 2.62-.08 3.38-2.27 3.38-5.08 0-2.8-1.51-5.1-3.38-5.07-2.3.03-3.26 2.3-3.26 5.1"></path></symbol><symbol viewBox="0 0 16 16" fill="none" id="marketplace-icon" xmlns="http://www.w3.org/2000/svg"><path fill-rule="evenodd" clip-rule="evenodd" d="M4.196 3.257a2.667 2.667 0 0 0-2.152 4.471C.945 8.308.168 9.357.023 10.584A3.558 3.558 0 0 0 0 11v1.583h2v-.896c0-.378.039-.747.113-1.104H2.06c.03-.105.073-.21.126-.31A5.662 5.662 0 0 1 4.15 7.325a4.317 4.317 0 0 1-.484-1.992c0-.752.191-1.46.529-2.076ZM13.814 10.273a5.661 5.661 0 0 0-1.964-2.948 4.317 4.317 0 0 0 .484-1.992c0-.752-.192-1.46-.53-2.076a2.667 2.667 0 0 1 2.152 4.471c1.098.579 1.875 1.628 2.02 2.855.016.137.024.276.024.417v1.583h-2v-.896c0-.378-.039-.747-.113-1.104h.052a1.66 1.66 0 0 0-.125-.31Z" fill="currentColor"></path><path fill-rule="evenodd" clip-rule="evenodd" d="M9.333 5.333a1.333 1.333 0 1 1-2.666 0 1.333 1.333 0 0 1 2.666 0Zm1.113 2.265a3.333 3.333 0 1 0-4.892 0C4.036 8.398 3.008 9.92 3 11.667v2h10v-2c-.008-1.748-1.036-3.269-2.554-4.069ZM5 11.667C5.012 10.309 6.23 9 8 9s2.988 1.31 3 2.667H5Z" fill="currentColor"></path></symbol><symbol viewBox="0 0 16 16" id="news-icon" xmlns="http://www.w3.org/2000/svg"><path fill-rule="evenodd" clip-rule="evenodd" d="M11.75 2v3H14v9H9.875v-1.5H12.5v-6H4.625a2.25 2.25 0 0 1-2.24-2.467A2.293 2.293 0 0 1 4.69 2h7.059ZM4.659 5h5.591V3.5H4.625a.75.75 0 0 0-.75.825A.772.772 0 0 0 4.66 5Z"></path><path d="M10.625 10.25a.75.75 0 1 0 0-1.5.75.75 0 0 0 0 1.5ZM6.875 13.25V14h1.5v-.938a5.626 5.626 0 0 0-5.438-5.437H2v1.5h.75a4.125 4.125 0 0 1 4.125 4.125Z"></path><path d="M3.875 14v-.75a1.124 1.124 0 0 0-1.125-1.125H2v-1.5h.938v.01a2.625 2.625 0 0 1 2.428 2.427h.01V14H3.874Z"></path></symbol><symbol viewBox="0 0 16 16" id="performance-icon" xmlns="http://www.w3.org/2000/svg"><path fill-rule="evenodd" clip-rule="evenodd" d="M5.429 6.385H2V14h12V8.923h-3.429V3H5.43v3.385Zm1.714-1.693v3.384h.001v4.23H5.43v-4.23H3.714v4.232h8.572v-1.693H10.57v1.692H8.855v-4.23h.002V4.691H7.143Z"></path></symbol><symbol viewBox="0 0 16 16" id="plus-icon" xmlns="http://www.w3.org/2000/svg"><path fill-rule="evenodd" d="M8.5 8.5V11h-1V8.5H5v-1h2.5V5h1v2.5H11v1H8.5Z" clip-rule="evenodd"></path></symbol><symbol viewBox="0 0 16 16" id="portfolios-icon" xmlns="http://www.w3.org/2000/svg"><path fill-rule="evenodd" clip-rule="evenodd" d="m15 3.581-1.126 3.384h-1.929l-1.99 3.988-1.931-.966L6.018 13l-2.224-2.228-2.214.739L1 9.768 4.29 8.67l1.443 1.446 1.663-2.498 1.738.87 1.678-3.36h1.74L13.26 3l1.74.581Z"></path></symbol><symbol fill="none" viewBox="0 0 14 12" id="premium" xmlns="http://www.w3.org/2000/svg"><path stroke="#00D885" d="M9 2h4v4"></path><path stroke="#00D885" d="M13 2 7.24 7.65 5.32 5.76 1 10"></path></symbol><symbol viewBox="0 0 22 26" id="presentation" xmlns="http://www.w3.org/2000/svg"><path fill-rule="evenodd" clip-rule="evenodd" d="M9 0h4v2H9V0zm4 9a1 1 0 0 1 1-1h3a1 1 0 1 1 0 2h-3a1 1 0 0 1-1-1zm0 3a1 1 0 0 1 1-1h3a1 1 0 1 1 0 2h-3a1 1 0 0 1-1-1zm-4 5v2h.14l-4.79 4.8c-.3.29-.3.77 0 1.07.29.3.77.3 1.06 0L11 19.28l5.59 5.6a.76.76 0 0 0 1.06-1.09L12.85 19H13v-2h7a1 1 0 0 0 1-1V5h1V3H0v2h1v11a1 1 0 0 0 1 1h7zM19 6H3v9h16V6zm-9.5 6.67A3 3 0 0 0 10 11H7V8a3 3 0 1 0 2.5 4.67z"></path><path opacity=".5" d="M11 10a3 3 0 0 0-3-3v3h3z"></path></symbol><symbol viewBox="0 0 23 16" id="pressRelease" xmlns="http://www.w3.org/2000/svg"><path fill-rule="evenodd" d="M16.52 3.16a.5.5 0 0 0 .03.7l.15.14c.2.2.52.18.7-.02l2.61-2.8a.5.5 0 0 0-.03-.7l-.14-.14a.5.5 0 0 0-.71.03l-2.6 2.79zM1.21 8.1l9.96-6.64c.15-.16.31-.28.5-.34 1.27-.38 3.1 1.88 4.07 5.06.97 3.18.73 6.08-.55 6.46-.19.06-.39.06-.6 0l-3.25.02a3.01 3.01 0 1 1-6.02.04l-2.7.01c-.64.2-1.47-.68-1.86-1.95C.37 9.49.57 8.3 1.21 8.1zm5.32 4.59a1.8 1.8 0 0 0 2.33 1.9 1.8 1.8 0 0 0 1.27-1.92l-3.6.02zm8.05-6.16c.78 2.55.9 4.77.26 4.96-.64.2-1.78-1.7-2.56-4.25s-.9-4.77-.26-4.96c.64-.2 1.79 1.7 2.56 4.25zm3.94-1.2a.5.5 0 0 0-.33.63l.06.2a.5.5 0 0 0 .62.32l3.65-1.11a.5.5 0 0 0 .33-.63l-.06-.2a.5.5 0 0 0-.62-.33l-3.65 1.12zm-.44 3.1a.5.5 0 0 1 .6-.37l3.72.86a.5.5 0 0 1 .37.6l-.04.2a.5.5 0 0 1-.6.38l-3.72-.86a.5.5 0 0 1-.38-.6l.05-.2z"></path></symbol><symbol viewBox="0 0 35 12" id="pro" xmlns="http://www.w3.org/2000/svg"><path fill="#fff" d="M4.17.09H0V11.9h.85V8.06h3.32c2.93 0 4.7-1.5 4.7-3.98C8.86 1.57 7.1.1 4.16.1zm0 7.18H.85V.87h3.32C6.67.86 8 2.02 8 4.06c0 2.03-1.33 3.2-3.83 3.2zm16.6 4.64-2.91-4.14a3.62 3.62 0 0 0 2.72-3.7c0-2.5-1.76-3.99-4.68-3.99h-4.18v11.83h.85V8.04h3.33c.4 0 .76-.03 1.13-.08l2.77 3.95h.97zm-8.2-4.63V.86h3.33c2.49 0 3.82 1.17 3.82 3.21 0 2.03-1.33 3.22-3.82 3.22h-3.33zM28.63 12c3.46 0 6.05-2.55 6.05-6s-2.6-6-6.05-6c-3.48 0-6.06 2.57-6.06 6s2.58 6 6.06 6zm0-.8a5.07 5.07 0 0 1-5.2-5.2c0-3 2.22-5.2 5.2-5.2A5.07 5.07 0 0 1 33.8 6c0 3-2.22 5.2-5.18 5.2z"></path></symbol><symbol viewBox="0 0 16 16" id="rated-icon" xmlns="http://www.w3.org/2000/svg"><path fill-rule="evenodd" clip-rule="evenodd" d="m4.1 3.5 1.4 3.7c-.5.3-.9.6-1.2 1L2 2h4.8l1.7 4.5H8c-.189 0-.355.022-.531.046A4.719 4.719 0 0 1 6.8 6.6L5.7 3.5H4.1Zm6.1 0h1.6l-1.4 3.7c.5.3.9.6 1.2 1L14 2H9.2l-.4 1.1.8 2.2.6-1.8ZM8 8c-1.9 0-3.5 1.6-3.5 3.5S6.1 15 8 15s3.5-1.6 3.5-3.5S9.9 8 8 8Zm1.3 5.5L8 12.7l-1.3.8.4-1.5-1.2-1 1.5-.1.6-1.4.6 1.4 1.5.1-1.2 1 .4 1.5Z"></path></symbol><symbol viewBox="0 0 16 16" fill="none" id="save" xmlns="http://www.w3.org/2000/svg"><path fill="currentColor" d="M13.746.004A.364.364 0 0 0 13.685 0H2.333c-.032.001-.063.007-.095.009L2.237.01A2.333 2.333 0 0 0 .008 2.263l-.007.007L0 2.268V15.53a.47.47 0 0 0 .69.416l5.62-2.942 5.62 2.942a.472.472 0 0 0 .69-.416V6.971h2.91c.26 0 .47-.21.47-.468V1.95C16 .813 14.896.046 13.746.004Zm-2.625 1.702c-.016.07-.032.144-.042.221a1.65 1.65 0 0 0-.014.231v11.696L6.53 11.479a.476.476 0 0 0-.439 0l-4.534 2.375V2.33c0-.503.408-.912.911-.912h8.754a1.835 1.835 0 0 0-.1.287Zm3.323 3.847H12.62V2.33a.912.912 0 0 1 1.824 0v3.222Z"></path></symbol><symbol viewBox="0 0 16 16" fill="none" id="saved" xmlns="http://www.w3.org/2000/svg"><path fill="currentColor" d="M13.746.004A.364.364 0 0 0 13.685 0H2.333c-.032.001-.063.007-.095.009L2.237.01A2.333 2.333 0 0 0 .008 2.263l-.007.007L0 2.268V15.53a.47.47 0 0 0 .69.416l5.62-2.942 5.62 2.942a.472.472 0 0 0 .69-.416V6.971h2.91c.26 0 .47-.21.47-.468V1.95C16 .813 14.896.046 13.746.004Zm.698 5.549H12.62V2.33a.912.912 0 0 1 1.824 0v3.222Z"></path></symbol><symbol viewBox="0 0 32 32" id="search" xmlns="http://www.w3.org/2000/svg"><path d="m27.64 25.91-7.16-7.16a9.13 9.13 0 0 0-.8-12.06A9.12 9.12 0 0 0 13.18 4c-2.45 0-4.75.96-6.49 2.7A9.12 9.12 0 0 0 4 13.18c0 2.45.96 4.76 2.7 6.5a9.12 9.12 0 0 0 12.05.8l7.16 7.15a1.22 1.22 0 0 0 1.73 0c.48-.48.48-1.25 0-1.73zM8.42 17.95a6.7 6.7 0 0 1 0-9.53 6.7 6.7 0 0 1 9.52 0 6.7 6.7 0 0 1 1.98 4.77 6.7 6.7 0 0 1-11.5 4.76z"></path></symbol><symbol viewBox="0 0 16 16" id="star" xmlns="http://www.w3.org/2000/svg"><path d="m8 11.706 3.608 1.829-.687-3.867 2.873-2.699-3.974-.557L8 2.86 6.18 6.412l-3.974.557L5.08 9.668l-.688 3.867L8 11.706Zm-4.945 3.627L4 10.026 0 6.269l5.528-.775L8 .666l2.473 4.828L16 6.269l-4 3.757.944 5.307L8 12.827l-4.945 2.506Z"></path></symbol><symbol viewBox="0 0 28 24" id="temple" xmlns="http://www.w3.org/2000/svg"><path d="m14.16.39 11.35 4.08a.98.98 0 0 1 .6 1.27 1 1 0 0 1-1.28.59l-11.14-4-11.42 4.1A1 1 0 0 1 1 5.83a.98.98 0 0 1 .59-1.26L13.3.35a1 1 0 0 1 .85.04zM24 8a1 1 0 0 1-1 1H4a1 1 0 1 1 0-2h19a1 1 0 0 1 1 1zM8 11a1 1 0 0 1-1 1v5a1 1 0 0 1-2 0v-5a1 1 0 0 1 0-2h2a1 1 0 0 1 1 1zm14 10a1 1 0 1 0 0-2H5a1 1 0 0 0 0 2h17zm2 3a1 1 0 0 0 0-2H3a1 1 0 0 0 0 2h21zM13 11a1 1 0 0 1-1 1v5a1 1 0 0 1-2 0v-5a1 1 0 0 1 0-2h2a1 1 0 0 1 1 1zm4 1a1 1 0 0 0 0-2h-2a1 1 0 0 0 0 2v5a1 1 0 0 0 2 0v-5zm6-1a1 1 0 0 1-1 1v5a1 1 0 0 1-2 0v-5a1 1 0 0 1 0-2h2a1 1 0 0 1 1 1z"></path></symbol><symbol viewBox="0 0 20 23" id="transcripts" xmlns="http://www.w3.org/2000/svg"><path d="M12.98 7.9a1 1 0 0 0 .14-.12l5.66-5.66A1 1 0 0 0 17.36.71l-5.08 5.08-3.16-3.15a1 1 0 0 0-1.08-.23 1 1 0 0 0-.68.3L1.71 8.36a1 1 0 1 0 1.41 1.42l5.16-5.16 3.28 3.28a1 1 0 0 0 1.41 0zM1 13a1 1 0 1 0 0 2h18a1 1 0 1 0 0-2H1zm0 4a1 1 0 1 0 0 2h18a1 1 0 1 0 0-2H1zm-1 5a1 1 0 0 1 1-1h8a1 1 0 1 1 0 2H1a1 1 0 0 1-1-1z"></path></symbol><symbol viewBox="0 0 16 16" id="upgrade-icon" xmlns="http://www.w3.org/2000/svg"><path fill-rule="evenodd" clip-rule="evenodd" d="M16 0H0v16h16V0ZM4 8.662h5.465l-2.401 2.402L8 12l4-4-4-4-.936.937 2.4 2.4H4v1.325Z"></path></symbol><symbol fill="none" viewBox="0 0 36 36" id="warning" xmlns="http://www.w3.org/2000/svg"><path d="M18 36a18 18 0 1 0 0-36 18 18 0 0 0 0 36z" fill="#C9392C"></path><path fill-rule="evenodd" clip-rule="evenodd" d="M19.7 9.7a2 2 0 0 0-3.4 0L8.2 22.97A2 2 0 0 0 9.92 26h16.16a2 2 0 0 0 1.7-3.04L19.72 9.7zm-.46 7.51v-3.94h-2.11v3.94c0 .43.02.85.08 1.27.05.41.12.83.2 1.26h1.54c.09-.43.16-.85.2-1.26.06-.42.09-.84.09-1.27zm-2.27 4.56a1.18 1.18 0 0 0 0 .93c.07.15.16.27.27.38a1.4 1.4 0 0 0 .92.34 1.39 1.39 0 0 0 .91-.34c.12-.11.2-.23.27-.38a1.1 1.1 0 0 0 0-.93 1.1 1.1 0 0 0-.27-.37 1.3 1.3 0 0 0-.91-.34c-.18 0-.35.03-.5.1a1.1 1.1 0 0 0-.69.61z" fill="#fff"></path></symbol></svg></span><div class="root" id="root"><div class="flex h-full flex-col"><div class="j_w r_4 aB_iS"><aside class="shrink-0 print:hidden x_eQ x_eR lg:ml-0 lg:pt-0" data-test-id="aside-nav-panel"><div class="flex max-w-full flex-col bg-share-aside-bg pl-safe fixed bottom-0 z-modal border-t border-solid border-navy lg:border-0 lg:pt-0 x_h x_eS lg:top-0"><div class="x_eT flex grow flex-col"><div class="aa_g6"><div class="flex items-center justify-between bg-share-aside-bg px-12 pt-18 mb-8 only:mb-18" data-test-id="aside-menu-header"><a data-test-id="logo" title="Home" class="aj_e2 r_4 r_am" href="/?source=content_type%3Areact%7Csource%3Asite_navigation"><span class="aj_hP r_4 r_aj"><svg class="aj_gy aj_gi aj_hL"><use xlink:href="#logo"></use></svg></span></a><button aria-label="Collapse main menu" class="inline-flex h-24 w-24 items-center justify-center bg-black-50 p-4 ml-auto translate-x-12" type="button"><svg viewBox="0 0 18 11" xmlns="http://www.w3.org/2000/svg" class="h-14 w-14 shrink-0 fill-white rotate-90" data-test-id="expand-collapse-arrow-button"><path d="M2.1 0 9 6.84 15.9 0 18 2.08 9 11 0 2.08z"></path></svg></button></div></div><nav class="h-0 grow" data-test-id="main-sidebar-nav" id="main-sidebar-nav"><div class="P_g relative h-full w-full P_gC P_gD"><div class="P_gB relative h-full overflow-y-auto overflow-x-hidden"><div></div><div class="pb-24 pt-14 lg:pt-0"><a class="z_eU" href="#content">Skip to content</a><div class="aa_g5"><ul class="cX_g r_4 r_am" data-test-id="account-menu"><li class=""><button aria-controls="accordion-section-account-menu" aria-expanded="false" class="cX_pf r_4 r_6 cX_ph s_as aS_jq aS_jH aS_jS aS_kz aS_kN aS_k2 px-12 py-0 text-white" id="accordion-caption-account-menu" type="button"><span class="flex w-0 grow items-center"><div class="mr-14 flex shrink-0 items-center justify-center relative w-36 h-36 rounded-full" data-test-id="user-pic-wrapper"><div class="" data-test-id="user-pic"></div></div><span class="w-0 grow truncate text-left text-large-b">No username</span></span><span class="cX_pm r_4 r_6 r_ab cX_pw s_cR cX_pp" data-test-id="accordion-arrow-wrapper"><svg viewBox="0 0 18 11" xmlns="http://www.w3.org/2000/svg" class="cX_hI cX_ps"><path d="M2.1 0 9 6.84 15.9 0 18 2.08 9 11 0 2.08z"></path></svg></span></button><div aria-labelledby="accordion-caption-account-menu" class="cX_pC s_by" data-test-id="accordion-content" hidden="" id="accordion-section-account-menu"><!--$--><div class="cV_eI relative"><ul class="m-0 list-none pl-0"><li data-test-id="set-username-menu-button"><button class="py-8 hover:no-underline text-white hover:text-white eY_G relative flex select-none items-center justify-center px-12 text-large-r lg:text-medium-2-r eY_gY eY_tu jQ_gY cv_oi r_ap" type="button"><span class="jQ_mB r_4 r_6 r_ap"><span class="jQ_f r_ap bh_l4 bi_fu eY_f no-underline">Set Username</span></span></button></li><li data-test-id="account-settings-menu-button"><a class="py-8 hover:no-underline text-white hover:text-white eY_G relative flex select-none items-center justify-center px-12 text-large-r lg:text-medium-2-r eY_gY eY_tu jQ_gY cv_oi r_ap" href="/account/user_settings"><span class="jQ_mB r_4 r_6 r_ap"><span class="jQ_f r_ap bh_l4 bi_fu eY_f no-underline">Account Settings</span></span></a></li><li data-test-id="manage-alerts-menu-button"><a class="py-8 hover:no-underline text-white hover:text-white eY_G relative flex select-none items-center justify-center px-12 text-large-r lg:text-medium-2-r eY_gY eY_tu jQ_gY cv_oi r_ap" href="/account/edit_stocks"><span class="jQ_mB r_4 r_6 r_ap"><span class="jQ_f r_ap bh_l4 bi_fu eY_f no-underline">Manage Emails &amp; Alerts</span></span></a></li><li data-test-id="saved-articles-menu-button"><a class="py-8 hover:no-underline text-white hover:text-white eY_G relative flex select-none items-center justify-center px-12 text-large-r lg:text-medium-2-r eY_gY eY_tu jQ_gY cv_oi r_ap" href="/account/saved_articles"><span class="jQ_mB r_4 r_6 r_ap"><span class="jQ_f r_ap bh_l4 bi_fu eY_f no-underline">Saved Articles</span></span></a></li><li data-test-id="read-articles-menu-button"><a class="py-8 hover:no-underline text-white hover:text-white eY_G relative flex select-none items-center justify-center px-12 text-large-r lg:text-medium-2-r eY_gY eY_tu jQ_gY cv_oi r_ap" href="/account/history"><span class="jQ_mB r_4 r_6 r_ap"><span class="jQ_f r_ap bh_l4 bi_fu eY_f no-underline">Read Articles</span></span></a></li><li data-test-id="my-notes-menu-button"><a class="py-8 hover:no-underline text-white hover:text-white eY_G relative flex select-none items-center justify-center px-12 text-large-r lg:text-medium-2-r eY_gY eY_tu jQ_gY cv_oi r_ap" href="/account/my-notes"><span class="jQ_mB r_4 r_6 r_ap"><span class="jQ_f r_ap bh_l4 bi_fu eY_f no-underline">My Notes</span></span></a></li><li data-test-id="sign-out-menu-button"><button class="py-8 hover:no-underline text-white hover:text-white eY_G relative flex select-none items-center justify-center px-12 text-large-r lg:text-medium-2-r eY_gY eY_tu jQ_gY cv_oi r_ap" type="button"><span class="jQ_mB r_4 r_6 r_ap"><span class="jQ_f r_ap bh_l4 bi_fu eY_f no-underline">Sign out</span></span></button></li></ul></div><!--/$--></div></li></ul></div><div class="hidden lg:hidden mx-12 h-1 bg-black-50  my-14 lg:my-12" data-test-id="aside-divider"></div><div class="cV_eI relative lg:hidden mb-18" data-test-id="upgrade-menu-top"><ul class="m-0 list-none pl-0 lg:flex-col flex flex-col-reverse"><li data-test-id="alpha-picks-top-menu-button"><a class="py-8 hover:no-underline text-white hover:text-white eY_G relative flex select-none items-center justify-center px-12 text-large-r lg:text-medium-2-r eY_gY eY_tu jQ_gY cv_oi r_ap" href="/alpha-picks/subscribe?source=explore_alpha_picks%3Aexpanded%3Anavbar_left"><span class="jQ_Hv r_ar jQ_Hw s_dm"><span class="flex h-24 w-24 shrink-0 items-center justify-center lg:h-16 lg:w-16"><svg class="h-full w-full shrink-0 fill-current"><use xlink:href="#alpha-picks"></use></svg></span></span><span class="jQ_mB r_4 r_6 r_ap"><span class="jQ_f r_ap bh_l4 bi_fu eY_f no-underline"><span data-test-id="alpha-picks-link-menu-button-top">Explore Alpha Picks</span></span></span></a></li><li data-test-id="upgrade-top-menu-button"><a class="py-8 hover:no-underline text-white hover:text-white eY_G relative flex select-none items-center justify-center px-12 text-large-r lg:text-medium-2-r eY_gY eY_tu jQ_gY cv_oi r_ap" href="/subscriptions?source=upgrade_to_pro%3Aexpanded%3Anavbar_left"><span class="jQ_Hv r_ar jQ_Hw s_dm"><span class="flex h-24 w-24 shrink-0 items-center justify-center lg:h-16 lg:w-16 text-brand-pro"><svg class="h-full w-full shrink-0 fill-current"><use xlink:href="#upgrade-icon"></use></svg></span></span><span class="jQ_mB r_4 r_6 r_ap"><span class="jQ_f r_ap bh_l4 bi_fu eY_f no-underline"><span data-test-id="upgrade-link-menu-button-top">Upgrade To PRO</span></span></span></a></li></ul></div><div class="mx-12 h-1 bg-black-50  my-14 lg:my-12" data-test-id="aside-divider"></div><div class="cV_eI relative" data-test-id="general-menu-module"><ul class="m-0 list-none pl-0"><li data-test-id="home-menu-button"><a class="py-8 hover:no-underline text-white hover:text-white eY_G relative flex select-none items-center justify-center px-12 text-large-r lg:text-medium-2-r eY_gY eY_tu jQ_gY cv_oi r_ap" href="/?source=home%3Aexpanded%3Anavbar_left"><span class="jQ_Hv r_ar jQ_Hw s_dm"><span class="flex h-24 w-24 shrink-0 items-center justify-center lg:h-16 lg:w-16"><svg class="h-full w-full shrink-0 fill-current"><use xlink:href="#alpha"></use></svg></span></span><span class="jQ_mB r_4 r_6 r_ap"><span class="jQ_f r_ap bh_l4 bi_fu eY_f no-underline">Home</span></span></a></li><li data-test-id="analysis-menu-button"><a class="py-8 hover:no-underline text-white hover:text-white eY_G relative flex select-none items-center justify-center px-12 text-large-r lg:text-medium-2-r eY_gY eY_tu jQ_gY cv_oi r_ap" href="/latest-articles?source=analysis%3Aexpanded%3Anavbar_left"><span class="jQ_Hv r_ar jQ_Hw s_dm"><span class="flex h-24 w-24 shrink-0 items-center justify-center lg:h-16 lg:w-16"><svg class="h-full w-full shrink-0 fill-current"><use xlink:href="#analysis-icon"></use></svg></span></span><span class="jQ_mB r_4 r_6 r_ap"><span class="jQ_f r_ap bh_l4 bi_fu eY_f no-underline">Analysis</span></span></a></li><li data-test-id="news-menu-button"><a class="py-8 hover:no-underline text-white hover:text-white eY_G relative flex select-none items-center justify-center px-12 text-large-r lg:text-medium-2-r eY_gY eY_tu jQ_gY cv_oi r_ap" href="/market-news?source=news%3Aexpanded%3Anavbar_left"><span class="jQ_Hv r_ar jQ_Hw s_dm"><span class="flex h-24 w-24 shrink-0 items-center justify-center lg:h-16 lg:w-16"><svg class="h-full w-full shrink-0 fill-current"><use xlink:href="#news-icon"></use></svg></span></span><span class="jQ_mB r_4 r_6 r_ap"><span class="jQ_f r_ap bh_l4 bi_fu eY_f no-underline">News</span></span></a></li><li data-test-id="market-performance-menu-button"><a class="py-8 hover:no-underline text-white hover:text-white eY_G relative flex select-none items-center justify-center px-12 text-large-r lg:text-medium-2-r eY_gY eY_tu jQ_gY cv_oi r_ap" href="/etfs-and-funds/etf-tables/key_markets?source=market_performance%3Aexpanded%3Anavbar_left"><span class="jQ_Hv r_ar jQ_Hw s_dm"><span class="flex h-24 w-24 shrink-0 items-center justify-center lg:h-16 lg:w-16"><svg class="h-full w-full shrink-0 fill-current"><use xlink:href="#performance-icon"></use></svg></span></span><span class="jQ_mB r_4 r_6 r_ap"><span class="jQ_f r_ap bh_l4 bi_fu eY_f no-underline">Market Data</span></span></a></li></ul></div><div class="mx-12 h-1 bg-black-50  my-14 lg:my-12" data-test-id="aside-divider"></div><div class="cV_eI relative" data-test-id="experts-menu-module"><div><div class="relative flex select-none items-center justify-center px-12 text-large-r lg:text-medium-2-r eY_gY eY_tu cV_pb py-8 hover:no-underline text-white hover:text-white eY_G jQ_gY cv_oi r_ap" data-test-id="menu-header"><span class="jQ_Hv r_ar jQ_Hw s_dm"><span class="flex h-24 w-24 shrink-0 items-center justify-center lg:h-16 lg:w-16"><svg class="h-full w-full shrink-0 fill-current"><use xlink:href="#marketplace-icon"></use></svg></span></span><span class="jQ_mB r_4 r_6 r_ap"><span class="jQ_f r_ap bh_l4 bi_fu eY_f no-underline cV_nr text-small-2-r uppercase">Investing Groups</span></span></div></div><ul class="m-0 list-none pl-0"><li data-test-id="all-experts-menu-button"><a class="py-8 hover:no-underline text-white hover:text-white eY_G relative flex select-none items-center justify-center px-12 text-large-r lg:text-medium-2-r eY_gY eY_tu jQ_gY cv_oi r_ap" href="/marketplace/directory?source=investing_groups%3Aexpanded%3Anavbar_left"><span class="jQ_mB r_4 r_6 r_ap"><span class="jQ_f r_ap bh_l4 bi_fu eY_f no-underline">Explore Investing Groups</span></span><span class="jQ_Hx s_cH jQ_Hv r_ar"><div class="flex items-center"><div class="ml-12 flex"></div></div></span></a></li></ul></div><div class="mx-12 h-1 bg-black-50  my-14 lg:my-12" data-test-id="aside-divider"></div><div class="cV_eI relative" data-test-id="portfolios-menu-module"><div><div class="relative flex select-none items-center justify-center px-12 text-large-r lg:text-medium-2-r eY_gY eY_tu cV_pb py-8 hover:no-underline text-white hover:text-white eY_G jQ_gY cv_oi r_ap" data-test-id="menu-header"><span class="jQ_Hv r_ar jQ_Hw s_dm"><span class="flex h-24 w-24 shrink-0 items-center justify-center lg:h-16 lg:w-16"><svg class="h-full w-full shrink-0 fill-current"><use xlink:href="#portfolios-icon"></use></svg></span></span><span class="jQ_mB r_4 r_6 r_ap"><span class="jQ_f r_ap bh_l4 bi_fu eY_f no-underline cV_nr text-small-2-r uppercase">Portfolios</span></span></div></div><ul class="m-0 list-none pl-0"><li data-test-id="create-portfolio-menu-button"><a class="py-8 hover:no-underline text-white hover:text-white eY_G relative flex select-none items-center justify-center px-12 text-large-r lg:text-medium-2-r eY_gY eY_tu jQ_gY cv_oi r_ap" href="/account/portfolio?source=portfolio%3Aexpanded%3Anavbar_left"><span class="jQ_mB r_4 r_6 r_ap"><span class="jQ_f r_ap bh_l4 bi_fu eY_f no-underline">Create Portfolio</span></span></a></li></ul></div><div class="mx-12 h-1 bg-black-50  my-14 lg:my-12" data-test-id="aside-divider"></div><div class="cV_eI relative" data-test-id="find-and-compare-menu-module"><div><div class="relative flex select-none items-center justify-center px-12 text-large-r lg:text-medium-2-r eY_gY eY_tu cV_pb py-8 hover:no-underline text-white hover:text-white eY_G jQ_gY cv_oi r_ap" data-test-id="menu-header"><span class="jQ_Hv r_ar jQ_Hw s_dm"><span class="flex h-24 w-24 shrink-0 items-center justify-center lg:h-16 lg:w-16"><svg class="h-full w-full shrink-0 fill-current"><use xlink:href="#comparison-icon"></use></svg></span></span><span class="jQ_mB r_4 r_6 r_ap"><span class="jQ_f r_ap bh_l4 bi_fu eY_f no-underline cV_nr text-small-2-r uppercase">Find &amp; Compare</span></span></div></div><ul class="m-0 list-none pl-0"><li data-test-id="top-stocks-menu-button"><a class="py-8 hover:no-underline text-white hover:text-white eY_G relative flex select-none items-center justify-center px-12 text-large-r lg:text-medium-2-r eY_gY eY_tu jQ_gY cv_oi r_ap" href="/screeners/96793299-Top-Rated-Stocks?source=top_stocks%3Aexpanded%3Anavbar_left"><span class="jQ_mB r_4 r_6 r_ap"><span class="jQ_f r_ap bh_l4 bi_fu eY_f no-underline">Top Stocks</span></span></a></li><li data-test-id="top-et-fs-menu-button"><a class="py-8 hover:no-underline text-white hover:text-white eY_G relative flex select-none items-center justify-center px-12 text-large-r lg:text-medium-2-r eY_gY eY_tu jQ_gY cv_oi r_ap" href="/screeners/etfs/922b797269-Top-Rated-ETFs?source=top_etfs%3Aexpanded%3Anavbar_left"><span class="jQ_mB r_4 r_6 r_ap"><span class="jQ_f r_ap bh_l4 bi_fu eY_f no-underline">Top ETFs</span></span></a></li><li data-test-id="stock-screener-menu-button"><a class="py-8 hover:no-underline text-white hover:text-white eY_G relative flex select-none items-center justify-center px-12 text-large-r lg:text-medium-2-r eY_gY eY_tu jQ_gY cv_oi r_ap" href="/screeners?source=stock_screener%3Aexpanded%3Anavbar_left"><span class="jQ_mB r_4 r_6 r_ap"><span class="jQ_f r_ap bh_l4 bi_fu eY_f no-underline">Stock Screener</span></span></a></li><li data-test-id="etf-screener-menu-button"><a class="py-8 hover:no-underline text-white hover:text-white eY_G relative flex select-none items-center justify-center px-12 text-large-r lg:text-medium-2-r eY_gY eY_tu jQ_gY cv_oi r_ap" href="/screeners/etfs?source=etf_screener%3Aexpanded%3Anavbar_left"><span class="jQ_mB r_4 r_6 r_ap"><span class="jQ_f r_ap bh_l4 bi_fu eY_f no-underline">ETF Screener</span></span></a></li><li data-test-id="comparisons-menu-button"><a class="py-8 hover:no-underline text-white hover:text-white eY_G relative flex select-none items-center justify-center px-12 text-large-r lg:text-medium-2-r eY_gY eY_tu jQ_gY cv_oi r_ap" href="/comparison?source=comparisons%3Aexpanded%3Anavbar_left"><span class="jQ_mB r_4 r_6 r_ap"><span class="jQ_f r_ap bh_l4 bi_fu eY_f no-underline">Comparisons</span></span></a></li></ul></div><div class="mx-12 h-1 bg-black-50  my-14 lg:my-12" data-test-id="aside-divider"></div><div class="cV_eI relative hidden lg:block mb-18" data-test-id="upgrade-menu-bottom"><ul class="m-0 list-none pl-0"><li data-test-id="alpha-picks-bottom-menu-button"><a class="py-8 hover:no-underline text-white hover:text-white eY_G relative flex select-none items-center justify-center px-12 text-large-r lg:text-medium-2-r eY_gY eY_tu jQ_gY cv_oi r_ap" href="/alpha-picks/subscribe?source=explore_alpha_picks%3Aexpanded%3Anavbar_left"><span class="jQ_Hv r_ar jQ_Hw s_dm"><span class="flex h-24 w-24 shrink-0 items-center justify-center lg:h-16 lg:w-16"><svg class="h-full w-full shrink-0 fill-current"><use xlink:href="#alpha-picks"></use></svg></span></span><span class="jQ_mB r_4 r_6 r_ap"><span class="jQ_f r_ap bh_l4 bi_fu eY_f no-underline"><span data-test-id="alpha-picks-link-menu-button-bottom">Explore Alpha Picks</span></span></span></a></li><li data-test-id="upgrade-bottom-menu-button"><a class="py-8 hover:no-underline text-white hover:text-white eY_G relative flex select-none items-center justify-center px-12 text-large-r lg:text-medium-2-r eY_gY eY_tu jQ_gY cv_oi r_ap" href="/subscriptions?source=upgrade_to_pro%3Aexpanded%3Anavbar_left"><span class="jQ_Hv r_ar jQ_Hw s_dm"><span class="flex h-24 w-24 shrink-0 items-center justify-center lg:h-16 lg:w-16 text-brand-pro"><svg class="h-full w-full shrink-0 fill-current"><use xlink:href="#upgrade-icon"></use></svg></span></span><span class="jQ_mB r_4 r_6 r_ap"><span class="jQ_f r_ap bh_l4 bi_fu eY_f no-underline"><span data-test-id="upgrade-link-menu-button-bottom">Upgrade To PRO</span></span></span></a></li></ul></div><div></div></div><div></div></div></div></nav></div></div></aside><div class="j_a r_4 r_am r_ap"><header class="B_B fixed left-0 top-0 w-full lg:sticky B_eX aQ_jg"><div class="container max-w-full xxl:px-safe-or-36 px-safe-or-18 bg-black-v2-90 pt-safe-or-6 flex w-full items-center pb-6 B_eY lg:bg-share-bg-4 shadow-none lg:py-20" data-test-id="grid-container"><div class="grow aa_g6"><!--$--><div class="relative align-middle B_eZ mr-24 grow" data-test-id="search-block"><div class="flex flex-wrap w-full flex-col"><div class="relative w-full"><input autoComplete="on" placeholder="Symbols, Analysts, Keywords" spellcheck="true" aria-label="Symbols, Analysts, Keywords" class="inline-block text-ellipsis bg-clip-padding h-50 py-12 px-12 text-medium-r border border-navy-40 text-black-v2-90 read-only:text-navy-80 placeholder:text-navy-80 bg-white focus-within:border-navy-40 dark:border-black-v2-70 dark:text-black-v2-20 dark:bg-black-v2-80 dark:placeholder:text-black-v2-30 dark:read-only:text-black-v2-30 dark:focus-within:border-black-v2-70 focus:border-black-35 dark:focus:border-black-30 disabled:text-black-10 disabled:bg-black-5 disabled:border-black-10 disabled:opacity-100 dark:disabled:border-black-80 dark:disabled:text-black-80 dark:disabled:bg-black-98 w-full read-only:opacity-100 invalid:shadow-none vendor-clear-input-button dark:placeholder:text-black-30 dark:read-only:text-black-30 pr-38" data-test-id="search-input" type="search" value=""/><span class="sr-only">Entering text into the input field will update the search result below</span><svg class="right-12 w-20 h-20 absolute top-1/2 shrink-0 -translate-y-1/2 pointer-events-none fill-current text-black-35 dark:text-black-30"><use xlink:href="#search"></use></svg></div></div></div><!--/$--></div><div class="aa_g7"><div class="flex items-center"><button aria-controls="main-sidebar-nav" aria-expanded="false" aria-haspopup="true" aria-label="Main menu" class="I_0 r_5 r_6 r_ab I_fz aS_jo aS_jE aS_jT I_fx B_0 mr-8 shrink-0 text-white" type="button"><span class="I_gk r_4 r_6 r_ab r_ar I_gl"><span class="R_gL t_eE"><span class="R_gM t_eD" data-test-id="hamburger-menu-button"></span></span></span><span class="I_gn"></span></button><a data-test-id="logo" title="Home" class="aj_e2 r_4 r_am" href="/?source=content_type%3Areact%7Csource%3Asite_navigation"><span class="aj_hP r_4 r_aj h-24 lg:mr-4 lg:h-32"><svg class="aj_gy aj_gi aj_hL B_e2"><use xlink:href="#logo"></use></svg></span></a></div></div><div class="Q_gE r_4 r_6"><div class="Q_0 s_dm r_4 r_6 r_ab aa_g7"><a aria-label="Search for Symbols, analysts, keywords" title="Search" class="I_0 r_5 r_6 r_ab I_fO aS_jn aS_jC aS_jS I_fx L_G L_gv text-white" href="/basic-search"><span class="I_gk r_4 r_6 r_ab r_ar I_gl"><svg width="24" height="24" viewBox="0 0 24 24" fill="none" xmlns="http://www.w3.org/2000/svg"><path fill-rule="evenodd" clip-rule="evenodd" d="M10.53 4a6.53 6.53 0 1 1 0 13.07 6.53 6.53 0 0 1 0-13.07Zm0 1.54a5 5 0 1 0 0 9.99 5 5 0 0 0 0-10Zm9.43 13.38L18.86 20l-2.55-2.59-.01-2.2 3.66 3.71Z" fill="currentColor"></path></svg></span><span class="I_gn">Search for Symbols, analysts, keywords</span></a></div></div></div><div class="absolute inset-x-0 top-full"></div><div></div></header><main class="j_t j_x r_4 r_am r_ap r_4 r_am j_y" id="content"><div class="j_z aQ_jg"></div><!--$--><div class="bL_mL r_4 r_am r_ap"><article class="container xxl:px-safe-or-36 md:px-safe-or-18" data-test-id="article-page"><script type="application/ld+json">{"@context":"https://schema.org","@type":"NewsArticle","mainEntityOfPage":{"@type":"WebPage","@id":"https://seekingalpha.com/article/4385063-orasure-technologies-inc-osur-ceo-stephen-tang-on-q3-2020-results-earnings-call-transcript"},"author":{"@type":"Person","name":"SA Transcripts","url":"https://seekingalpha.com/author/sa-transcripts"},"publisher":{"@type":"Organization","name":"Seeking Alpha","logo":{"@type":"ImageObject","height":60,"url":"https://seekingalpha.com/samw/static/images/PublisherLogo.1a0fb372.png","width":360}},"datePublished":"2020-11-05T01:58:06.000Z","dateModified":"2020-11-05T01:58:07.000Z","description":"OraSure Technologies, Inc. (NASDAQ:NASDAQ:OSUR) Q3 2020 Earnings Conference Call November 4, 2020 5:00 PM ETCompany ParticipantsJeanne Mell - Vice President...","headline":"OraSure Technologies, Inc. (OSUR) CEO Stephen Tang on Q3 2020 Results - Earnings Call Transcript","about":[{"@type":"Corporation","name":"OraSure Technologies, Inc.","tickerSymbol":"NASDAQ:OSUR","url":"https://seekingalpha.com/symbol/OSUR"}],"image":{"@type":"ImageObject","url":"https://seekingalpha.com/samw/static/images/DefaultArticleImage.f1f9250c.png","height":1200,"width":1200}}</script><div class="cC_ox"><div class="sa-row-gap-18 xl:sa-row-gap-36 sa-row-collapse-v-gutter flex-wrap flex grow last:mb-0 print:block sa-row-gap-18 xl:sa-row-gap-36" data-test-id="grid-row"><div class="grow w-0 basis-0 empty:hidden relative min-h-1 min-w-0 w-full max-w-full grow sa-col" data-test-id="grid-col"><div class="" data-test-id="article-section"><section class="mx-auto flex w-full flex-col justify-between bg-white dark:bg-black-95 pt-0 p-0 mb-8 md:mb-18 print:block" data-test-id="card-container"><div class="flex flex-col flex-wrap print:block"><div class="w-full max-w-full"><div class="lI_qh s_aG s_aZ s_bm s_aE"><div class="lI_KU s_ed"><a data-test-id="logo" title="Home" class="aj_e2 r_4 r_am" href="/?source=content_type%3Areact%7Csource%3Asite_navigation"><span class="aj_hP r_4 r_aj"><svg class="aj_gy aj_fP aj_hM"><use xlink:href="#logo"></use></svg></span></a></div><header class="sQ_G3 r_4 r_7 r_af r_am"><div class="wv_g r_4 r_7 r_af s_eb cv_oi" data-test-id="quick-links"><div class="wv_Y4 r_4 r_6 r_ah r_ap s_cM s_b7"><div class="wv_Xo s_aW s_aA s_bf"><div class="zi_io" data-test-id="themes-list"><ul class="zi_mY r_4"><li class="zi_mZ r_4 r_6 s_d1"><a data-test-id="theme-links-item" class="I_0 r_5 r_6 r_ab I_f9 I_fw aS_jn aS_jC aS_jT L_G" href="/earnings/earnings-call-transcripts?source=content_type%3Areact%7Csection%3Amain_content%7Csection_asset%3Athemes%7Cbutton%3Atranscripts%7Cfirst_level_url%3Aarticle"><span class=""><span class="zi_1y it_w0">Transcripts</span></span></a></li></ul></div></div></div><div class="wv_Y3 r_4 r_6 r_af"></div></div><div class="nW_i6 r_4 r_af"><h1 class="nW_Y s_eb aS_jv aS_jN aS_jT aS_kG aS_kY aS_k3" data-test-id="post-title">OraSure Technologies, Inc. (OSUR) CEO Stephen Tang on Q3 2020 Results - Earnings Call Transcript</h1></div><div class="nW_a r_4 r_af s_eb aS_jo aS_jD aS_jS sQ_Ut r_4 r_6" data-test-id="post-page-meta"><div><span class="nW_ND nW_gY t_eC" data-test-id="post-date">Nov. 04, 2020 8:58 PM ET</span><span class="nW_gY t_eC" data-test-id="post-primary-tickers"><a class="wq_YW" href="/symbol/OSUR?source=content_type%3Areact%7Csection%3Amain_content%7Csection_asset%3Ameta%7Cfirst_level_url%3Aarticle%7Csymbol%3AOSUR">OraSure Technologies, Inc. (OSUR)</a></span><span class="nW_Nt t_eE"><a class="nW_G aS_jo aS_jD aS_jS" data-test-id="post-comments-count" href="#comments" id="commentsPianoElement">1 Comment</a></span></div></div></header><div class="uw_QM r_4 r_7 r_af s_eb" data-test-id="author-brief"><div class="uw_4 r_4"><a class="uw_Nq tm_Nq" href="/author/sa-transcripts?source=content_type%3Areact%7Curl_first_level%3Aarticle%7Csection%3Aauthor_brief%3Asa-transcripts%7Csection_asset%3Aauthor_brief%7Cauthor_icon"><div class="flex shrink-0 items-center justify-center relative w-36 h-36 rounded-full" data-test-id="user-pic-wrapper"><img alt="SA Transcripts profile picture" class="dark:text-black-100 flex w-full items-center justify-center overflow-hidden bg-white-96 text-white-96 dark:bg-black-30 rounded-full h-full" data-test-id="user-pic" height="36" loading="lazy" src="https://static3.seekingalpha.com/images/users_profile/000/101/639/small_pic.png" srcSet="https://static3.seekingalpha.com/images/users_profile/000/101/639/big_pic.png 2x, https://static3.seekingalpha.com/images/users_profile/000/101/639/big_pic.png 3x" width="36"/></div></a><div class="uw_QN r_4 r_ab r_am s_cL"><a class="uw_Nq tm_Nq uw_Md aS_jp aS_jD aS_jT s_dX tm_Md" data-test-id="author-name" href="/author/sa-transcripts?source=content_type%3Areact%7Curl_first_level%3Aarticle%7Csection%3Aauthor_brief%3Asa-transcripts%7Csection_asset%3Aauthor_brief%7Cauthor_name">SA Transcripts</a><div class="uw_rj r_4 r_ah"><div class="sx_T3 aS_jn aS_jC aS_jS uw_QL t_eC aS_jn aS_jC aS_jS">140.69K<!-- --> <!-- -->Follower<!-- -->s</div></div></div></div><div class="mC_LW" role="none"><button data-state-text="Following" class="I_0 r_5 r_6 r_ab I_fP I_fz aS_jo aS_jE aS_jT ky_IU s_ay s_bC s_aZ s_bm qO_I0 r_ar uw_Bf s_cy aQ_jg" data-test-id="follow-button" type="button"><span class=""><span class="ky_IW r_4 r_ab" data-state-placeholder="Following"><span class="ky_IX">Follow</span></span></span></button></div></div><div><div class="paywall-full-content jB_f r_4" data-test-id="article-content"><div class="jB_mC r_ap"><div class="jB_il" data-test-id="content-container"><p>OraSure Technologies, Inc. (<span class="ticker-hover-wrapper">NASDAQ:<a href="https://seekingalpha.com/symbol/OSUR" title="OraSure Technologies, Inc.">OSUR</a></span>) Q3 2020 Earnings Conference Call November 4, 2020 5:00 PM ET</p> <p><strong>Company Participants</strong></p> <p>Jeanne Mell - Vice President of Corporate Communications</p> <p>Stephen Tang - President &amp; Chief Executive Officer</p> <p>Roberto Cuca - Chief Financial Officer</p> <p><strong>Conference Call Participants</strong></p> <p>Vijay Kumar - Evercore ISI</p> <p>Frank Takkinen - Lake Street Capital</p> <p>Casey Woodring - JPMorgan</p> <p>Andrew Cooper - Raymond James</p> <p>Patrick Donnelly - Citigroup</p> <p>Jacob Johnson - Stephens</p> <p><strong>Operator</strong></p> <p>Good afternoon, everyone, and welcome to the OraSure Technologies 2020 Third Quarter Financial Results Conference Call and Simultaneous Webcast. As a reminder, today's conference is being recorded. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be question-and-answer period. [Operator Instructions]</p> <p>I would turn the call over to Jeanne Mell, Vice President of Corporate Communications for OraSure. Jeanne?</p> <p><strong>Jeanne Mell</strong></p> <p>Thank you, operator. With us today are Dr. Stephen Tang, President and Chief Executive Officer; and Mr. Roberto Cuca, Chief Financial Officer. Dr. Tang and Mr. Cuca will begin with opening statements, which will be followed with a question-and-answer session.</p> <p>Before I turn the call over to Dr. Tang, you should note that this call may contain certain forward-looking statements, including statements with respect to revenues, expenses, profitability, earnings or loss per share, and other financial performance, product development, performance, shipments and markets business plans, regulatory filings and approvals, expectations and strategy.</p> <p>Actual results could be significantly different. Factors that could affect results are discussed more fully in the company's SEC filings, including its registration statements, its annual report on Form 10-K for the year ended December 31, 2019, its quarterly reports on Form 10-Q and its other SEC filings.</p> <p>Although, forward-looking statements help to provide complete information about future prospects, listeners should keep in mind that forward-looking statements are based solely<span class="paywall-full-content"> on information available to management as of today. The company undertakes no obligation to update any forward-looking statements to reflect events or circumstances after this call.</span></p> <p class="paywall-full-content">With that, I will turn the call over to Dr. Stephen Tang.</p> <p class="paywall-full-content"><strong>Stephen Tang</strong></p> <p class="paywall-full-content">Thank you, Jeanne, and thank you everyone for joining us<span class="paywall-full-content no-summary-bullets"> today. I know, last night was a late night for many. So I appreciate your attention and interest this afternoon. I hope you and your families are faring well during these challenging times. As you will hear today, OraSure had a strong quarter.</span></p> <p class="paywall-full-content no-summary-bullets">Our molecular sample collection devices are widely used for lab-based COVID-19 molecular tests. We've submitted our lab-based oral fluid SARS-CoV-2 antibody test to the FDA for emergency use authorization or EUA, and we expect a rapid coronavirus antigen test to be ready for EUA submission in Q1 2021.</p> <p class="paywall-full-content no-summary-bullets">Overall, our ability to address the COVID-19 pandemic through sample collection has contributed positively to our business in the third quarter. We generated $48 million revenue this quarter, a 33% increase over the prior year. This performance was driven by our Molecular Solutions business unit. Our products continue to be in demand as the need for COVID-19 testing continues to rise.</p> <p class="paywall-full-content no-summary-bullets">The Molecular Solutions business unit generated $18.4 million in COVID-19 related sales in Q3, which is more than double the COVID-19 revenue achieved in the first half of the year. Globally, we're seeing what appears to be the third wave of the pandemic, as the number of COVID-19 cases surges here in the U.S. and around the world.</p> <p class="paywall-full-content no-summary-bullets">COVID-19 forecasts are not completely in alignment, but most predict that the current impact will be felt for another year or two years with COVID-19 existing at some level in perpetuity as the disease becomes endemic. While there is hope that, a vaccine will be approved by year-end or early 2021, we expect it will take quite some time for a vaccine to be broadly available in the U.S. and internationally.</p> <p class="paywall-full-content no-summary-bullets">And until then and beyond, testing will continue to play a critical role in managing the pandemic. We expect OraSure to continue to play an important and growing role, to address the massive and persistent need for COVID-19 testing and sample collection.</p> <p class="paywall-full-content no-summary-bullets">During our Q2 earnings call, I cited an estimate from the Rockefeller Foundation that call for 1.5 billion COVID-19 tests per year to get the pandemic under control. Since then, the foundation has increased its estimate to approximately 2.3 billion tests per year in the U.S. alone.</p> <p class="paywall-full-content no-summary-bullets">With this in mind, we expect there will continue to be strong demand for COVID-19 testing for the foreseeable future. And we are prepared to help meet that need with our innovative solutions for testing and sample collection.</p> <p class="paywall-full-content no-summary-bullets">All of OraSure's COVID-19 products are centered on the easy subcollection of samples by individuals an area which we have long experience. Our products are designed to make it easier to obtain results either through oral fluid sample collection for PCR and antibody testing or through a full diagnostic test that consumers can conduct on their own.</p> <p class="paywall-full-content no-summary-bullets">I'd like to address our current COVID-19 innovations, beginning with sample collection for molecular or PCR testing, which is the gold standard when it comes to detecting active COVID-19 infection. Our experience in innovating devices to facilitate at-home self-collection of samples has led to significant interest in our collection devices for molecular COVID-19 testing.</p> <p class="paywall-full-content no-summary-bullets">Devices made by our DNA Genotek subsidiary support both PCR and sequencing-based COVID-19 tests. And these collection kits are now being used for collection at home by consumers or by laboratory staff and healthcare providers. Notably, two of our sample collection devices ORAcollect RNA and OMNIgene Oral received EUAs from the FDA in October. Both EUAs allow for the collection, stabilization and transport of saliva specimens suspected containing SARS-CoV-2 RNA.</p> <p class="paywall-full-content no-summary-bullets">The authorization also allows the products to be used as a component of an authorized or cleared subcollection kit for unsupervised home use. This means the devices can be part of a kit that is authorized under its own EUA for the use of an individual to collect saliva specimens at home. It's important to note that these devices are not COVID tests. They are components of test that would be run in a lab.</p> <p class="paywall-full-content no-summary-bullets">DNA Genotek's customers which are typically laboratories offering COVID-19 test pipeline would use devices as a sample saliva selection -- collection method for their lab-based COVID-19 tests. OMNIgene Oral and ORAcollect RNA are two of three molecular test collection kits that have been included in six EUAs DNA Genotek customers obtained from the FDA.</p> <p class="paywall-full-content no-summary-bullets">But the EUAs are only one part of the molecular success story. About half of the third quarter sales of molecular sample collection devices for COVID applications were to customers not currently holding EUAs with the balance of customers operating their COVID tests as Laboratory Developed Tests or LDTs. Use of DNA Genotek collection kits continues to grow in back-to-work settings, back-to-school programs and laboratory testing.</p> <p class="paywall-full-content no-summary-bullets">For example, 30,000 students were tested at the University of Kansas before returning to campus using kits from Clinical Reference Laboratory. And 64 state University of New York campuses are testing students and employees with tests developed by Quadrant Biosciences.</p> <p class="paywall-full-content no-summary-bullets">Our Oragene Dx saliva collection device is available at Albertsons Companies pharmacies throughout the U.S. as part of Phosphorus Diagnostics' COVID-19 testing program. And back-to-work programs are integrating COVID-19 testing, monitoring assessment and access to telemedicine visits for companies through Azova Inc.</p> <p class="paywall-full-content no-summary-bullets">Additionally, Costco was selling COVID-19 saliva collection kits in conjunction with P23 Labs which received an FDA EUA for the laboratory test workflows with their PCR test. The workflow includes OMNIgene Oral as a saliva collection device. Easy self-collection samples is essential to ensuring the safety of workers and students and their families by helping to curtail the spread of the virus as people resume normal aspects of life. We expect the sales of molecular collection kits for COVID-19 testing to continue to grow within the U.S. with existing and new customers, but also outside the U.S. as other nations complete their validation work around saliva as a sample type.</p> <p class="paywall-full-content no-summary-bullets">Moving on to antibody testing. We have submitted an EUA application to the FDA for our oral fluid SARS-CoV-2 antibody ELISA and are in the review process. To date, there are no oral fluid antibody tests for COVID-19 authorized for sale in the U.S. Pending receipt of an EUA from the FDA we have the potential to be the first. This saliva-based oral fluid test is intended for the qualitative detection of total antibodies to SARS-CoV-2. </p> <p class="paywall-full-content no-summary-bullets">We have a number of interested customers and are prepared to commercialize our antibody test in the fourth quarter of this year subject to receipt of the EUA. Oral sample collection is quick, painless, noninvasive and requires less human contact in comparison to blood draw both minimizing the need for personal protective equipment or PPE and reducing exposure to potentially infected patients. </p> <p class="paywall-full-content no-summary-bullets">With OraSure's tests individuals would use a collection pad to self-collect an oral fluid sample under the direction of a healthcare professional. The sample will then be placed in the OraSure oral antibody collection device buffer for storage and transport. The sample would later be dispensed onto our proprietary ELISA microplate for analysis in a commercial laboratory to determine the presence of antibodies in the oral fluid sample. </p> <p class="paywall-full-content no-summary-bullets">Potential locations for sample collection include physician's offices, labs, testing facilities and drive-through testing sites. We are evaluating whether the EUA subsequently could be amended to permit an unsupervised in-home sample collection option with the sample sent to a central laboratory for testing. </p> <p class="paywall-full-content no-summary-bullets">At an epidemiological level, it is extremely important for public health officials to have an accurate understanding of who's been infected. Antibody tests are well suited for community surveillance and seroprevalence studies as they can help identify people in a population or a community that have mounted antibodies against COVID-19. </p> <p class="paywall-full-content no-summary-bullets">According to the Centers for Disease Control and Prevention CDC, this information could be used to estimate the number of people who have been previously infected with SARS-CoV-2 and were not included in official case counts. This is critical to maintaining an accurate count of infection rates and in forming decisions that can advance public health. Antibody tests could also potentially complement vaccine development and implementation. </p> <p class="paywall-full-content no-summary-bullets">Turning to our antigen test. OraSure continues to make tangible progress in the development of our OraQuick Coronavirus Rapid Antigen Self-Test. Subject to receipt of an EUA this product would test for active COVID-19 infection using nasal samples self-collected from the lower nostril. Results would be available at the point of collection with no instrumentation needed to interpret results. </p> <p class="paywall-full-content no-summary-bullets">To date, there are no self-test authorized in the U.S. that enable individuals to test themselves and read the results at the point of collection with no instrumentation needed. We are highly confident that we can bring to market an accurate test and meets FDA standards for a rapid self-test. And as we disclosed previously, we intend to sequentially introduce our antigen test for three different uses subject to regulatory authorization. </p> <p class="paywall-full-content no-summary-bullets">First, a professional test for use at drive-thru sites, physician offices, public health testing sites and employer and university health centers. In this instance, a physician would prescribe the test and the patient would conduct a self-swab in the presence of a healthcare provider who would then interpret the results. </p> <p class="paywall-full-content no-summary-bullets">Second, a prescription self-test for use by individual consumers which could be offered by employers or universities on or off-site or by physicians or public health authorities via remote testing or telemedicine. In this instance a physician will prescribe the test and the consumer would conduct the self-swab at home or any location where they would then interpret their own results. </p> <p class="paywall-full-content no-summary-bullets">Thirdly, an over-the-counter or OTC self-test for use by consumers who would purchase online or at retail without prescription would conduct the test and receive the results themselves anytime, anywhere. We expect to file for the professional test EUA in Q1 2021 and the prescription self-test and OTC self-test EUAs to follow as soon as possible thereafter. </p> <p class="paywall-full-content no-summary-bullets">This is a complex process that cannot be rushed. Between now and the filing of the EUA application, we will finalize the device design and complete the EUA studies necessary to determine the achievement of the high-performance standards that the FDA demands of a self-test. We are committed to delivering a rapid antigen self-test that meets FDA requirements for self-tests and the needs of the pandemic as well as our own rigorous standards for quality and performance.</p> <p class="paywall-full-content no-summary-bullets">We have made a great amount of progress and completed important benchmarks. Limits of detection studies were conducted with live coronavirus at a certified third-party laboratory to evaluate the analytical sensitivity in comparison to an EUA-authorized instrument-free rapid antigen test.</p> <p class="paywall-full-content no-summary-bullets">The results from the comparison provided further confidence that the proprietary chemistries incorporated in OraSure's lateral flow test strip will deliver the sensitivity needed. In addition the company currently has prototypes on the OraQuick platform under evaluation at clinical testing locations continually providing data on the performance of the design against FDA requirements.</p> <p class="paywall-full-content no-summary-bullets">Based on what we know at this time, we believe there will be significant demand for our antigen test self-test in 2021 as it puts control of the process in the hands of the user.</p> <p class="paywall-full-content no-summary-bullets">In the U.S. alone the Rockefeller Foundation estimates demand at approximately 2.3 billion tests annually. The Rockefeller Foundation and others have identified fast and frequent testing as a key to getting COVID-19 under control. This is exactly what our antigen tests will deliver. The timing of the EUA is subject to FDA review. Once EUA is obtained, we are prepared to launch the test without delay.</p> <p class="paywall-full-content no-summary-bullets">Moving on to manufacturing. Early on in this pandemic we understood that increasing our manufacturing capacity would be key. To that end, we are confirming that our plans to increase manufacturing capacity to meet demand for COVID-19 sample collection kits and test continues on track as outlined last quarter.</p> <p class="paywall-full-content no-summary-bullets">With that, I'll hand it over to Roberto for a report on the quarter's financials. Roberto?</p> <p class="paywall-full-content no-summary-bullets"><strong>Roberto Cuca</strong></p> <p class="paywall-full-content no-summary-bullets">Thanks Steve. As Steve mentioned earlier, our third quarter net revenues increased 33% to $48 million from the $36 million reported in the third quarter of 2019, primarily as a result of strong sales of molecular sample collection kits for COVID-19 testing, increased international sales of the company's HIV self-test, and higher laboratory services revenues, partially offset by lower sales across all of our other product lines, primarily due to the impact of the COVID-19 pandemic.</p> <p class="paywall-full-content no-summary-bullets">Net product and service revenues were $46.7 million, a 32% increase from the third quarter of 2019. Total product and services revenues for the company's molecular business unit were $31.2 million during the third quarter of 2020, an increase of 79% from the third quarter of 2019. This increase included $18.4 million in sales of oral food sample collection devices for COVID-19 molecular testing, which was partially offset by a decrease in genomic sales.</p> <p class="paywall-full-content no-summary-bullets">International sales of the company's OraQuick HIV Self-Test increased 17% compared to the third quarter of 2019, largely due to higher sales in Africa. Gross profit percentages were 63% and 60% for the three months ended September 30th, 2020 and 2019 respectively. Gross profit percentage in the third quarter of 2020 benefited from an improved product mix associated with higher gross profit percentage product sales.</p> <p class="paywall-full-content no-summary-bullets">Net income for the third quarter of 2020 was $1 million or $0.01 per share on a fully diluted basis compared to net income of $13.1 million or $0.21 per share on a fully diluted basis for the third quarter of 2019.</p> <p class="paywall-full-content no-summary-bullets">Third quarter 2019 results included two gains associated with the sale of a business and a change in the estimated fair value of our acquisition-related contingent consideration together totaling $12.5 million which accounted for approximately $0.16 per share in 2019. Cash and investments totaled $263.7 million at September 30th, 2020.</p> <p class="paywall-full-content no-summary-bullets">As we disclosed in our press release, we expect revenues of $55 million to $60 million in the fourth quarter of 2020. As we discussed on our second quarter earnings call, we expect that as we've just seen with the third quarter non-COVID revenues will be flat or improved for each business unit in the fourth quarter compared with second quarter and that COVID-19 product sales will add to this performance.</p> <p class="paywall-full-content no-summary-bullets">For the full year, we continue to expect that excluding cryosurgical revenues from 2019, non-COVID-19 revenues in both the infectious disease and molecular collection lines of business will be down in 2020 compared to the year ago period, with molecular collection bearing the greater impact. However, as our revenue guidance for the fourth quarter indicates, we anticipate that the revenue opportunities for our COVID-19 sample collection, products and tests will more than offset the year-on-year decrease in our non-COVID-19 lines of business, such that our total revenues will be higher in 2020 than in 2019.</p> <p class="paywall-full-content no-summary-bullets">With that I'll turn the call back over to Steve.</p> <p class="paywall-full-content no-summary-bullets"><strong>Stephen Tang</strong></p> <p class="paywall-full-content no-summary-bullets">Thank you, Roberto. Turning to our legacy businesses. HIV testing remains an important area of global focus for OraSure. Access to testing during the pandemic has been challenging as in-person testing facilities for HIV in the United States have been in many cases shut down. Self-testing, which enables social distancing and helps protect healthcare workers and test users alike is a key strategy in the efforts to help people know their HIV status, especially under the current global pandemic conditions.</p> <p class="paywall-full-content no-summary-bullets">Overall, our net HIV test revenues increased 6% over Q3 2019. This was driven by strong international sales of our OraQuick HIV Self-Test that increased 17% compared to the third quarter of 2019. To put this in perspective, a UNAIDS report noted significant decreases in HIV testing services between January and July in nearly all countries with available data.</p> <p class="paywall-full-content no-summary-bullets">CDC and other government agencies have encouraged health departments at all levels to consider HIV self-testing as an additional testing strategy to reach persons most affected, which speaks to the usability and convenience of our at-home test, which allows individuals to test themselves and receive the results at home.</p> <p class="paywall-full-content no-summary-bullets">To date, OraSure offers the only over-the-counter self-test for HIV in the United States and the only World Health Organization or WHO prequalified rapid oral fluid HIV self-test globally.</p> <p class="paywall-full-content no-summary-bullets">I'd also like to briefly touch on our collection business outside of COVID-19. Although not yet back to pre-COVID levels, we saw increases in our genomics and microbiome kit sales quarter-over-quarter. Third quarter kit sales for genomics and microbiome were up 32% and 114% versus the prior quarter respectively, driven by strength in the commercial market.</p> <p class="paywall-full-content no-summary-bullets">Academic sales also increased quarter-over-quarter, but to a lesser degree. Our laboratory services revenue showed a slight increase over the previous quarter. We continue to innovate in the microbiome arena, adding new products and services.</p> <p class="paywall-full-content no-summary-bullets">Our DNA Genotek subsidiary has launched a skin microbiome collection kit. OMNIgene SKIN offers a standard method for collecting skin microbiome samples from sebaceous dry and wet skin sites, which will aid researchers in obtaining reproducible high-quality samples. And a great example of how our microbiome services and products team complement each other a start-up company Pure Culture Beauty has partnered with DNA Genotek and Diversigen to use data and science to deliver a comprehensive customized skincare regimen to its customers.</p> <p class="paywall-full-content no-summary-bullets">DNA Genotek will supply the OMNIgene SKIN microbiome collection kits and Diversigen will provide full microbiome service – analytical services offering a complete understanding of the user's skin microbiome. We continue to believe in the promise of our microbiome products and services, and look forward to continued growth.</p> <p class="paywall-full-content no-summary-bullets">In closing, our business momentum is strong and we expect that trend to continue as evidenced by our guidance. We see COVID-19 testing as a robust part of our business for now and in the foreseeable future. With molecular collection devices already driving significant revenue and our antibody and antigen tests on the road to commercialization OraSure is poised for continued and sustained growth.</p> <p class="paywall-full-content no-summary-bullets">Our work with COVID-19 will help accelerate our growth significantly. We understand the opportunity for our tests and sample collection kits is substantial and their role in the fight against COVID-19 is vital. We want to reiterate our confidence in OraSure's ability to bring our antibody and antigen test to market. We believe they will be worthy of joining the list of our other highly regarded OraSure products.</p> <p class="paywall-full-content no-summary-bullets">With that, I will open it up the call for your questions.</p> <p id="question-answer-session" class="paywall-full-content no-summary-bullets"><strong>Question-and-Answer Session</strong></p> <p class="paywall-full-content no-summary-bullets"><strong>Operator</strong></p> <p class="paywall-full-content no-summary-bullets">Thank you. [Operator Instructions] Our first question comes from the line of Vijay Kumar with Evercore ISI. Your line is now open.</p> <p class="paywall-full-content no-summary-bullets"><strong><span class="question">Vijay Kumar</span></strong></p> <p class="paywall-full-content no-summary-bullets">Hey guys, thanks for taking my question. Maybe for the first one, Steve, I want to touch on the collection kit opportunity here, $18 million of revenues in the Q. The Q4 guidance implies a modest step up. And I think when you look at the capacity expansion, the goals that you guys had ramping up kit expansion from $35 million to $80 million. So I'm just curious where are we on the expansion? What is the current capacity? Are you selling every single kit that you're making? What should the normalized revenues be for this part of the business once the capacity ramps up?</p> <p class="paywall-full-content no-summary-bullets"><strong><span class="answer">Stephen Tang</span></strong></p> <p class="paywall-full-content no-summary-bullets">Thank you, Vijay. I'll start by first saying, we are very pleased with the performance of our Molecular Solutions business unit. And in particular the COVID-19 products that they're selling three into molecular PCR tests, two products were seeing EUAs as we noted in my prepared remarks.</p> <p class="paywall-full-content no-summary-bullets">While we're not breaking out revenue specifically, you're right that there is a step-up that's for molecular collection kits for COVID-19 that's embedded in our guidance of $55 million to $60 million for the fourth quarter. By the way that $55 million to $60 million would be a record fourth quarter for us as a company.</p> <p class="paywall-full-content no-summary-bullets">We are moving ahead with our expansion plans. We are almost to the point of selling everything we can make, which I think makes up -- so I think that as we look into 2021, the expansion that we announced in August will serve us well in terms of providing additional capacity to meet enormous demand in the marketplace. So this area of our business, which I think has come to fruition nicely in the second and third quarter will continue to grow.</p> <p class="paywall-full-content no-summary-bullets"><strong><span class="question">Vijay Kumar</span></strong></p> <p class="paywall-full-content no-summary-bullets">Understood. And then I guess one for the follow-up, maybe on the antigen testing side. I understand that there'll be a push out here from Q4 to Q1. Maybe can you give us some color on what drove the push out? I guess, the question on investors' minds is what is causing the delay? Are there any technical challenges here? And as you think about that, I guess the language in the press release said that version two the at-home or self-swabbing version would follow soon after. Is that a first half event? Or I'm curious on how we should be thinking on the self-swab at-home version of the test?</p> <p class="paywall-full-content no-summary-bullets"><strong><span class="answer">Stephen Tang</span></strong></p> <p class="paywall-full-content no-summary-bullets">Right. So we've only forecasted as you noted an EUA for our professional version of the test in the first quarter. But you may recall, Vijay from our second quarter call back in August that we indicated that even though we were going to seek sequential EUAs. So as you noted professional then prescription self-test then over-the-counter self-test, we will actually be conducting the clinical trials in parallel to shorten the time between each approval.</p> <p class="paywall-full-content no-summary-bullets">So part of our plan remains to do so. And while we're not providing specific information about when the prescription self-test and the over-the-counter self-test would be on the market, we believe it will be soon after the professional product is approved. And so we'll leave it at that for now.</p> <p class="paywall-full-content no-summary-bullets">But I think it's important to step back and see what's been accomplished. What's been impressive to us is the technical work that's gone to essentially validate that our -- the core of our OraQuick technology, which is a test strip effectively. It's performing exceptionally well in limited detection studies, compared to rapid antigen tests that are already on the marketplace.</p> <p class="paywall-full-content no-summary-bullets">And so that is a significant progress for us right now. And the clinical trials that will go through between now and the EUA submission process in the first quarter, I think we are very confident we'll validate the success of the product.</p> <p class="paywall-full-content no-summary-bullets">What we are trying to do is something that no other company has done before. And that is essentially have a one-step rapid antigen test that is essentially the same design we'll use for the professional the Rx self-test and the OTC self-test ready in design in the professional product. So no other product that's on the market today was designed specifically for that purpose even though all of them are professionally used products in their own right. So we're taking the extra care based on our experience in putting the OraQuick HIV in-home test on the market. And also by the way developing the Ebola Rapid Antigen test back in 2017 in nine months' time to get this on the market as quickly as possible. So, there are always things that are unanticipated that come along in product development, but I think we're very confident in that first quarter EUA with the Rx self-test and the OTC self-tests coming soon thereafter. </p> <p class="paywall-full-content no-summary-bullets"><strong><span class="question">Vijay Kumar</span></strong></p> <p class="paywall-full-content no-summary-bullets">Sorry, what is the LoD on your antigen testing? And how does it compare to competition?</p> <p class="paywall-full-content no-summary-bullets"><strong><span class="answer">Stephen Tang</span></strong></p> <p class="paywall-full-content no-summary-bullets">Well, so we haven't disclosed the numbers Vijay, but they are competitive with the products that are already on the market. And those are -- that's public information. </p> <p class="paywall-full-content no-summary-bullets"><strong>Operator</strong></p> <p class="paywall-full-content no-summary-bullets">Our next question comes from the line of Frank Takkinen with Lake Street Capital. Your line is now open.</p> <p class="paywall-full-content no-summary-bullets"><strong><span class="question">Frank Takkinen</span></strong></p> <p class="paywall-full-content no-summary-bullets">Hi guys. Thanks for taking my questions. Just a couple for you here today. I heard you guys talk in your prepared remarks a little bit about the October EUAs for the two DNA Genotek products. I was hoping you could just go a little bit deeper on that and how that could potentially debottleneck the process to continue to drive the momentum behind this business into the fourth quarter as well as into 2021?</p> <p class="paywall-full-content no-summary-bullets"><strong><span class="answer">Stephen Tang</span></strong></p> <p class="paywall-full-content no-summary-bullets">Yes. So Frank thanks for the question. So, I think these are important breakthroughs for the two products that received EUAs. And so that's our ORAcollect RNA and our OMNIgene Oral products. And it's important because essentially there's a pathway now for subcollection that wasn't available on the market before these products were approved provided that they are used in a product that has also received in EUA for an individual to collect their own saliva specimen.</p> <p class="paywall-full-content no-summary-bullets">So the use of the product if you will very clearly mimics what we've done for in genomic testing used by companies like 23andMe and others. And so from a technical perspective it was very much in line with our expertise. And so it really does allow a pathway for self-collection for saliva. And I think it's important to recognize how far we've come in molecular testing from nasopharyngeal and oropharyngeal swabs to really the breakthrough which is using saliva which allows people to take their own sample and not subject themselves to the discomfort or pain associated with those deep swabs. So that's the breakthrough.</p> <p class="paywall-full-content no-summary-bullets">And I think that evidence of that we provided through the work of our customers. 30000 students at the University of Kansas tested 64 campuses of the State University of New York using the product. So you see widespread distribution of our product and even into the retail channels that we mentioned in our prepared remarks. So that is clearly the breakthrough and that's why we're so excited about the progress and growth in our molecular collections, Molecular Solutions business unit and that will continue into 2021 and beyond. </p> <p class="paywall-full-content no-summary-bullets"><strong><span class="question">Frank Takkinen</span></strong></p> <p class="paywall-full-content no-summary-bullets">Great. And then maybe one for Roberto. We saw gross margins came in at 63%. It's definitely a nice contributor to flipping the model back to profitable fourth quarter. I was curious if you could comment on that level of margins given the increasing mix of molecular collection and the expected continued momentum behind this business?</p> <p class="paywall-full-content no-summary-bullets"><strong><span class="answer">Roberto Cuca</span></strong></p> <p class="paywall-full-content no-summary-bullets">Sure. So, you correctly deduced that the driver of that is the COVID-19 products and we continue to expect those to be growing contributors to our revenues. So versus the third quarter and the fourth quarter -- in the fourth quarter we expect gross margin to be at least as good as the third quarter and likely a bit better given the historical seasonality in our commercial genomics business. There will be some moderation to the gross margin as we see continued growth in our HIV international business, which is a lower gross margin business. But we do overall see this as a sustainable gross margin level that will see some seasonality from quarter-to-quarter in the coming year.</p> <p class="paywall-full-content no-summary-bullets"><strong><span class="question">Frank Takkinen</span></strong></p> <p class="paywall-full-content no-summary-bullets">Great. Thanks for taking the questions and congrats on the progress this quarter. </p> <p class="paywall-full-content no-summary-bullets"><strong><span class="answer">Steve Tang</span></strong></p> <p class="paywall-full-content no-summary-bullets">Thanks, Frank.</p> <p class="paywall-full-content no-summary-bullets"><strong><span class="answer">Roberto Cuca</span></strong></p> <p class="paywall-full-content no-summary-bullets">Thanks, Frank.</p> <p class="paywall-full-content no-summary-bullets"><strong>Operator</strong></p> <p class="paywall-full-content no-summary-bullets">Thank you. Our next question comes from the line of Tycho Peterson with JPMorgan. Your line is now open.</p> <p class="paywall-full-content no-summary-bullets"><strong><span class="question">Casey Woodring</span></strong></p> <p class="paywall-full-content no-summary-bullets">Hi, guys. This is Casey on for Tycho. I guess first question I have is – are you guys baking in any COVID antibody revenue into your 4Q guide? And then how do you see the market evolving for this test? I guess how much of an advantage is perhaps using oral fluid how much of a competitive advantage is that?</p> <p class="paywall-full-content no-summary-bullets"><strong><span class="answer">Steve Tang</span></strong></p> <p class="paywall-full-content no-summary-bullets">So Casey, we have not broken out individual products into our guide for $55 million to $60 million. But I think as we announced back in August, once we locked prototype on the antibody test we would begin building inventory that is manufacturing at risk. That has come to fruition. We have customers that are now evaluating our product on a research-use-only basis before we get our EUA. So that's moving along nicely.</p> <p class="paywall-full-content no-summary-bullets">I think the market for this oral fluid antibody test is going to be expansive. It's coming at a great time when the discussion in the pandemic has moved towards seroprevalence and surveillance. There was an article out just today that said that there's probably 20% of New York City residents that have been exposed to the disease but they haven't been counted or measured yet. So we really do not know the seroprevalence [indiscernible] possibilities for our product in 2021 and 2022.</p> <p class="paywall-full-content no-summary-bullets">In the rollout of a vaccine this will be a powerful tool to accompany the vaccine to see what – how much of the population are mounting antibodies to this virus overall. So – and we know from our own experience with genomic testing that oral fluid sampling is a lot better than blood-based sampling. And this is the only product if and when it's approved for EUA by the FDA to use an oral fluid. I think there are over 300 antibody tests that use blood. So it – in the tradition of OraSure these are unique products with unique applications.</p> <p class="paywall-full-content no-summary-bullets"><strong><span class="question">Casey Woodring</span></strong></p> <p class="paywall-full-content no-summary-bullets">Got it. Thanks for that. And maybe just one on the antigen pushout. Just sort of a little more color on the reasoning behind it. I saw last week the FDA updated its antigen test template that called for more studies to be submitted in the asymptomatic population. Just wondering is it a matter of more studies that need to be done? Or was it about getting the sensitivity up to where it needs to be? Just any more color on the reasoning behind the push out?</p> <p class="paywall-full-content no-summary-bullets"><strong><span class="answer">Steve Tang</span></strong></p> <p class="paywall-full-content no-summary-bullets">Well of course, when you're doing product development, there's always an iterative process involved with it. And then you add to that they need to get clinical data from the field. So that interplay between let's say change in the chemistry and changing aspects of the design of the product to get to the point where we are comfortable with it I think contribute to the new forecast for the first quarter of next year.</p> <p class="paywall-full-content no-summary-bullets">And I think that ultimately the pushout won't matter to us commercially because I think we're very confident that once the product is on the market we'll sell as many as we can make. So it has nothing to do with the external factors of what FDA is doing and everything to do with our own standards of performance.</p> <p class="paywall-full-content no-summary-bullets">And as I said before, we are the only company that's designing a product specifically to ultimately be a self-test whether it's an Rx self-test or an OTC self-test and designing those principles into the professional use product for which we'll seek the initial EUA. So to do all those things to create a one-step rapid antigen test is a challenge that's not been accomplished by anybody yet. So that's why we're investing the time and effort to do it right.</p> <p class="paywall-full-content no-summary-bullets"><strong><span class="question">Casey Woodring</span></strong></p> <p class="paywall-full-content no-summary-bullets">Okay. Thank you.</p> <p class="paywall-full-content no-summary-bullets"><strong><span class="answer">Steve Tang</span></strong></p> <p class="paywall-full-content no-summary-bullets">Thank you, Casey</p> <p class="paywall-full-content no-summary-bullets"><strong>Operator</strong></p> <p class="paywall-full-content no-summary-bullets">Thank you. Our next question comes from the line of Andrew Cooper with Raymond James. Your line is open.</p> <p class="paywall-full-content no-summary-bullets"><strong><span class="question">Andrew Cooper</span></strong></p> <p class="paywall-full-content no-summary-bullets">Hey, thanks for the questions guys. I guess maybe first on the antibody test and thinking about sort of the demand there. I know we've touched on it. But if I think back to when you guys initially talked about it I think the statement was this was somewhat pulled from your substance of user or risk assessment customers saying "Hey we've got empty labs and we can do this." Has that expanded potentially as you're approaching that getting it to market hopefully to additional customers potentially kind of bringing your platform in and your place and going beyond sort of those labs? Or how do we think about the commercial opportunity there?</p> <p class="paywall-full-content no-summary-bullets"><strong><span class="answer">Stephen Tang</span></strong></p> <p class="paywall-full-content no-summary-bullets">Yes. Andrew, you've recounted our previous statements correctly. And I think you're also right that we've moved even further beyond that with commercial opportunities. And I think the reason for that is that the use and need for antibody tests has changed since the pandemic first started back in March. And as I said earlier, we are now at a stage where antibody tests are going to be more important than they were in the beginning of the pandemic, particularly with prospects of a vaccine coming into play here. So with that in mind, there's a lot more commercial interest than we started from and we are pursuing that as I said with research-only customers right now in the queue in anticipation of the EUA for the oral fluid antibody ELISA test. So yes, things are moving along and we're seeing a lot of tailwinds for this part of the business.</p> <p class="paywall-full-content no-summary-bullets"><strong><span class="question">Andrew Cooper</span></strong></p> <p class="paywall-full-content no-summary-bullets"> </p> <p class="paywall-full-content no-summary-bullets">Okay. Great. And then maybe just quickly on antigen side. Just want to confirm like you said for antibody, like you said before kind of that manufacturing at risk comfort. Is that still the plan once you do have the final design locked in and sort of know what you're submitting to the FDA that you would still start manufacturing as soon as that's done? </p> <p class="paywall-full-content no-summary-bullets"><strong><span class="answer">Stephen Tang</span></strong></p> <p class="paywall-full-content no-summary-bullets">Yes. That is still the plan. And based on significant inbound interest there is very good reason for doing so. We want to be able to satisfy pent-up demand in the marketplace. And as I said the design of the product which aims for ultimately a self-test even though the first EUA is a professional test is something that will be unique in the marketplace.</p> <p class="paywall-full-content no-summary-bullets"><strong><span class="question">Andrew Cooper</span></strong></p> <p class="paywall-full-content no-summary-bullets">Okay. And then maybe just one last one if I could sneak it in. On that understand that there is some of the kind of time line dynamics that have adjusted. But when we think about running some of the trials in parallel, does delaying the professional test maybe push the over-the-counter or the prescription self-test closer to that initial time line? Is there any chance where you can kind of compress the gap between the two as you've had more time to develop some of the data and fine-tune things? Or is it still kind of the same sort of lag here that we might expect as you go from one to two to three?</p> <p class="paywall-full-content no-summary-bullets"><strong><span class="answer">Stephen Tang</span></strong></p> <p class="paywall-full-content no-summary-bullets">Well the lag period is somewhat in our control as you can imagine with the design and resourcing of clinical trials, but it's somewhat out of our control because of course FDA makes the final call on the EUA approval process, right? So we're doing everything we can to ensure that there's minimal time between the EUA submissions and hopefully the approvals. We have evolved our thoughts thinking a lot about what it will take to accomplish these clinical trials and we'll make the investments we need to ensure that we shorten the time as much as possible. So I think that's been an evolving set of priorities for us since we spoke at our second quarter earnings call back in August. And so I think we're in a very good position there to minimize the amount of time overall and control what we can control.</p> <p class="paywall-full-content no-summary-bullets"><strong><span class="question">Andrew Cooper</span></strong></p> <p class="paywall-full-content no-summary-bullets">Okay. Great. I’ll stop there. Thanks again.</p> <p class="paywall-full-content no-summary-bullets"><strong><span class="answer">Stephen Tang</span></strong></p> <p class="paywall-full-content no-summary-bullets">Thanks, Andrew.</p> <p class="paywall-full-content no-summary-bullets"><strong>Operator</strong></p> <p class="paywall-full-content no-summary-bullets">Thank you. Our next question comes from the line of Patrick Donnelly with Citigroup. Your line is now open.</p> <p class="paywall-full-content no-summary-bullets"><strong><span class="question">Patrick Donnelly</span></strong></p> <p class="paywall-full-content no-summary-bullets">Thanks guys. Steve maybe just following on on the capacity side. I mean with the 1Q launch obviously kind of ramping at risk a little bit ahead of time, what type of capacity should we be expecting upon launch of the self-antigen test? I know you talked about expectations of selling pretty much everything you guys can make. So how are you thinking about capacity? And then at the same time, are you thinking about carving that up and directing a certain amount of capacity towards professional prescription OTC? What's the right way to think about that from your side?</p> <p class="paywall-full-content no-summary-bullets"><strong><span class="answer">Stephen Tang</span></strong></p> <p class="paywall-full-content no-summary-bullets">Yes. So we are on plan for what we announced previously and that is, we're going to move from 35 million tests per year to 55 million tests per year by the first quarter of 2021 and 70 million tests per quarter by the third quarter 2021.</p> <p class="paywall-full-content no-summary-bullets">And remember, embedded in that capacity is about 17 million to 18 million units per year of capacity for our existing HIV, HCV and Ebola tests. So when we come on stream ready to serve the professional market, we will have the capacity that you can calculate from our previous information.</p> <p class="paywall-full-content no-summary-bullets">I think, we're going to sell as many as we can make for the professional products. And then, as we have more certainty about the timing for the Rx self-test and for the OTC self-test, we'll begin making allocation decisions about which products to get what capacity.</p> <p class="paywall-full-content no-summary-bullets">I think we really do see a sweet spot in the self-test whether it's Rx or OTC and we'll make the combination that we need to from there. And I think as I've said before, the design considerations here are to try to make the same form factor and product design for all three use cases, professional Rx self-test and OTC self-test.</p> <p class="paywall-full-content no-summary-bullets">That's an approach that I think -- I don't think any other company has taken in the marketplaces yet. So that design for manufacturing is really built into our plan here and that's what allows us to have a more fungible discussion between</p> <p class="paywall-full-content no-summary-bullets">[Audio Gap]</p> <p class="paywall-full-content no-summary-bullets"><strong><span class="question">Patrick Donnelly</span></strong></p> <p class="paywall-full-content no-summary-bullets">Okay. Yes. You dropped off there at the end. I think I got most of it. And then one -- </p> <p class="paywall-full-content no-summary-bullets"><strong><span class="answer">Stephen Tang</span></strong></p> <p class="paywall-full-content no-summary-bullets">Sorry about that. </p> <p class="paywall-full-content no-summary-bullets"><strong><span class="question">Patrick Donnelly</span></strong></p> <p class="paywall-full-content no-summary-bullets">No, no problem. One more on the antigen self-test. I apologize for circling back on this. But just on the time line, I just wanted to clarify. Last quarter you guys kind of shifted from saliva to lower nasal. Obviously -- I just want to make sure, the design approach, they're fully locked in right now and it's just kind of refining things on your end. The data looks compelling. There's no big changes here outside of, again, kind of the normal course shifting in a few months. Is that correct?</p> <p class="paywall-full-content no-summary-bullets"><strong><span class="answer">Stephen Tang</span></strong></p> <p class="paywall-full-content no-summary-bullets">That is basically correct, although, we haven't announced prototype lock or anything like that. And we may not announce that. I think our goal is, at least, right now, to announce when we actually submit the EUA for the professional application.</p> <p class="paywall-full-content no-summary-bullets">But I think we're comfortable with our progress, without revealing too much about what the final design will look like. And because we've had experience with HIV, HCV and Ebola, I think we know a lot about how to scale the manufacturing from there.</p> <p class="paywall-full-content no-summary-bullets"><strong><span class="question">Patrick Donnelly</span></strong></p> <p class="paywall-full-content no-summary-bullets">All right. Thanks.</p> <p class="paywall-full-content no-summary-bullets"><strong><span class="answer">Stephen Tang</span></strong></p> <p class="paywall-full-content no-summary-bullets">Thank you, Patrick.</p> <p class="paywall-full-content no-summary-bullets"><strong>Operator</strong></p> <p class="paywall-full-content no-summary-bullets">Thank you. Our next question comes from the line of Jacob Johnson from the line of Stephens. Your line is now open.</p> <p class="paywall-full-content no-summary-bullets"><strong><span class="question">Jacob Johnson</span></strong></p> <p class="paywall-full-content no-summary-bullets">Hi. Thanks. On COVID-19 collection kits, can you just talk about what you're hearing from customers in terms of near and long-term demand for their tests? I think, given your fourth quarter guidance, it would suggest that demand is pretty strong, at least in the near term. But I would just be interested in any other color there.</p> <p class="paywall-full-content no-summary-bullets"><strong><span class="answer">Stephen Tang</span></strong></p> <p class="paywall-full-content no-summary-bullets">Jacob, I would say that, we are approaching a point where we will sell everything we can make and the capacity increases that we forecasted back in August will serve us well. And so, we are seeing a rather insatiable demand for our products for molecular testing that we believe will continue, certainly, through 2021 and probably well into 2022.</p> <p class="paywall-full-content no-summary-bullets">It began certainly in North America and in the U.S., but we're looking outside the U.S. as well right now. So these are great discussions to have, because I think people have really gravitated to the fact that you need saliva and self-collection saliva as a key part of testing.</p> <p class="paywall-full-content no-summary-bullets"><strong><span class="question">Jacob Johnson</span></strong></p> <p class="paywall-full-content no-summary-bullets">Got it. That's helpful. And then, just maybe one question on the non-COVID front. You had a nice rebound in the HIV franchise in the quarter both internationally and in the U.S. I guess, on the domestic side, are you beginning to see signs of clinics reopening and domestic test volumes increasing?</p> <p class="paywall-full-content no-summary-bullets">And then a quick little aside there would be with the, I guess, third wave as you described it in COVID here in the U.S. Should we think of, I think, Roberto said fourth quarter you expect to be better than the second quarter. But could we see maybe some of that rebound be muted here in the fourth quarter with COVID cases ticking back up?</p> <p class="paywall-full-content no-summary-bullets"><strong><span class="answer">Stephen Tang</span></strong></p> <p class="paywall-full-content no-summary-bullets">Yes. I would say directionally, we are seeing -- we've been seeing a pickup as I think Roberto alluded to in our U.S. based HIV business. Some of that because with the clinic closings, CDC has actually issued guidelines urging those clinics to direct there would-be patients to our self-test. And so having that as an alternative in the marketplace has served us incredibly well.</p> <p class="paywall-full-content no-summary-bullets">And so the hedge against the third wave of COVID creating a shutdown again will benefit our OraQuick HIV in-home test domestically for that reason. But we'd rather bet on the economy and clinics staying open which benefit their professional products. So while we haven't given specific guidance by product line that's the way we view the situation. So I think there's upside for us in both scenarios. </p> <p class="paywall-full-content no-summary-bullets"><strong><span class="question">Jacob Johnson</span></strong></p> <p class="paywall-full-content no-summary-bullets">Got it. That's helpful. Thanks for taking the question.</p> <p class="paywall-full-content no-summary-bullets"><strong><span class="answer">Stephen Tang</span></strong></p> <p class="paywall-full-content no-summary-bullets">You’re welcome.</p> <p class="paywall-full-content no-summary-bullets"><strong>Operator</strong></p> <p class="paywall-full-content no-summary-bullets">Thank you. [Operator Instructions] Our next question comes from the line of Brandon Couillard with Jefferies. </p> <p class="paywall-full-content no-summary-bullets"><strong><span class="question">Unidentified Analyst</span></strong></p> <p class="paywall-full-content no-summary-bullets">Thanks guys. This is Matt on for Brandon today. Quick one on the Phase 1 rollout of your antigen test into the professional market. Any updated color on how you're thinking about ASP there? And then as well on the gross margin side given the initial customer will largely be in the setting of doctor offices or university health centers that are likely to go through distribution channel, any color there on the margin side as well?</p> <p class="paywall-full-content no-summary-bullets"><strong><span class="answer">Stephen Tang</span></strong></p> <p class="paywall-full-content no-summary-bullets">Roberto, would you like to take that one?</p> <p class="paywall-full-content no-summary-bullets"><strong><span class="answer">Roberto Cuca</span></strong></p> <p class="paywall-full-content no-summary-bullets">Sure. So we haven't disclosed the pricing for the antibody test yet -- excuse me, the antigen test yet other than to say that we expect it to be in line with the other products on the same technological platform and with products generally in that market. We have said that we expect the gross margin percentage to be at least as good as for our other products.</p> <p class="paywall-full-content no-summary-bullets">And as a reminder because there are three potential product types and product distribution channels, a lot of the actual achieved ASP and gross margin will depend on the mix amongst those three. And that will be an evolving mix as we first of all get the EUAs for the products and then optimize the mix for our customers.</p> <p class="paywall-full-content no-summary-bullets"><strong><span class="question">Unidentified Analyst</span></strong></p> <p class="paywall-full-content no-summary-bullets">Makes sense. And then Stephen if we look at the balance sheet you guys have $260 million of cash. You've done a number of smaller deals here one divestiture. You're clearly spending right now to build out manufacturing, but curious how if at all your M&amp;A appetite has evolved over the last few months. And if anything in the funnel is perhaps more actionable today than it was coming into this year. Thanks.</p> <p class="paywall-full-content no-summary-bullets"><strong><span class="answer">Stephen Tang</span></strong></p> <p class="paywall-full-content no-summary-bullets">Yeah. We continue to look for attractive opportunities to leverage our balance sheet. I think that our business circumstances have certainly changed with the COVID-19 opportunities. And it remains our objective to look at acquiring companies products technologies that are accretive to our overall growth strategy. But as we look ahead to 2021 and 2022, the growth is going to be, I think, fairly enormous at current course and speed. And so we'll be adjusting our expectations of business development and the size and types of deals accordingly.</p> <p class="paywall-full-content no-summary-bullets">But the pipeline has been robust, I think, as you suggested both with our own outreach and inbound interest from potential prospects, and we'll continue to look at that. Our balance sheet, I think is stellar. No debt at all on the balance sheet. And I think that will lead us to some interesting opportunities in the very near future.</p> <p class="paywall-full-content no-summary-bullets"><strong><span class="question">Unidentified Analyst</span></strong></p> <p class="paywall-full-content no-summary-bullets">Super. Thank you.</p> <p class="paywall-full-content no-summary-bullets"><strong><span class="answer">Stephen Tang</span></strong></p> <p class="paywall-full-content no-summary-bullets">You’re welcome.</p> <p class="paywall-full-content no-summary-bullets"><strong>Operator</strong></p> <p class="paywall-full-content no-summary-bullets">Thank you. We do have a follow-up question from the line of Vijay Kumar with Evercore ISI. Your line is now open.</p> <p class="paywall-full-content no-summary-bullets"><strong><span class="question">Vijay Kumar</span></strong></p> <p class="paywall-full-content no-summary-bullets">Steve just I have one quick follow-up on the antigen testing. Maybe can you -- what should investors expect, over the next few months, right? One, will we have any update -- will The Street have any update? And I'm asking because, we had a push out to Q4 and now it's Q1.</p> <p class="paywall-full-content no-summary-bullets">And I think The Street would like some updates in the interim. And the second was when are the trials starting right? Are these in-field clinical trials as in you're testing, in the field on live cases given these have to be self-swabbed? Is that what's causing the delay perhaps? And has the prototype for the device been locked yet? Thank you.</p> <p class="paywall-full-content no-summary-bullets"><strong><span class="answer">Stephen Tang</span></strong></p> <p class="paywall-full-content no-summary-bullets">Yeah, Vijay, we have not announced prototype locks. So we haven't said anything about that. I do understand the interest in our product and the product development. I mentioned earlier, in response to a separate question, that we do plan to announce the submission of our EUA application, for the professional test. That's our plan right now.</p> <p class="paywall-full-content no-summary-bullets">Beyond that we will have to see, what we'll communicate and when. There are obviously some competitive issues that would -- we have to account for, in any particular announcement. But, the delays are not due to any particular factor other than we had very high expectations, for the performance of the product. And the clinical trials are running to validate the particular design and performance of the product.</p> <p class="paywall-full-content no-summary-bullets">So that interplay has continued and ramped up, since our August Q2 earnings call. So that will [Indiscernible] what I said before is that, we will use what we understand are the standards for the FDA targeting a self-test. And our own internal quality and performance standard as the measuring stick. And that's a very high bar, which is why it takes time to get this product on the market. But we are very confident that we're on the road to getting this product to the EUA process in the first quarter. And following with the Rx self-test and the OTC self-test shortly thereafter.</p> <p class="paywall-full-content no-summary-bullets"><strong><span class="question">Vijay Kumar</span></strong></p> <p class="paywall-full-content no-summary-bullets">Thanks Steve.</p> <p class="paywall-full-content no-summary-bullets"><strong><span class="answer">Stephen Tang</span></strong></p> <p class="paywall-full-content no-summary-bullets">Thank you, Vijay.</p> <p class="paywall-full-content no-summary-bullets"><strong>Operator</strong></p> <p class="paywall-full-content no-summary-bullets">Thank you. This concludes today's question-and-answer session. I would now like to turn the call back to, Stephen Tang, for closing remarks.</p> <p class="paywall-full-content no-summary-bullets"><strong>Stephen Tang</strong></p> <p class="paywall-full-content no-summary-bullets">We'd like to thank everybody for participating on the call and your interest in OraSure Technologies. We hope that, you keep well and safe wherever you are. And continue to enjoy your afternoon or your evening. Thank you very much.</p> <p class="paywall-full-content no-summary-bullets"><strong>Operator</strong></p> <p class="paywall-full-content no-summary-bullets">Ladies and gentlemen, this concludes today's conference call. Thank you for your participation. You may now disconnect.</p></div><div class="above_now_read-piano-placeholder"></div><div><ul><li class="jB_Gz" data-test-id="analysis-and-news-bullet">Read more current<!-- --> <!-- -->OSUR<!-- --> <a class="I_0 r_5 r_6 r_ab L_G L_gv" href="/symbol/OSUR"><span class="">analysis and news</span></a></li><li class="jB_Gz" data-test-id="earnings-call-transcripts-bullet">View all<!-- --> <a class="I_0 r_5 r_6 r_ab L_G L_gv" href="/earnings/earnings-call-transcripts"><span class="">earnings call transcripts</span></a></li></ul></div></div></div></div><div class="piano-paywall-container"></div><div></div><footer class="nO_S r_4 r_af aQ_jg paywall-full-content" data-test-id="post-footer"><span class="nP_G nP_Nx r_4 r_6 s_aG s_bJ s_aQ s_bd"><button class="vt_p9 sA_T6 r_4 r_6 vt_hT" data-test-id="like-button" type="button"><svg viewBox="0 0 19 16" xmlns="http://www.w3.org/2000/svg" class="vt_fd"><path d="M17.8 7.18h-2.69V15h2.69zm-4.86 6.4s.1 1.32-1.34 1.32H4.26s-1.86-2.13-3.2-6.7C.64 6.78 2.7 6.57 2.7 6.57h5.17S5.9 4.04 5.7 2.21C5.5.38 7.26.69 8.39 2.71c1.14 2.04 4.55 3.86 4.55 3.86v7z"></path></svg><span class="vt_hV vt_gn">Like</span></button></span><button aria-expanded="false" aria-label="Share options" class="dV_ry dV_rw r_ar r_4 r_6 r_ab dV_fy aS_jp aS_jD aS_jS dV_o4" data-test-id="custom-share-button" type="button"><span class="dV_h bh_l4"><span class="nP_G nP_Nx r_4 r_6 s_aG s_bJ s_aQ s_bd"><svg viewBox="0 0 18 18" xmlns="http://www.w3.org/2000/svg" class="nP_fd"><path d="M14.8 17.14a2.7 2.7 0 0 1-2.13-2.7l.01-.3-3.88-1.73-3.97-1.77c-.07-.03-.11 0-.3.17a2.67 2.67 0 1 1 0-3.83l.23.23 3.96-1.77 3.96-1.76-.01-.3c-.04-.7.24-1.44.74-1.97.64-.67 1.7-.96 2.6-.72A2.73 2.73 0 0 1 18 3.13a2.67 2.67 0 0 1-4.56 2.02l-.19-.18L9.3 6.73 5.33 8.5v.83l3.94 1.75 3.95 1.76.24-.22a2.67 2.67 0 1 1 1.35 4.52z"></path></svg><span class="nP_hV s_cL nP_gn">Share</span></span></span></button><a class="nP_G nP_Nx r_4 r_6 s_aG s_bJ s_aQ s_bd nO_Ns" data-test-id="comment-button" href="/article/4385063-orasure-technologies-inc-osur-ceo-stephen-tang-on-q3-2020-results-earnings-call-transcript#comments"><svg viewBox="0 0 16 15" xmlns="http://www.w3.org/2000/svg" class="nP_fd nO_Nw"><path d="M7.04 12.28a8.8 8.8 0 0 1-4.6 2.21.79.79 0 0 1-.63-.2.91.91 0 0 1-.28-.45.61.61 0 0 1-.01-.4c0 .03-.01.04 0 .07-.03-.14.01-.21.1-.37l.08-.12.06-.07.05-.07.04-.04.23-.28.27-.32a4.07 4.07 0 0 0 .7-1.37 6.3 6.3 0 0 1-1.76-1.8 4.84 4.84 0 0 1-.17-5c.4-.73.94-1.36 1.62-1.88A7.87 7.87 0 0 1 5.12.95a9.23 9.23 0 0 1 6.6.32 6.87 6.87 0 0 1 2.74 2.12 4.93 4.93 0 0 1 0 6.05c-.68.9-1.6 1.6-2.74 2.12a8.97 8.97 0 0 1-4.68.72z" fill="none"></path></svg><span class="nP_hV s_cL nO_gn">Comment<!-- --> (1)</span></a></footer></div></div></div></section><!--$--><section class="mx-auto flex w-full flex-col justify-between bg-white dark:bg-black-95 pt-24 md:pt-12 pb-24 px-safe-offset-18 md:pb-20 md:px-safe-or-24 mb-8 md:mb-18 print:hidden" data-test-id="recommended-section"><div class="flex flex-col flex-wrap print:block"><div class="w-full max-w-full"><div class="paywall-full-content"><div class="w-full pb-6 pt-24 md:pb-10 md:pt-20"><div class="-mx-12 -my-4 flex flex-grow items-center flex-wrap"><div class="mr-auto flex flex-shrink flex-grow-0 px-12 py-4"><h4 class="m-0 inline-block text-5x-large-r text-black-35 dark:text-black-30 md:text-4x-large-r" data-test-id="recommended-for-you-card-title">Recommended For You</h4></div></div></div><div data-test-id="post-skeleton"><div class="gY_a fF_gY r_4 lz_KI s_aE s_bH lz_KI s_aE s_bH lz_KM lz_KM" data-test-id="post-skeleton-row" style="opacity:1"><span class="fY_uZ t_eD fY_vV gY_e9 s_ds" data-test-id="loader"></span><div class="gY_hV r_4 r_ab r_am"><span class="fY_uZ t_eD fY_vV gY_Y gY_qw s_d1" data-test-id="loader"></span><span class="fY_uZ t_eD fY_vV gY_D" data-test-id="loader"></span></div></div><div class="gY_a fF_gY r_4 lz_KI s_aE s_bH lz_KI s_aE s_bH lz_KM lz_KM" data-test-id="post-skeleton-row" style="opacity:0.8333333333333334"><span class="fY_uZ t_eD fY_vV gY_e9 s_ds" data-test-id="loader"></span><div class="gY_hV r_4 r_ab r_am"><span class="fY_uZ t_eD fY_vV gY_Y gY_qw s_d1" data-test-id="loader"></span><span class="fY_uZ t_eD fY_vV gY_D" data-test-id="loader"></span></div></div><div class="gY_a fF_gY r_4 lz_KI s_aE s_bH lz_KI s_aE s_bH lz_KM lz_KM" data-test-id="post-skeleton-row" style="opacity:0.6666666666666667"><span class="fY_uZ t_eD fY_vV gY_e9 s_ds" data-test-id="loader"></span><div class="gY_hV r_4 r_ab r_am"><span class="fY_uZ t_eD fY_vV gY_Y gY_qw s_d1" data-test-id="loader"></span><span class="fY_uZ t_eD fY_vV gY_D" data-test-id="loader"></span></div></div><div class="gY_a fF_gY r_4 lz_KI s_aE s_bH lz_KI s_aE s_bH lz_KM lz_KM" data-test-id="post-skeleton-row" style="opacity:0.5"><span class="fY_uZ t_eD fY_vV gY_e9 s_ds" data-test-id="loader"></span><div class="gY_hV r_4 r_ab r_am"><span class="fY_uZ t_eD fY_vV gY_Y gY_qw s_d1" data-test-id="loader"></span><span class="fY_uZ t_eD fY_vV gY_D" data-test-id="loader"></span></div></div><div class="gY_a fF_gY r_4 lz_KI s_aE s_bH lz_KI s_aE s_bH lz_KM lz_KM" data-test-id="post-skeleton-row" style="opacity:0.33333333333333337"><span class="fY_uZ t_eD fY_vV gY_e9 s_ds" data-test-id="loader"></span><div class="gY_hV r_4 r_ab r_am"><span class="fY_uZ t_eD fY_vV gY_Y gY_qw s_d1" data-test-id="loader"></span><span class="fY_uZ t_eD fY_vV gY_D" data-test-id="loader"></span></div></div><div class="gY_a fF_gY r_4 lz_KI s_aE s_bH lz_KI s_aE s_bH lz_KM lz_KM" data-test-id="post-skeleton-row" style="opacity:0.16666666666666674"><span class="fY_uZ t_eD fY_vV gY_e9 s_ds" data-test-id="loader"></span><div class="gY_hV r_4 r_ab r_am"><span class="fY_uZ t_eD fY_vV gY_Y gY_qw s_d1" data-test-id="loader"></span><span class="fY_uZ t_eD fY_vV gY_D" data-test-id="loader"></span></div></div></div></div></div></div></section><!--/$--></div></div><div class="lg:basis-auto lg:w-auto lg:flex lg:flex-col grow-0 sm:basis-full sm:flex sm:flex-col grow-0 empty:hidden relative min-h-1 min-w-0 w-full max-w-full grow sa-col" data-test-id="grid-col"><div class="ja_qj aQ_jg r_4 r_am s_bH" data-test-id="right-rail"><!--$--><div></div><!--/$--></div></div></div></div></article></div><!--/$--></main><div class="l_L"><div></div><div></div></div><!--$--><!--/$--><div data-test-id="after-layout-content-slot"></div></div></div><div class="e_a s_eA s_cy s_dd s_dS r_4 r_ac s_aU s_bh" id="google-one-tap-popup-container"></div><div class="g_p t_eB" id="px-captcha-wrapper"><div class="g_g s_eA s_cy s_dd s_dS s_aE s_bH"><div class="g_f"><div id="px-captcha"></div><div><div class="g_q s_d9">To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.</div><div class="g_q s_d9">Is this happening to you frequently? Please<!-- --> <a href="https://seekingalpha.userecho.com/?source=captcha">report it on our feedback forum.</a></div><div class="g_q s_d9">If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.</div></div><div class="px-reference-id"></div></div></div></div></div></div><noscript><iframe height="0" src="https://www.googletagmanager.com/ns.html?id=GTM-MSK9R8B" style="display:none;visibility:hidden" title="google-tag-manager" width="0"></iframe></noscript><script async="" src="/samw/static/js/app.982fa237.js"></script></body></html>